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forEword 
Sooner or later, most of us will have some sort of encounter with medical technology 
for a shorter or longer period of time, either directly or indirectly. The list of medical 
aids and devices for diagnosis, monitoring or treatment is very long and continues 
to grow steadily, in step with advances in research and innovation. Medical technol-
ogy covers a broad spectrum of devices and procedures: from an echo at 20 weeks’ 
pregnancy to an MRI of a fractured knee, and from a pump to administer narcosis 
or painkillers intravenously to – more dramatically – a pacemaker or a complete hip 
replacement. 
Every medical device must not only be entirely safe, but it must also work as it was 
meant to. That is true both for the equipment that medical professionals use on our 
behalf and for the aids that we are increasingly using ourselves, for example diagnostic 
tests and blood pressure meters. Moreover, when new medical technology becomes 
available, we should be able to assume that it is at least as good as what the market 
already offers, and that it also costs less if at all possible. That is no unnecessary luxury 
if we remember that there are already approximately 500,000 types of medical devices 
in circulation, from thermometers to surgical robots.
It is quite difficult to evaluate whether a new medical device offers any advantages, 
and what those advantages are. After all, there is more involved than technical quality 
and safety. Any evaluation also has to consider the varying usage and user requirements, 
sector-specific guidelines and legislation. But all the ‘ifs, ands and buts’ should never 
throw up insurmountable barriers to the introduction of new medical technologies. 
This advisory report was prepared by an Academy foresight committee chaired by 
Professor Carl Moons. The report aims to offer the various stakeholders guidelines for 
selecting the research method that best suits the relevant medical device, including 
postmarketing surveillance. The report makes clear that there are different ways of 
tackling such evaluations, and that a ‘one-size-fits-all’ approach is insufficient. 
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We hope that this foresight study will help stakeholders subject new medical tech-
nology to proper testing so that users can depend on safe, good quality, user-friendly 
diagnostic and therapeutic medical devices. 
Hans Clevers
President of the Royal Netherlands Academy of Arts and Sciences 
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prEviEw – main points
The aim of this report is to provide explicit guidance for research suitable for assessing 
and inferring the benefits and performance of medical devices, tailored to the various 
types of devices, their specifics, and the intended contexts, indications and individuals 
for which they are used.
Establishing the benefits of medical devices poses specific challenges because they 
are intrinsically diverse in terms of use, users, sector and regulation. All this makes 
it a complex matter to design and conduct valid research into the merits of medical 
devices and their use. In light of this diversity, this report considers:
• why there is no one-size-fits-all approach to evaluating the risks, performance and 
benefits of devices;
• why and how research on the benefits and performance of devices differs between 
‘therapeutic’ devices (e.g. pacemakers, nerve stimulators, prostheses) and 
‘non-therapeutic’ devices (e.g. diagnostic, monitoring, screening or prognostic 
tests); 
• the key principles of device evaluations; 
• the optimal approach for evaluating the benefits of devices; 
• alternative research approaches, in view of the specifications and the targeted 
context, users and individuals/patients of a device;
• why and how device evaluations are enhanced when device developers, manufac-
turers and end-users (e.g. professionals and targeted individuals/patients) collab-
orate and describe at an early stage the potential mechanisms/pathways through 
which, and in whom, device use leads to intended (i.e. benefits) and unintended 
(i.e. risks) effects on health or health care;
• how knowledge of these ‘working mechanisms’ helps to place evidence taken from 
multiple studies on a device – e.g. technical, safety and clinical studies – into a 
‘linked’ or ‘network of evidence’ perspective;
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• why a linked or network of evidence approach is better suited to device evaluations 
than a ‘hierarchy of evidence’ approach.
This report is meant to help stakeholders involved in the manufacturing, evaluation, 
use, and regulation of medical devices choose the proper approach for assessing the 
health and health care benefits of medical devices, given the device specifics. It gives 
numerous empirical examples involving a wide variety of medical devices. It should be 
read against the background of current international policy development, registries 
regarding the use of medical devices following their market introduction, user involve-
ment, end-user training requirements, and (cost-)effectiveness assessments. This 
guidance report ultimately aims to protect society and users/end-users against the 
introduction and use of devices that are ‘unsafe’ or ‘unnecessary’.
10 evaluation of new technology in health care
ExEcutivE summary
Scope
The development, evaluation and introduction of medical innovations and technolo-
gies in general and innovative medical devices in particular are considered an increas-
ingly important factor in addressing the grand societal challenge related to health and 
wellbeing. In view of the rapid technological advances in and the rising cost of health 
care, society expects new medical devices to have added benefits. 
The main topic of this report is how to address the added benefits of medical 
devices. The overarching principle that actually drives the evaluation and regulation of 
any health care intervention, including medical devices, is: 
To generate and accumulate evidence that the use of a device is not only safe but also has 
benefits, preferably added benefits beyond existing care, for the health or health care of 
the intended individuals, patients, professionals or for society at large. 
Benefits can include a direct therapeutic effect yielding improved health outcomes 
for the targeted individuals or users. But it may also include indirect benefits by 
improving ease of use, facilitating or improving screening or diagnosis of diseases, or 
reducing the burden on patients or the costs associated with medical care. Establish-
ing the benefits of medical devices poses specific challenges. This report provides tools 
to support and enhance the clinical research tradition of assessing those benefits.
Aim and targeted readership
The first aim of the report is to provide explicit guidance concerning the application of 
research methods and approaches suitable for assessing the benefits and performance 
of medical devices. The second aim is to tailor this guidance to the various device types 
and specifics, as well as to the contexts and indications in which they are used, and the 
individuals in and users by whom they are used. 
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This guidance is meant for all stakeholders involved in the evaluation, use, and 
regulation of medical devices, including researchers and professionals in health care, 
the medical device industry (SMEs in particular), Notified Bodies, health insurance 
companies, hospital boards, regulatory agencies, funding agencies and medical ethical 
review committees. 
Motivation
In this report, the Royal Netherlands Academy of Arts and Sciences (KNAW) aims to 
contribute to the European Union’s request that its Member States ‘take into account 
that improved research frameworks and criteria are needed to enhance reliability, 
predictability, speed and transparency in the decision-making on the introduction, use 
and reimbursement of medical devices’. The specifics of medical devices, however, call 
for a tailored approach, as they could hamper innovation and economic opportunities 
in Europe. 
Medical Device Variety and Specifics
Chapter 2 of this report offers an overview of the variety of medical devices and asso-
ciated regulatory aspects. There are many different medical devices (almost 500,000). 
They are intrinsically diverse in terms of use, users, sector and policy, making it a 
complex matter to design and conduct valid research into a device’s merits. 
• Device use differs in its aims (e.g. for diagnostic, prognostic, screening, therapeutic, 
or supportive purposes), durability (e.g. disposable vs. implantable) and mode of 
action. The need to collect evidence about its (added) benefits is more pressing the 
higher the risk involved in using a device. However, there is no need to explicitly 
establish clinical benefits for all medical devices that are used in health care: there 
is no one-size-fits-all. 
• Consumers, professional caregivers and health care policymakers may have dif-
fering user perspectives. Consumers need to be assured that the use of the device 
is safe and has a positive benefit/risk ratio. Policymakers want the introduction 
of new, often costly devices to be safe, beneficial and cost-effective. Health care 
professionals share the concerns of both consumers and policymakers; they can, 
moreover, influence a device’s performance, benefits and safety by the way they 
handle it and by their skills.
• The market for medical devices stretches far beyond the professional care setting. 
Devices are sold by large European multinationals, by SMEs and over the counter. 
Decentralised health care solutions and widespread use of mobile technologies are 
opening up innovative ways of increasing patient self-management. The life cycle 
of medical devices is relatively short (2.5-6 years on average) and in many cases, 
incremental modifications improve a device over time. 
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All this contributes to the complexity of research assessing the benefits of device use. 
Stakeholders Views
Chapter 3 presents the results of a field survey among stakeholders. All of the 
stakeholders warned against comparing medical devices with pharmaceuticals and 
implementing a research paradigm similar to that used in drug approval and reim-
bursement. However, they also identified critical issues and challenges related to new 
developments and device evaluation: 
• In recently amended EU legislation on medical devices, the emphasis on clinical 
evaluation has increased but actual guidance on how to design such research is 
not elaborated. More awareness is needed of the challenge posed by new types of 
medical devices, such as combination products and self-management products.
• Research into the benefit of a device after CE certification to encourage its use and 
uptake by intended users, suffers from inadequate knowledge of the pros and cons 
of different research approaches. Frequently, line extensions of existing devices 
have resulted in numerous small datasets, whereas research commonly takes place 
in highly controlled settings of experts having undergone extensive user training, 
which all is very different from regular care. 
• There are safety issues related to device use in regular care because devices are 
commonly applied by untrained professionals. This report does not explicitly pro-
vide recommendations for training professionals in new device use, as this subject 
is addressed by the Dutch Order of Medical Specialists (OMS). 
• Registries, including clinical data on using a device in regular care, are crucial for 
assessing the long-term safety, performance, benefits and cost-effectiveness of 
devices. 
• Health technology assessments (HTA) are hardly ever conducted for medical 
devices, let alone endorsed. However, in the current era of evidence-based medi-
cine, the benefits and economic considerations of device use need to be taken into 
account. This should ideally happen in an early phase of new device development. 
Research Approaches Tailored to Medical Devices 
Given the concerns of the stakeholders, Chapter 4 focuses on the main principles of 
research into the performance, benefits and added benefits of medical devices. The 
chapter provides explicit guidance concerning the pros and cons of different study 
approaches, given the device specifics and the targeted context, patients and users of a 
device. This guidance enhances ones understanding of the available evidence, helps in 
planning subsequent studies, and improves the dissemination, uptake and application 
of safe and beneficial devices by professionals, patients and other stakeholders. 
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No one-size-fits-all approach
The guidance in Chapter 4 departs from the above overarching principle. It continues 
to make a distinction between two main categories of devices, therapeutic devices 
versus non-therapeutic devices. The latter include diagnostic, monitoring, screening 
or prognostic devices or rather tests. Therapeutic devices usually interfere directly 
with – often targeted – bodily systems and mechanisms. Examples are pacemak-
ers, nerve stimulators, prostheses, breast implants and surgery robots. Therapeutic 
devices treat specific diseases directly, alleviate specific symptoms or complaints, or 
improve daily activities. Diagnostic, prognostic, monitoring or screening test devices 
do not treat or alleviate diseases, symptoms or signs directly, but indirectly. Examples 
include imaging tests, companion diagnostics, laboratory tests, or point-of-care tests. 
Such devices provide information to users, e.g. professionals or patients, which in turn 
direct subsequent actions (e.g. therapies or lifestyle changes) that may lead to bene-
fits, e.g. improved health. However, test devices may also be beneficial because they 
facilitate better therapeutic action by medical drugs (such as companion diagnostics), 
or because they lead to less invasive, burdensome or costly detection of disorders 
(such as screening or point-of-care tests). Finally, unlike therapeutic devices, many test 
devices, e.g. imaging tests, are not intended for just one specific medical condition or 
indication. 
Research approaches to assessing the risks, benefits and performance of both types 
of devices are markedly different. This is why there is no one-size-fits-all approach 
possible for the evaluation of medical devices.
Pathway of device benefits
The variation in devices is reflected in the many different working pathways or mech-
anisms through which each device leads to intended (benefits) and unintended (risks) 
effects on health or health care. Deciding which evidence and research are actually 
needed can first and foremost be enhanced by device developers, manufacturers and 
end-users (i.e. targeted professionals and patients) collaborating and describing in 
detail the potential pathways through which device benefits and risks are likely to 
arise. This working pathway is ideally defined in the very earliest development stages 
or even at the conception of a device. A detailed description of the following issues can 
serve to put evidence from different types of device studies – e.g. technical, safety and 
clinical studies – into a linked or network of evidence perspective:
• the anticipated technical or analytical capabilities of a device;
• the expected unintended and intended effects in the targeted context;
• in whom these effects are likely to occur, e.g. in the targeted individuals/patients, in 
the care providers or in health care at large;
• the anticipated mechanisms through which these potential risks and benefits will 
occur or be achieved in the intended context;
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• the existing care in the targeted context and individuals; 
• the expected time frame in which potential risks and benefits might occur.
The optimal study approach and alternative strategies
To accumulate evidence that the use of a device is safe and has positive effects on 
health or health care beyond those achieved by current practice, one could design an 
ideal study that measures all these aspects directly in the most valid and informative 
way. Chapter 4.4 describes the essentials of such a pragmatic or comparative effec-
tiveness trial. Such randomised comparative effectiveness studies are methodologi-
cally much more challenging for medical devices than for medical drugs. This is due 
to the interplay between technical device complexities, user skills and learning-curve 
issues, all of which influence the benefits and risks of a device and its use. Alternative 
research approaches are needed to evaluate the performance and benefits of device 
use. 
Three main approaches
To generate evidence that the use of a device has benefits, preferably added benefits 
beyond existing care, for the intended individuals, professionals or society at large, we 
can make use of three main study approaches, each with its own merits and vulnera-
bilities. Chapter 4.7 provides detailed guidance on these approaches, complemented 
by numerous examples applied to a variety of medical devices in Appendix IV. 
1. Studies providing direct evidence of the benefits or added benefits of a device use 
for health or health care. 
Such studies basically address all the issues related to the device use as in practice, 
the intended context, a comparison strategy, the relevant effects and timing of these 
effects, and required study size. In addition to the ideal large-scale, long-term, com-
parative effectiveness trial, there are numerous alternative study approaches that may 
also provide direct evidence. These include the traditional randomised designs. But 
they also include more innovative and efficient randomised approaches, as well as 
non-randomised study approaches that can help generate direct evidence about the 
long-term performance and benefits of device use. 
2. Studies providing indirect evidence of the benefits or added benefits of device use 
for health or health care, using a quantitative linked-evidence approach. 
Indirect evidence approaches have in common that they do not directly measure 
the ultimate health outcomes relevant for the targeted individuals, context or users. 
Instead, such approaches focus on outcomes measuring intermediate changes along 
the working pathway of device use. Indirect evidence approaches are very useful in 
situations where the direct evaluation of device use is absent. Their validity depends 
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on how well the ‘intermediate’ outcomes relate to long-term health (or health care) 
outcomes. Linked-evidence modelling approaches link various types of evidence, 
ranging from technical performance to clinical performance or clinical benefits stud-
ies. Quantitative linked-evidence approaches are very relevant for test devices and for 
devices that are modifications of an existing device. They can quantify to what extent 
a minor device improvement leads to health benefits for the targeted individuals, con-
text and users, using study results from previous versions of the device.
 
3. Studies providing indirect evidence on the benefits or added benefits of device use 
on health or health care, using a qualitative linked-evidence approach. 
Evidence of a device’s benefits on long-term health or health care outcomes in a 
specific indication, context or user group, may also be inferred indirectly, for exam-
ple, when adapting evidence from studies conducted in different individuals, patients 
or users or from studies across different indications of device use. Evidence gained 
from technical performance studies, safety studies, studies on related devices or 
preceding versions of the device, should be linked and put into perspective. This again 
requires knowing the working pathway through which device use may lead to benefits 
for health or health care. Inferences about the relevant, long-term health or health 
care benefits (and risks) of device use taken from such qualitative linked-evidence 
approaches do not have the same validity as the approaches discussed under 1 and 2. 
Nevertheless, qualitative linked evidence is currently often considered sufficient for 
market access, and perhaps even for reimbursement decisions.
Complementary issues 
Chapter 5 addresses a number of issues that go beyond the explicit guidance for 
research strategies in Chapter 4, set against the backdrop of European policymaking 
concerning medical devices. These issues include: registries on the use of medical 
devices after market access; user involvement; end-user training; and evaluation of the 
cost-effectiveness (HTA) of devices. 
Recommendations for stakeholders
• For researchers and industry, explicit guidance for assessing the benefits of device 
use is presented in Chapter 4 and illustrated across a wide range of medical devices 
in Appendices Iv and v. If this guidance is properly introduced at an early stage of 
device development, a wealth of suitable research approaches becomes available.
• For regulatory agencies, including Notified Bodies, Competent Authorities, medi-
cal ethical review committees, and health research funders, Chapters 2 and 3 and 
Appendix III discuss general regulatory issues. These agencies will also benefit 
from the general research guidance described in Chapter 4 when judging device 
research proposals and interpreting the results of such research 
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• For health care professionals and hospital boards, the guidance presented in Chapter 
4 is useful for judging what evidence is actually available and what evidence is still 
lacking when deciding to purchase and implement a particular device. 
• For health insurance companies and health care policy at large, Chapters 3 and 5 and 
Appendices III and vI demonstrate that medical devices have their own intrinsic 
issues and challenges. At the same time, Chapter 4 illustrates the level of evidence 
that the various research approaches should produce when judging the potential 
benefits of a particular device.
In conclusion
This report guides stakeholders involved in the evaluation, use, and regulation of 
medical devices, towards choosing the proper approach for assessing the benefits and 
performance of a device for health care, given the specifics of the device. The report 
also offers guidance on how to interpret existing evidence on the risks (safety), per-
formance, and benefits of device use, and how to put this evidence into perspective so 
as to make better-informed decisions regarding the introduction, use, and reimburse-
ment of a device. This guidance ultimately aims to protect society, users and end-users 
against the introduction and use of devices that are ‘unsafe’ or ‘unnecessary’.
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1. scopE, aims and targEt 
rEadErship
1.1 Scope and motivation
Europe faces major long-term societal challenges in health care, for one thing because 
it has an ageing population and consequently a growing proportion of the overall pop-
ulation with co-morbidities that call for high-quality and innovative health care sys-
tems.1 The introduction of medical innovations, including innovative medical devices, 
will be increasingly crucial to efforts to address the challenge of sustained health and 
wellbeing.2 As health is central to people’s lives, access to safe products and good qual-
ity health care services is one of the fundamental human rights. 
In the Netherlands, the Life Sciences & Health sector – one of the country’s key 
economic sectors – encompasses an innovative industry, an excellent knowledge base 
and a long tradition of collaborative and integrative development between industry, 
academia, health care professionals and health policymakers. The sector aims to 
develop effective and cost-effective health solutions and to accelerate their delivery.3 
This involves considering the impact – safety and benefits – of the total health solu-
tion enabled by innovations, complemented by applying more comprehensive Health 
Technology Assessment (HTA) approaches. It is therefore crucial that breakthrough 
medical innovations, including medical devices, demonstrate their clinical and other 
benefits and performance for health care, as well as their safety. 
1  ERAB (2009), Preparing Europe for a New Renaissance – A Strategic View of the European 
Research Area.
2  European Council conclusions on innovation in the medical device sector; 2011/C 202/03.
3  Summary Innovatiecontract Topsector LSH, April 2012.
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1.2 Problem definition – medical devices
According to European Union legislation, the introduction and assessment of medical 
devices depend on a ‘suitable, robust, transparent and sustainable regulatory frame-
work for the benefit of European patients, consumers and health care professionals, 
adapted to the needs of tomorrow’.4 ‘To create the proper conditions allowing safe and 
beneficial (innovative) medical devices to be deployed within a well-functioning inter-
nal market’: that is the motivation for the proposed amendment of the EU’s medical 
device legislation (2012).5 The proposals are meant to maintain consumer confidence 
and adapt to a global market; at the same time, they acknowledge the medical devices 
sector as a key driver of the EU’s economic growth. They place more emphasis on the 
clinical benefits of medical devices. 
What are benefits?
In the current situation of rapid technological advances and spiralling health care 
costs, society expects new medical devices to produce benefits, and preferably added 
benefits beyond existing or prevailing care. Benefits can be broadly defined as: direct 
therapeutic effects on patients; indirect benefits that enhance screening, monitoring, 
diagnosis or prognosis and treatment response; indirect benefits that improve ease 
of use by professionals or other end-users; and benefits in terms of reducing costs or 
the burden on patients associated with medical care. More generally stated, medical 
devices are beneficial if they provide a good and efficient means to address a medical 
problem. The challenge for society, however, is how to demonstrate the added benefits 
of a medical device. 
Establishing the benefits of medical devices poses specific challenges when com-
pared to pharmaceuticals. The current regulation of medical devices primarily focuses 
on safety and product performance. There is a less explicit demand for evidence con-
cerning the benefits for users, targeted individuals or patients, let alone for health care 
at large. New clinical research may not always be necessary to demonstrate a device’s 
benefits, but when such research is needed to produce evidence of a device’s benefits, 
including performance, explicit guidance is required on how to provide such evidence 
and on the pros and cons of different research approaches. 
4  Communication from the European Commission to the European Parliament, the Coun-
cil, the European Economic and Social Committee, and the Committee of the Regions (COM 
(2012)540 final, accompanying two revised regulations).
5  Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on 
in vitro diagnostic medical devices, COM(2012) 541 final; Proposal for a REGULATION OF THE 
EUROPEAN PARLIAMENT AND OF THE COUNCIL on medical devices, and amending Directive 
2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009, COM(2012) 
542 final.
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Evaluation principle
This report starts from the overarching principle that actually drives the evaluation 
and regulation of any health care intervention: 
To generate and accumulate evidence that the use of an intervention, including a medical 
device, is not only safe but also has benefits, preferably added benefits beyond existing 
care, for the health or health care of the intended individuals, patients, professionals or 
for society at large.
The main reason for this report is the current lack of guidance on methods or 
designs that can help collect evidence allowing for the assessment of the benefits (or 
added benefits) of medical devices, which in turn would justify their introduction and 
use in practice and public investment in health care as well as guide reimbursement 
decisions. 
Academy request
In view of the foregoing, the Royal Netherlands Academy of Arts and Sciences (KNAW) 
decided to initiate an advisory project and installed a committee to develop a strat-
egy that would increase awareness of methodological considerations and provide 
guidance concerning the research requirements for evaluating medical technology, 
with a focus on medical devices. The guidance covers existing and novel research 
approaches to facilitating rapid production of the necessary evidence. The resolution 
inaugurating the committee is given in Appendix I. 
1.3 Aim and target readership 
In this report, the Academy aims to respond to the EU’s request that its Member 
States ‘take into account that improved research frameworks and criteria are needed 
to enhance reliability, predictability, speed and transparency in the decision-making on 
the introduction (and reimbursement) of medical devices’.6 To this end, the Academy’s 
Council for Medical Sciences has assumed responsibility for building on its independ-
ent scientific knowledge base. In addition, the research infrastructure for the scientific 
evaluation of medical innovations and technologies is crucial, as concluded by Euro-
pean7 and Dutch (Academy)8 institutions. More specifically:
• the first aim of this report is to provide explicit guidance concerning the appli-
cation of research methods and approaches suitable for assessing the clinical 
6  European Council conclusions on innovation in the medical device sector; 2011/C 202/03.
7  The European Clinical Research Infrastructures Network (ECRIN) is a sustainable, not-for-
profit infrastructure supporting multinational clinical research projects in Europe. 
8  Briefadvies KNAW aan de minister van vWS over versterking infrastructuur klinisch onder-
zoek (2010). (http://www.knaw.nl/smartsite.dws?lang=NL&id=26103&pub=20101058). The 
NFU and ZonMw endorsed the request for a more sustainable clinical research infrastructure.
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performance and benefits or added benefits of medical devices; 
• the second aim is to tailor this research guidance to the various device types and 
specifications as well as the contexts in which and the individuals by whom they 
are used. 
Stakeholders addressed
This guidance intends to support current national and international medical device 
research and review guidelines and planned developments pertaining to this matter, 
aligned with other activities in this area. This guidance thus addresses and is meant 
for various stakeholders and parties involved in the evaluation, use, and regulation of 
medical devices, both in the Netherlands and abroad. These include:
• Researchers and professionals in health care; 
• Medical device industry, and SMEs in particular;
• Notified Bodies (e.g. Dekra);
• Health insurance companies;
• Hospital boards; 
• Regulatory agencies both in the Netherlands (e.g. Health Insurance Board) and 
abroad (e.g. European Medicines Agency);
• Funding agencies in the Netherlands (e.g. ZonMw) and abroad (EU, Horizon 2020);
• Medical ethical review committees (MERC). 
1.4 Breadth and limitations of the report
The committee has made the following decisions concerning the breadth of the advi-
sory report:
• The report covers all types of medical devices for therapy, diagnosis, prognosis, 
screening and monitoring, thus including active implantable devices and in vitro 
diagnostic devices. 
• The report covers the whole life cycle of a medical device. 
• The report intends to make explicit which type of clinical research approaches 
and methods are needed to assess the clinical performance and benefits of devices 
in view of the type of device and intended context. The report does not provide 
a standard clinical research approach (one-size-fits-all approach) suitable for all 
medical devices, but rather tailored to the types and intended context and use of 
devices.
• The report focuses on guidance to support the evaluation of the clinical perfor-
mance and benefits of devices. 
• The report does not specifically address novel Health Technology Assessment 
(HTA) approaches, other than referring to existing activities in that field.
• The report does not intend to change existing rules for market access or reim-
bursement decisions, but only provides guidance to allow for informed clinical and 
policy decision-making. 
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Finally, the committee has explored whether the burden of proof that is required 
for the effectiveness and safety of pharmaceuticals could be applied to non-pharma-
ceutical medical technologies. It concluded that in view of current legislation, and in 
view of the variety of medical devices available, such a discussion should take place 
in the appropriate policy organisations. Accordingly, the report does not necessarily 
depart from a ‘hierarchy of evidence’ approach, but rather promotes a ‘network’ or 
‘linked-evidence’ approach. To this end, the report also considers how to use cumula-
tive datasets, and how to align data collected pre-CE and post-CE approval, in order to 
increase the value of data used to infer the benefits or added benefits and performance 
of a device. In addition, the report discusses parameters for registration that will help 
build clinical evidence. 
1.5 Approach
The committee began by holding several meetings to discuss at length the scope, 
breadth and limitations of the report, as well as the definitions of benefit, added bene-
fit, performance, clinical value, and the aim and target readership of this guidance. The 
discussions were followed by input from stakeholders in the fields of policy, research 
and industry. The input was obtained at several different points by means of a field 
survey, interviews, a parallel session at the KIvI-NIRIA Technology and Care confer-
ence on 11 October 2012,9 and by inviting experts to various committee meetings. 
A list of all interviewees and contributors is provided in Appendix vII. Finally, based 
on the discussions and a review of the methodological literature focusing on medical 
devices, the committee formulated the guidance for research approaches to assessing 
the benefits or added benefits of such devices. 
1.6 In this report
This report has surveyed the potential approaches that can be used to assess the 
health care benefits or added benefits, including performance, of a medical device. 
Chapter 2 gives a concise overview of the variety of medical devices available and the 
consequences this has for research into benefits. Appendix III explains the EU and 
USA legislation on medical devices in more detail. Chapter 3 summarises what stake-
holders believe are the most important issues and challenges posed by medical device 
evaluations. Chapter 4 provides an exhaustive overview of and explicit guidance for 
research approaches that can help demonstrate and infer the benefits and added 
benefits of medical devices for health and health care, given the type, intended context, 
indication and use of the device. This guidance is illustrated by numerous empirical 
examples involving a wide variety of medical devices, detailed in Appendices Iv and v. 
Chapter 5 provides final remarks and recommendations. 
9  http://www.kiviniria.net/a/PAG000009587/.
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1.7 Guidance and recommendations per stakeholder 
The guidance in this report is meant for various stakeholders and parties involved in 
the evaluation, use, and regulation of medical devices. Specifically:
• For researchers and industry, Chapter 4 and Appendices IV and V offer explicit 
guidance for assessing the benefits of device use and the key principles involved. 
The guidance is explicitly illustrated by numerous real-life examples across the 
wide range of medical devices, given a device’s specifics, its intended indication, 
users and targeted individuals or patients. The report distinguishes between 
research aimed at providing direct, quantitative evidence of the added health or 
health care benefits of device use and research aimed at providing indirect evi-
dence of a device’s added benefits, which can be furnished quantitatively or quali-
tatively. Knowledge of the pathway by which a particular device’s risks and benefits 
are addressed, and in whom, is extremely important. If these key principles and pa-
thways are properly addressed at the earliest possible stage of device development, 
then a wealth of suitable research approaches is available. Chapter 4 also provides 
a list of key issues that need to be considered by researchers and industry in any 
study concerning the health and health care benefits of devices.
• For regulatory agencies, including Notified Bodies, Competent Authorities, 
medical ethical review committees, and health research funders, the general 
regulatory issues are discussed in Chapters 2 and 3 and Appendix III. These regu-
latory agencies may also benefit from the general research guidance given in Chap-
ter 4 when judging research proposals on devices and interpreting the results of 
such research. Notably, it is useful for regulatory stakeholders to have a knowledge 
of: the pathways or mechanisms through which the risks and benefits of a parti-
cular device can be addressed and in/for whom; the key issues of device research; 
and the type of evidence that is required in connection with the regulatory require-
ments. This applies not only to national but also to international regulatory bodies.
 
• For health care professionals and hospital boards, Chapter 4 offers guidance 
on ascertaining what evidence is available and what evidence is still lacking when 
making decisions on purchasing and implementing a particular device. This know-
ledge, plus a knowledge of the pathways or mechanisms through which the risks 
and benefits of a particular device are addressed and in/for whom, will increase 
their awareness and motivate them to ask manufacturers for such information, and 
not simply introduce and use devices without such information.
 
• For health insurance companies and health care policy at large, Chapters 2, 
3 and 5, and Appendices III and VI demonstrate that medical devices have their 
own intrinsic issues and challenges. At the same time, Chapter 4 illustrates the 
degree of evidence required in the different research approaches when judging the 
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potential health benefits of a particular device. These approaches can be incorpora-
ted into formal cost-effectiveness or health technology assessments (HTA), tailored 
to the medical device concerned. Only such HTA approaches make it possible to as-
sess the risks and benefits of introducing a health care device into society at large. 
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2. mEdical dEvicEs: 
variEty, stakEholdErs, 
usErs and clinical 
EvidEncE
This chapter summarises the variety of medical devices available and the relevant 
issues involved in evaluating them. The benefits of such devices are described from 
the perspective of the intended user and patient. The chapter further discusses the 
context in which devices are used in health care. It also introduces the medical devices 
industry and briefly reviews the regulatory requirements. The chapter ends with a 
description of the different phases in the medical device life cycle. 
2.1 Definition and indication of variety
Definition
The committee adopted the European Commission definition of a medical device: 
‘any instrument, apparatus, appliance, software, material or other article, whether used 
alone or in combination, including the software intended by its manufacturer to be used 
specifically for diagnostic and/or therapeutic purposes and necessary for its proper 
application, intended by the manufacturer to be used for human beings’ (Directive 
93/42/EC). 
See Appendix III for more details on medical device definitions and legislation. 
In addition to diagnostic and therapeutic purposes, we explicitly note that medical 
devices can also be used for screening, prognostics, and disease or therapy monitor-
ing. This definition actually encompasses a very broad range of medical devices. While 
maintaining this breadth, it goes without saying that the guidance for clinical research 
approaches provided in this report does not truly cover all medical technology or 
innovations, but focuses on those used for therapy, diagnosis, prognosis, screening or 
monitoring. 
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Variety of medical devices
There are many different types of devices in different classes, ranging from medical 
implants and medical aids to in vitro diagnostic tests and medical imaging, to mention 
only a few. Of the almost 500,000 different medical devices, the majority are relatively 
simple, e.g. a disposable syringe or an ear thermometer. various devices are complex, 
however, and reflect the latest advances in medical technology, for example new imag-
ing equipment, various heart, vessel, bone and joint implants, and advanced point-
of-care lab tests. Medical devices are thus intrinsically diverse: their lifespan varies 
widely, with extremes ranging from a few seconds for disposable devices to several 
decades for some implantable devices and medical equipment. Some medical devices 
have expiration dates, whereas other long-lived individual equipment may undergo 
replacement of components. 
Variety in medical device use
Medical devices are used for a variety of diagnostic, prognostic, screening, monitoring 
and therapeutic indications. Consequently, there are differences in the level of risk 
and in the regulatory systems used to manage those risks; in the manufacturing costs 
and sale prices; in the standards and in the nomenclature systems; and in the various 
approaches used to determine their safety, performance, and benefits.10 The devices 
market stretches far beyond the professional care relationship. Devices are also sold 
over the counter. They may be developed for use in laboratories, in first aid kits, in kin-
dergartens and in homes for the elderly. In the coming years, the market for medical 
devices will become even more crowded. Companies are preparing a range of self-test-
ing devices, and major European multinationals such as DSM, Philips and Siemens are 
also investing a great deal of effort in health care devices and other types of medical 
support, often intended for primary and home care and for patient self-management. 
The question is how to deal with the wide variety of existing medical devices, which is 
set to increase, perhaps in ways that we cannot anticipate. 
2.2 Regulatory bodies
The variety of medical devices available and the growing number of technological 
innovations are also having a significant impact on the methodologies and types of 
study needed to collect evidence in order to ensure the introduction not only of ‘safe’ 
but also of ‘useful’ and ‘beneficial’ devices in health care. Box 2.1 lists some key defini-
tions and concepts of medical device research. 
Legislation imposes an obligation to assess the balance between risk and 
performance, where performance means the ability of a device to achieve its intended 
10  Medical devices: managing the mismatch: an outcome of the priority medical devices project 
(2010), World Health Organisation. ISBN 978 92 4 156404 5.
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purpose (or use) as claimed by the manufacturer. Performance is thus not necessarily 
clinical performance, let alone clinical or health/health care benefits. Clinical evalua-
tion is, moreover, not needed for all medical devices. The variety of different devices 
makes it difficult if not impossible to define a common (one-size-fits-all) framework 
for clinical investigations evaluating the risks and performance of a device (and its 
use), let alone to define its benefits or added benefits for health care. 
box 2.1 tErminology, concEpts and principlEs usEd for  
mEdical dEvicEs
The definitions given below are derived from the Global Harmonization Task Force 
(GHTF) and its follow-up initiative, the International Medical Devices Regulators Forum 
documents. There are no restrictions on reproducing this information; however, it should 
be noted that reproduction does not convey or represent an endorsement of any kind by 
the GHTF.
Clinical evidence – The information or clinical data that supports the scientific validity 
and performance (analytical performance and, where applicable, clinical performance) of 
a device when used as intended by the manufacturer.
Analytical/Technical Performance – The ability of a device to correctly detect or meas-
ure a particular analyte.
Clinical evaluation – The assessment and analysis of clinical data pertaining to a medical 
device to verify the clinical safety and performance of the device when used as intended 
by the manufacturer. Clinical evaluation is an ongoing process; information about clinical 
safety and performance (e.g. adverse event reports, results from any further clinical inves-
tigations, published literature, etc.) should be monitored routinely by the manufacturer 
once the device is available on the market and the benefits and risks reassessed in light of 
this additional information.
Clinical investigation (synonymous with ‘clinical trial’ and ‘clinical study’) – Any sys-
tematic investigation or study in or on one or more human subjects, undertaken to assess 
the safety and/or performance of a device.
Clinical utility – A concept generally used for diagnostic devices that refers to the likeli-
ness of the test significantly improving the health outcomes of the targeted individuals. In 
other words, the capacity of the test to rule in and/or rule out the disorder of interest, and 
to facilitate a decision to adopt or to reject a subsequent (e.g. therapeutic) action. Clinical 
utility is an increasingly common concept in health care, but one that lacks an agreed for-
mal definition or conceptualisation. The term is commonly used as a synonym for clinical 
effectiveness.
Clinical performance – The ability of a device to yield results that are correlated with a 
particular clinical condition or a physiological state in accordance with a target popula-
tion and intended user. Interventional clinical performance is where the test results may 
influence patient management decisions and/or may be used to guide treatment.
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EU legislation on medical devices in brief
A diagram of medical device regulatory requirements is presented in Figure 2.1. More 
detailed explanations on the medical device regulatory framework are available in 
Appendix III. 
EU legislation concerning medical devices is subject to constant improvement, with 
more emphasis on clinical evaluation and on obtaining data through clinical investiga-
tions.11 The relevant directives and MEDDEv guidance documents clearly state when 
investigations are needed to obtain sufficient evidence on clinical benefit, but not how 
11  See http://ec.europa.eu/health/medical-devices/documents/guidelines/ for an overview 
of all guidance documents. See http://ec.europa.eu/enterprise/policies/european-standards/
harmonised-standards/medical-devices/ for harmonized standards for industry.
Figure 2.1 Diagram of EU legislation concerning medical devices.  
Blue boxes at the left represent the directives covering medical devices (MD, including In vitro 
devices or IVD, and active implantable medical devices or AIMD), and the Guidance indicating how 
to interpret the legislation (MEDDEV Guidance). In a lighter color, the four risk categories are de-
picted from low-risk (class I) to high-risk (class III) devices. To obtain market access (i.e. a CE mark 
in blue circle), a decision from the relevant authorities (in grey) is required, which depends on 
compliance with the directives. The higher the risk, the more requirements there are with regard 
to safety, performance, and clinical evaluation (in black). For lower risk devices, clinical evaluation 
may depend on the literature or existing data; for higher risk devices, new clinical investigations 
are requested. 
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this should be done; that is the motivation for this report.12 All this, however, does 
not necessarily mean that the directives are properly enforced. It is up to the Notified 
Bodies and Competent Authorities to demand new clinical investigations or not. The 
Working Group on Clinical Investigation and Evaluation (CIE) welcomes methodolog-
ical contributions and a rationale for clinical research on medical devices.13 The fact 
that it is rather difficult to establish the clinical benefit of device use poses even more 
challenges when it comes to assessing the relative or added benefits (effectiveness) of 
a device compared with another device or with care as usual.
Notified Bodies in the EU
When the regulatory process is more stringent, the Notified Body must implement and 
impose these stricter requirements. Notified Bodies in Europe are formally autono-
mous from the Competent Authorities. In Europe, they have been organised to discuss 
the European guidelines.14 The Notified Bodies take a somewhat technical approach, 
focusing primarily on device safety and technical performance. One major problem, 
however, is that the quality of the Notified Bodies in the Member States varies widely, 
affecting the quality of the decision-making process across countries. In addition, 
the Notified Bodies’ internal procedures are often not very transparent. It is easier to 
access the market in some EU countries than in others, and industry can choose their 
own Notified Body. The EU is currently addressing the uneven quality of the Notified 
Bodies. 
USA legislation
In the case of breakthrough medical device innovations, the regulatory requirements 
in the USA are stricter than in the EU. In the USA, a Pre Market Approval (PMA) for 
new devices is required. But the impression is that in practice the equivalence argu-
ment is also used regularly to replace a PMA by the more flexible 510(k) procedure.15 
There is a tendency for industry to choose Europe for innovative new devices so that 
they can enter the market faster, whereas the USA 510(k) procedure is used more 
frequently for line extensions (modifications) of existing devices, building upon equiv-
alence arguments.16 For more on the differences between EU and USA device legisla-
tion, see Appendix III. 
12  MEDDEv 2.7.1, see also Annex 3.
13  http://ec.europa.eu/health/medical-devices/dialogue-parties/working-groups/index_en.htm.
14  The European Association for Medical Devices of Notified Bodies; http://www.team-nb.org/.
15  There is a fundamental difference between the PMA and 510(k) pathways. In a PMA 
review, the FDA determines whether the device is reasonably safe and effective for its intended 
use. In a 510(k) review, the FDA determines whether the device is substantially equivalent to 
another device whose safety and effectiveness may never have been assessed.
16  Congressional Research Service Report for Congress: FDA Regulation of Medical Devices. J.A. 
Johnson, June 25, 2012.
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Global Harmonisation
Although there has been progress in the worldwide standardisation of medical device 
regulation, the process is not finished and differences between the USA and Europe 
remain. The Global Harmonization Task Force (GHTF), and its follow-up initiative 
the International Medical Devices Regulatory Forum (IMDRF),17 will continue col-
laborating with the WHO on harmonising regulatory practices, which will eventually 
be implemented in national legislation. They recognised that the first step towards 
international harmonisation in the regulation and convergence of data requirements 
for medical devices is to arrive at a common terminology, concepts and principles. The 
GHTF’s five study groups, of which Study Group 5 focused on clinical safety/perfor-
mance, created several guidance documents providing key definitions and concepts for 
medical devices (see also Box 2.1).
Postmarketing surveillance
Postmarketing surveillance (PMS) is obligatory in both EU and USA legislation and 
should include a follow-up involving broader user populations to further build datasets 
on the device. Manufacturers are responsible for PMS, but the Notified Bodies should 
supervise, in collaboration with the Competent Authorities. Our interviewees felt that 
PMS supervision could improve in individual Member States and in the registries (e.g. 
Eudamed) (see Chapter 3). Registries could help amass the knowledge needed to prop-
erly review the larger follow-up studies, as we will discuss in Chapter 5. 
Reimbursement of devices in the Netherlands
Reimbursement of medical devices in a Dutch hospital setting is part of an agreement 
covering ‘hospitals buying’ and ‘industry delivering’. Hospitals sometimes do purchase 
devices even when the evidence for clinical benefit, let alone cost-effectiveness, is 
insufficient (see Chapter 3 for example). Appendix III provides more background on 
the Dutch reimbursement system. Rising health care costs have revealed an apparent 
need for evidence-based medicine, cost-effectiveness, and general health technology 
assessment. This is likely to continue in the coming years, largely due to the continu-
ous advances in medical technology rather than increasing life expectancy.18 
 
17  http://www.imdrf.org/.
18  CPB Netherlands Bureau for Economic Policy Analysis (www.cpb.en), published 21 March 
2013.
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2.3 Medical device industry 
Given the variety of different medical devices available, the medical devices market 
is equally diverse, making it difficult to provide a general description. The market 
dynamics differ from those of the pharmaceuticals market, particularly with regard 
to the life cycle of medical devices and the innovation processes (see also Appendix 
VI). From conception to obsolescence, many medical devices have relatively short 
product cycles of 2.5 years on average (ranging to up to 6 or 7 years for imaging 
devices). Often, they undergo incremental modifications over time, renewing the cycle. 
Improved versions of a basic prototype may have even shorter commercial life cycles. 
Patents also play a different role than in the pharmaceutical sector: the focus is more 
on freedom to operate than exclusivity. Generally, many patents are needed to protect 
all the innovations in one medical device. But there are also many devices for which 
patents are not critical. The return on investment is based on quick market access, and 
the increase in the number of new patents applications coincides with the advent of 
new business models (like pay per use). 
The medical devices industry (both large companies and SMEs) often collaborates 
closely with medical doctors in hospitals who are involved in clinical studies. But 
similarly to the pharmaceutical sector, when a ground-breaking new device enters the 
market, safety and performance requirements are crucial; clinical research is com-
pulsory, and it is expensive to build up dossiers of clinical research data. The medical 
device sector in Europe comprises around 18,000 SMEs.19 A large number of new and 
innovative medical devices are thus expected to enter the market. Globally, SMEs com-
prise about 80% of the market.20 
2.4 Health care professionals
The development of new medical devices and their subsequent introduction into the 
health care system is often the result of close collaboration between developers and 
health care professionals. Depending on the type of device, health care professionals 
are frequently involved in different stages of the medical devices life cycle in the fol-
lowing ways (see also Figure 2.2): 
a. as co-developers, in the device development phase. With regard to clinical research 
involving a prototype, this requires the approval of the local medical ethical review 
committee (MERC) as well as of hospital instrument services.
b. as researchers, participating in the clinical evaluation/implementation phase. 
This takes place in the context of medical scientific research that is often (partly) 
19  Council of the European Union; Council conclusions on innovation in the medical device 
sector; 3095th EMPLOYMENT, SOCIAL POLICY, HEALTH and CONSUMER AFFAIRS Council meet-
ing- Health issues – Luxembourg, 6 June 2011.
20  http://www.eucomed.org/newsroom/66/57/Enabling-European-medical-technolo-
gy-SMEs-to-innovate?cntnt01homepage=yes&cntnt01origid=103.
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sponsored by industry.
c. as users of a new device in regular health care. This type of use cannot be com-
pared to device use in a research setting (under b), which usually involves well-
trained researchers, professionals and a support team.
Knowledge about possible alternative clinical research approaches to assessing 
the health benefits and added benefits of medical devices is relevant for all health care 
professionals and researchers. It is equally relevant for the committees (MERCs, but 
also funding agencies and regulatory agencies) that review device research propos-
als and device research results to know about the potential research approaches to a 
given device and what evidence is actually produced by which research approach. This 
was part of the motivation for the present report. 
User interference, learning curve aspects, and user risks are particularly relevant 
in the case of inexperienced use in regular care. To tackle this issue, the Dutch Order 
of Medical Specialists (OMS) is collaborating with the Dutch Health Insurance Board 
(CvZ) to prepare a guideline on the safe introduction of new medical devices in regular 
health care (see also Chapter 5). In this report, we therefore do not address these 
types of risks in detail.
2.5 The user and health policy perspective
The user perspective is important when assessing the performance of a device, largely 
because many, if not most, devices have no direct therapeutic use or benefit for the 
targeted patients or individuals (as we will explain in detail in Chapter 4.3). These 
notably include devices used for diagnostic, screening, monitoring or prognostic pur-
poses. Such devices commonly consist of tests that generate information, which in turn 
directs further clinical, therapeutic or lifestyle actions that subsequently may change 
patients’ health. The health effects are thus indirect. Such devices sometimes provide 
abstract information, which first needs to be interpreted by professionals before 
decisions can be made and the health consequences for the patient can be inferred. 
Interpretation and subsequent decision-making depend not only on the properties 
(e.g. performance) of the device, but also on the judgment or expertise of the profes-
sional, who takes other parameters into account as well.
Consumers and professional perspectives
Medical devices are used by:
1. the patient or consumer;
2. the professional or caregiver.
The user perspective is not always clear and this impairs any assessment of risk 
and performance and hence the risk/benefit ratio. For example, consumers may 
influence the risk/benefit ratio by their use of and adherence (or non-adherence) to 
the device. If a medical doctor is the user, there is a difference one who is trained and 
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one who is not trained. Furthermore, there may be differences between professional 
and non-professional (e.g. patient) user perspectives for the same device.21 Another 
relevant factor in this regard is that devices are used in different settings: in hospitals 
by experts; in decentralised settings by professionals; or at home by professionals or 
patients/clients.
Eventually, the individuals or patients in or for whom the device is to be used need 
to be assured that such use will have a positive risk/benefit ratio. There should be 
evidence of the positive (intended) and negative (unintended) effects of the device in 
the specific context of the individuals in which the device is to be used. In addition, the 
device should – ultimately – have benefits beyond prevailing care. 
The health policy perspective
Today, with efforts being made to contain health care costs on the one hand and 
introduce new, often costly medical devices on the other, it is important that market 
access and reimbursement are provided for those medical devices that are (relatively) 
safe and – ultimately – lead to improvement of patients’ or clients’ health or of health 
care at large. The more invasive, burdensome and perhaps costly the devices are, the 
greater the need to provide evidence that the device has a positive risk/benefit ratio. 
In other words, there should be a balance between added benefit and extra burden, 
risks or monetary costs. From a monetary cost perspective, a less advanced, cheaper 
device that carries a similar risk and offers a similar performance or benefits may be 
acceptable as well. 
In summary, the direct or indirect benefits of a medical device, the type of setting, 
user and his or her experience in handling a device, the regular adaptation of previous 
versions, and the short life cycle all go to create a dynamic process that increases the 
complexity of clinical research design. 
2.6 Clinical evidence 
The committee takes the view that regardless of the type of device, evidence of some 
form of benefit to be gained from using the device should be addressed. The commit-
tee has therefore introduced (in Chapter 1.2) the overarching principle that actually 
drives the evaluation and regulation of any health care intervention, including medical 
devices: To generate and accumulate evidence that the use of a device is not only safe but 
also has benefits, preferably added benefits beyond existing care, for the health or health 
care of the intended individuals, patients, professionals or for society at large.
How much evidence, however, and what form it should take may differ according to 
21  Hauber, A.B, et al. (2009). Older Americans’ risk-benefit preferences for modifying the 
course of Alzheimer disease. Alzheimer Dis Assoc Disord, 23:23-32; Nigel K. Arden, N.K, et al. 
(2012). How do physicians weigh benefits and risks associated with treatments in patients with 
osteoarthritis in the United Kingdom? J.Rheum., DOI:10.3899.
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the device’s risk classification and its life cycle phase: is it a breakthrough device that 
is ready for a first-in-man study, or is it the fifteenth version of a device that already 
has a CE marking and whose precursors are regularly being used in health care? 
Regardless of the phase, there are three crucial aspects to bear in mind when design-
ing research into the benefit or added benefit of devices. 
1. Safety: In essence, the need to collect evidence is more important for devices 
associated with a higher risk during device use. The EU concept of risk classification 
(see Appendix III) depends on the intended use of the device and distinguishes four 
classes of risks, ranging from low to high. A risk category is linked to specific require-
ments for manufacturers to demonstrate safety and performance. Safety according 
to the Directive (MDD 93/42/EEC) means that the clinical condition or the safety of 
patients, or the safety and health of users, or, where applicable, other persons, is not 
compromised. Furthermore, it means that any risks that may be associated with the 
devices intended use constitute acceptable risks when weighed against the benefits for 
the patient and are compatible with a high level of protection of health and safety. 
2. The performance and thus benefit of medical devices is heavily influenced by 
the intended use and the mode of action. Medical devices produce mainly local and 
physical effects on the body. They may contain single or multiple active components, 
and both single (e.g. disposables) and multiple uses by one user (e.g. a blood glucose 
self-monitoring device) of the same device are possible. In fact, there are often mul-
tiple users of the same device (e.g. most imaging devices). Cessation of use can be 
simple for external devices and temporary implants, but it can be complex as well (e.g. 
for long-term implants). 
3. User interference. As stated above, the safety and performance of a device depends 
not only on the device itself but also on how it is used. The user interface of a medical 
device is often not direct (device–patient), but in many cases involves an indirect or 
intermediary (device–operator–patient) situation. There is often a ‘learning curve’ 
associated with the use of medical devices, particularly in the case of complex high-
tech devices, and a need for technical training and support. This may have a major 
impact on the benefits for the intended patients or individuals or their health out-
comes. User interference becomes even more crucial when a medical device is applied 
in a wider population than it was originally evaluated in, emphasising the need for 
extensive postmarketing surveillance. In addition, the health benefits or outcomes are 
influenced by the fact that heterogeneous populations are tested. There is an inherent 
need to take both user interference and heterogeneous populations into account when 
designing research and judging the benefits of the device. 
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Added health benefit of a medical device 
As we explain in Chapter 4, the term ‘added health benefit’ can be interpreted in a 
number of ways but it is commonly accepted to mean that the device demonstrates an 
improvement in a certain parameter of health compared to some alternative manage-
ment or intervention, e.g. no intervention or the prevailing intervention. Added health 
benefit may also include non-inferiority to a known effective intervention but with 
less burdensome or more efficient care. In other cases, added benefit includes a clear 
improvement in the time required to detect disease, leading to earlier effective inter-
vention, which in turn leads to an improvement in the patient’s symptoms or quality of 
life.22 
Prominent questions concerning the investigation of a device’s added benefit are:
•  Which study results or evidence needs to be produced given the type of device and 
its intended use?
• Which study designs may be used, and what are their pros and cons?
• Which patients or clinical context and indication may need to be studied?
• Which types of health benefits or outcomes need to be studied?
• Which type of data analysis is recommended?
• Which study results or evidence needs to be produced?
• When and how should these studies be set up in view of the life cycle and the type 
of medical device (e.g. diagnostic, screening or other type)?
All these questions are discussed and illustrated in detail in Chapter 4. The basic con-
cept of evaluation is similar to that of pharmaceuticals, but in practice medical devices 
have a larger number of variables (see Appendix VI).
2.7 The medical device life cycle and the stakeholders in-
volved
We can divide the medical device life cycle into four discrete phases. Each of these 
phases has specific characteristics that have consequences for the way in which the 
added clinical benefit can or cannot be determined. Figure 2.2 presents an overview of 
the phases, the stakeholders involved and the key requirements.
Phase 1: From idea to product
Phase 2: Experimental use in practice
Phase 3: Uptake in regular care
Phase 4: Long-term implementation and reimbursement
The transition between the first and the second phase is the CE certification allow-
ing market access (see Appendix III). The transition between the second and the third 
phase is the gradual dissemination of devices into regular care, imposing new issues 
22  End points in cancer clinical trials and the drug approval process, Richard L. Schilsky. Clin 
Cancer Res April 2002 8; 935. 
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with respect to safety, performance and benefits. The essential difference is that phase 2 
is research-based, whereas phase 3 is implementation-based. Long-term implementa-
tion of a device in regular care and its reimbursement often depend on the assessment 
of its cost-effectiveness. 
From idea 
to product
Experi-
mental use 
in health 
practice
Reimburse-
ment
Uptake in 
regular 
care
• Responsibility industry or entrepreneurial researcher
• Safety & performance, clinical investigation limited
• EC regulation in revision
• Researcher/company: approval research design via MERC
• Safety, performance, AND benefit in selected population
• Responsibility hospitals & healthcare professionals
• Safety, performance, benefit AND quality in the context 
of other ‘users’ 
• Evidence based medicine, HTA
• Safety, performance, benefit, quality AND (cost-)effectiveness 
(also in comparison to practice as usual)
Figure 2.2 Phases in the medical device life cycle
Each of the phases involves different stakeholders and different needs. In phase 1, 
industry, researchers and, eventually, the Notified Bodies and Competent Authorities 
are involved. The medical ethical review committees (MERCs) and professionals may 
also be involved when investigating a device for its safety and performance in a new 
clinical investigation. 
In phase 2, health care professionals, researchers and industry are directly 
involved; indirectly, the stakeholders are the medical ethical review committees, 
hospital instrument committees, and health research funders as representatives of 
intermediary organisations.
Phase 3 sees an increasing number of health care professionals, institutions and 
boards getting involved, such as health insurance boards and companies, hospital 
boards, health care professional organisations, and health research funding agencies. 
Industry continues to play a role in introducing a new device into regular practice. 
In phase 4, the stakeholders include health care quality institutes, health insurance 
boards, health insurance companies, hospital boards, funding agencies as well as var-
ious other regulatory and advisory agencies, for example policy advisors who advise 
on developing user protocols and guidelines and advisory agencies for reimbursement 
decisions. 
Regulatory approval is not sufficient for the successful implementation of a new 
device in health care. In the current era of evidence-based medicine, the benefits and 
36 evaluation of new technology in health care
indeed health care-related economic considerations need to be taken into account. 
They should ideally be included from the early phase of a new device’s development. 
More comprehensive health technology assessment approaches should cover all 
phases to consider the new device’s total impact on health care.
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3. stakEholdEr viEws 
on mEdical dEvicE 
innovation and 
Evaluation
In this chapter we consider the issues and challenges raised during our field survey 
by various stakeholders who are involved in developing, evaluating, introducing and 
using medical devices. The stakeholders can be roughly divided into four categories 
that are closely related: industry, health care professionals (e.g. medical doctors and 
nursing staff), regulators, and targeted patients and clients (users). Their perspec-
tives were presented in Chapter 2. The field investigation took the form of interviews, 
invitations to participate in committee meetings, and feedback from the representa-
tives of the various parties at a health technology conference. A list of the participants 
involved in the field investigation is provided in Appendix VII. 
In this chapter, we begin (in Section 3.1) by discussing general points raised by the 
stakeholders concerning the evaluation of medical devices. These general points are 
summarised in the context of the device’s life cycle. Section 3.2 discusses more issues 
and challenges raised by the stakeholders with regard to establishing evidence of the 
performance and added clinical or other benefit of medical devices. The list of issues is 
not exhaustive.
Both general and specific issues and challenges must be taken into account when 
providing guidance for clinical investigations of medical devices. The field survey 
indicated that a one-size-fits-all approach for clinical investigations of medical devices 
is not feasible: the variety of medical devices available and their market sector require 
a flexible approach to clinical investigation. 
What do we know about clinical research involving medical devices?
Given the increasingly stringent clinical requirements for medical devices, both in the 
EU (amendment of directives) and in the USA (FDA), we are witnessing a clear 
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tendency towards more transparency in clinical device research. The website of the US 
National Institutes of Health (NIH) provides a register of clinical studies (both closed 
and on-going), including clinical studies of devices, conducted worldwide (see Box 
3.1).23 The majority of clinical trials registered involve pharmaceutical products. In the 
Netherlands, clinical studies are registered in the Dutch trial register.24 Appendix IV 
gives numerous examples from these registries to illustrate each clinical research 
approach (discussed in Chapter 4) that can be used in evaluating a device’s benefits 
or added benefits and performance. In this chapter, we give some of the examples 
described in Appendix Iv to show the limitations and potential of clinical research 
involving medical devices. 
3.1 General issues per phase of the life cycle of medical devices 
This section summarises general issues and bottlenecks per phase of a device’s life cycle 
(Chapter 2.7; see Figure 2.2) that were addressed by various stakeholders. 
Phase 1 From idea to product
• There are regulatory guidelines and harmonised standards for assessing safety 
and performance and sufficient awareness that compliance with these is required 
for CE approval.25 There is also a growing emphasis on clinical evaluations in all 
the regulatory guidelines, but no explicit guidance on designing, conducting and 
analysing clinical investigations for manufacturers, researchers, policymakers and 
health care professionals. 
23  http://clinicaltrials.gov/ct2/resources/trends, accessed 18 April 2013.
24  http://www.trialregister.nl/trialreg/index.asp, accessed 24 January 2014.
25  See http://ec.europa.eu/health/medical-devices/documents/guidelines/ for an overview 
of all guidance documents. See http://ec.europa.eu/enterprise/policies/european-standards/
harmonised-standards/medical-devices/ for harmonized standards for industry.
Box 3.1
ClinicalTrials.gov currently lists 143,826 studies with locations in 184 countries. Of these, 
around 10% (14,473 studies) involve medical devices (using the key word ‘device’), and 
a roughly similar amount involves surgical procedures. Eighty per cent of the studies reg-
istered are interventional, whereas 20% are observational. The majority of these studies 
have been or are being performed in the US (6145) and Europe (4523).
The Dutch Trial Register lists 4,159 studies. Of these, 35 (<1%) involve a device (using the 
key word ‘device’). Other key words relevant for medical devices are: imaging (in 108 stud-
ies); hip (76); monitoring (70); surgical (57); stent (54); diagnostic (47); implant (31); 
biomarker (23); prognostic (14); robot and in vitro (8 studies each).
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• Knowledge about useful, alternative designs or approaches to clinical research 
is relevant for all health care professionals and device researchers. This was also 
the reason behind a recent report on alternatives for randomised clinical trials in 
research into the effect of therapeutic l interventions, which was commissioned by 
the Netherlands Organisation for Health Research and Development (ZonMw).26 
Chapter 4 and Appendix Iv build on this overview.
• In many cases of CE certification, a clinical study is not necessary. Companies use 
lab or benchmark tests whenever possible by claiming that a device that has been 
altered incrementally does not aim to address a different context, users or patients 
than the original device. This is often considered sufficient by the Notified Bodies 
and other regulatory agencies, although the concept of equivalence (see 3.2 and 
Appendix III) is not always used appropriately, according to the Dutch Health Care 
Inspectorate (IGZ).27 
• The quality of the Notified Bodies in Europe differs from one country to another, 
and they do not focus specifically on clinical evaluations, hampering enforcement 
of the changing legislation.
• More awareness is needed of the challenge involved in studying new types of med-
ical devices for which the existing clinical research paradigm is less suitable. Exam-
ples are: combination products, self-management products, AMTPs. For these types 
of medical devices, a ‘network of evidence’ approach may be more appropriate.
Phase 2 Experimental use in practice
• In the Netherlands, the local medical ethical review committee (MERC) and instru-
mentation departments of hospitals frequently request a CE certificate for the 
clinical study plan to guarantee the safety of the product. The majority of MERC 
requests for medical devices already have a CE certificate. This may mean that 
clinical investigations have been carried out outside the Netherlands as part of the 
CE certification process, or that CE certification focuses primarily on performance 
rather than on the clinical benefits of device use. 
• Clinical research (after CE certification) on the benefits of a device meant to 
encourage its use and uptake suffers from inadequate knowledge of the possible 
research approaches, each with its pros and cons. 
• Having a large number of incremental changes/line extensions/new versions of an 
existing device results in many small datasets, each of them inadequate as statisti-
cal evidence.
• Clinical studies of devices by health care professionals often take place in the 
26  Alternatieven voor Randomized Clinical Trials in onderzoek naar de effectiviteit van inter-
venties. M. Langendam, L. Hooft, R. Scholten, P. Bossuyt. Dutch Cochrane Centre (DCC), Acade-
misch Medisch Centrum, Amsterdam, February 2013.
27  Inspectie voor de gezondheidszorg, May 2013. Metaal-op-metaal-heupimplantaten. De 
keten voor de kwaliteitsborging van medische hulpmiddelen moet beter functioneren. 
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context of scientific research that is sponsored (at least in part) by industry. In 
these situations, the health professionals usually receive extensive training in how 
to handle a device safely, and the conditions under which the intervention is used 
are standardised as well. For devices in cardiology (stents and pacemakers: both 
class III devices, see Appendix III), rehabilitation care and orthopaedics, clinical 
research is fairly large-scale. The main channel of communication for this type of 
clinical research is through scientific publications. 
Phase 3 Uptake in regular care
• There are no systematic registries for postmarketing surveillance and long-term 
benefit assessment of devices.
• Uptake of devices in regular care is hampered by a new set of safety issues related 
to their use by untrained professionals. Inexperience in handling a device creates 
another type of risk and may lower the expected benefits, negatively influencing 
the benefit/risk ratio of a device. User interference and learning curve aspects are 
particularly relevant in the case of inexperienced use in regular care. To tackle this 
issue, the Dutch Order of Medical Specialists (OMS) is collaborating with the Dutch 
Quality Institute and the Health Insurance Board on a guideline for the safe intro-
duction of new medical devices in regular health care (see also Chapter 5.1). We 
therefore do not address these risks in detail in this report. 
Phase 4 Long-term implementation and reimbursement
• Lack of transparency and openness about regulatory practices between countries.
• Clinical benefit is usually discussed at the point where reimbursement (and thus 
cost-effectiveness) is being considered, and not when the device is being intro-
duced. 
• In response to the rising cost of health care and society’s need for devices that 
are not only safe but also beneficial (especially when they are expensive and/or 
high-risk), calls are growing for a framework of research approaches to assess the 
benefits and added benefits of devices and for health technology assessment (HTA) 
models. 
3.2 Issues related to the clinical evaluation of devices 
Table 3.1 lists the issues or challenges mentioned by the various stakeholders, related 
to the clinical evaluation of medical devices. Setting up a traditional randomised clini-
cal trial (see Appendix IV) of a medical device is considered complicated because, e.g.:
• for many devices (e.g. prostheses, robots and implants), it is not possible to per-
form double-blind randomised studies;
41stakeholder views on medical device innovation and evaluation
• the benefits often vary considerably due to user interference and expertise;
• there are often multiple effect and safety outcomes to be defined;
• multiple outcomes are not of equal significance. 
Accordingly, it is often hard to formally assess the risk/benefit ratio of a device 
using the traditional intervention research methodology used for pharmaceutical 
products. Below, we describe the issues listed in Table 3.1 in more detail without nec-
essarily providing a solution for each issue.
1. No specific medical indication
The intended application of a medical device is often broad and not limited to a spe-
cific medical indication. A good example is imaging devices (CT, PET, SPECt, or MRI 
scanners) that are used for diagnosis and monitoring of a wide range of medical condi-
tions, e.g. in cancer and cardiology. However, when an improved version of the device 
shows more detail, the consequences for patient management and thus for patients’ 
health are not always straightforward. Is it always beneficial to see more, or does it 
lead to over-diagnosis and overtreatment?
Table 3.1 Issues and challenges in the clinical evaluation of medical devices, addressed by 
the stakeholders and illustrated by examples of medical devices.
Issue or challenge Medical device example Clinical research example 
1. No specific medical indica-
tion: general purpose devices 
Imaging devices – phantom 
images
Postmarketing outcome study 
(Appendix  Iv C1.1)
2. User interference; long-term 
adverse effects
Hip implants Device-based registries (see 
Appendix Iv B2.2.1)
3. Co-development diagnostic 
marker and pharmaceutical
Companion diagnostics Herceptin and many more to 
follow
4. Equivalence and incremental 
improvement
Therapeutic (surgical) support 
device
Case series, controlled before and 
after (Appendix Iv B1.2)
5. Combination products:  
Medical device and pharma-
ceutical in one product
Inhaler devices for asthma and 
COPD
Adaptive trial design (Appendix 
Iv A4)
6. Self-management products 
and online monitoring
Mobile phone health applications Guidance for Mobile Medical 
Applications (FDA)
7. Expensive devices and 
cost-effectiveness
da vinci robots Large-scale follow-up studies
8. The balance between 
regulation and speed of 
introduction
Stem cells (Advanced Medicinal 
Therapeutic Products)
Conditional market approval in 
combination with pivotal trials
9. Health Technology  
Assessment (HTA)
HTA International Policy Forum 
and Dutch Innovative Medical 
Devices Initiative (IMDI)
NICE (UK)
On the one hand, it may not be sensible to require new clinical investigations for each 
new version or small adaptation of an existing imaging device. A small increase or 
adaptation of such a device may only need a few calibration or recalibration studies 
and tests by imaging phantoms, or a comparison with computer-generated results 
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followed by subsequent inter-observer and intra-observer variation studies.28 
On the other hand, when the device improvements are so major that it seems neces-
sary to carry out a clinical investigation in order to demonstrate that the use of a new 
imaging device is beneficial for patient management and ideally for patients’ health, 
the question is what type of research will show these benefits. Clearly, from a health 
perspective, it is relevant to show that the benefits of using the new imaging device are 
at least equal to the benefits of existing care.
Example C1.1 in Appendix 4 shows a single device study to assess the benefit 
(defined here in terms of percentage of accurate diagnosis) of PET-FDG in determining 
regional nodal spread of breast cancer (ClinicalTrials.gov/ NCT00201942) by com-
paring it to the more burdensome and cumbersome reference standard involving the 
histologic examination of all excised (sentinel and non-sentinel) axillary lymph nodes. 
2. The role of user interference and long-term adverse effects
When the user of a medical device is a professional, user interference may influence 
the outcome of device use. The more experienced and trained the professional, the 
less influence the user will have on the potential benefits and risks of device use. One 
example of the influence of user interference on device benefits and risks is total hip 
replacement surgery. Hip-replacement devices are classified in EU risk category IIB 
(see Appendix III), which means that they do not need to be formally evaluated in 
patients before entering the market. However, long-term follow-up studies recently 
revealed the metal-to-metal hip implants wear out more quickly and caused adverse 
effects when not precisely positioned.29 Adverse effects were also reported for specific 
metal-to-metal hip devices that were not user-related, and this device was eventually 
recalled.30 Interestingly, all this could not have been shown by any clinical investiga-
tion, which would generally lack a long-term follow up of ten to twenty years. This 
illustrates that the influence of users on the benefits and risks of device use need to be 
carefully addressed in the clinical evaluation of devices, pre-market and post-market.
Discussions of the adverse effects of total hip replacement overshadow the fact that 
this intervention has also been called one of the most successful operations of the 20th 
century and that it is currently performed on one million patients each year world-
wide (see footnote 29). In the Netherlands, the Health Care Inspectorate has therefore 
investigated how to improve the quality chain of medical devices in general and those 
28  Das IJ, Cao M, Cheng CW, Misic v, Scheuring K, Schüle E, Johnstone PA. A quality assurance 
phantom for electronic portal imaging devices. J Appl Clin Med Phys. 2011 Feb 2;12(2):3350.
29  A series of papers in BMJ 21 May 2011, vol. 342:1115-1130. In this issue of BMJ, serious 
concerns were raised about the regulation of high-risk medical devices and how well they are 
tested before they come to market, taking the example of metal-to-metal hip implants, while at 
the same time mentioning the success of these interventions.
30  Cohen, D. Out of joint. BMJ (2011) 342: 1116-1122; d3009. In August 2010, DePuy Ortho-
paedics issued a voluntary recall of its ASR™ XL Acetabular Hip System and DePuy ASR™ Hip 
Resurfacing System.
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of metal-to-metal hip replacements in particular.31 Internationally, the International 
Consortium of Orthopaedic Registries (ICOR) is a US FDA-sponsored initiative consist-
ing of a public-private partnership, with over 30 registries participating worldwide 
since 2011.32 The aim is to facilitate and enhance inter-registry collaboration on total 
hip replacements by providing a supportive infrastructure and the development of 
a distributed data network that uses innovative approaches to analyse the available 
postmarketing surveillance data. 
3. Companion diagnostics 
Companion diagnostic devices constitute a specific category of diagnostic devices. 
A companion diagnostic device can be an in vitro diagnostic device that provides 
information essential for the safe and effective use of a corresponding therapeutic 
product. Such devices are aimed at aiding the development and use of disease-specific 
pharmaceuticals. Biomarkers, molecular imaging, microdosing and pharmacogenetics 
are companion diagnostics approaches. They help optimise therapy and drug therapy 
options and early detection and treatment of disease and disease prevention. They 
also may assist in studying specific targets for drug delivery, in reducing the time and 
costs involved in drug development, and in eventually enhancing the intended effects 
and decreasing the unintended effects of a drug. Incorporating new diagnostic tech-
nology helps us understand disease processes and as well as patient diversity and 
predisposition, thereby offering an opportunity to change the current drug discovery 
and development paradigm. One example of a medicinal product that uses a compan-
ion diagnostic is Herceptin (HER2 breast cancer).
There has been a boom in new companion diagnostic devices, as shown by the 7% 
growth (between 2005 and 2010) in the global in vitro diagnostics market and the 
40% increase in funding (in 2010 compared to 2009) raised for diagnostic compa-
nies.33 Companion diagnostics devices’ access to the market is also regulated by the 
medical device directives (IvDD or MDD). Their development is often combined with 
that of a therapeutic drug, organised directly by pharmaceutical companies. 
4. Equivalence and incremental improvement 
Equivalence refers to a new device (or parts of a new device) that either continues 
the development of an existing version or is similar in type to an existing device. 
Equivalence claims in the EU are made explicit in guidance documents.34 There are 
nine criteria for assessing equivalence: four technical, four clinical and one biolog-
ical (Appendix III). If there is information available for six of the nine criteria, for 
31  Metaal op metal heupimplantaten: De keten voor de kwaliteitsborging van medische 
hulpmiddelen moet beter functioneren. Inspectie voor de gezondheidszorg, Utrecht May 2013 
(in Dutch only).
32  http://www.icor-initiative.org/.
33  Personalized Medicine and Companion Diagnostics, DutchCC workshop, 15 November 2011.
34  MEDDEv 2.7.1, see also Annex 3.
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example, then new clinical investigations can be requested focusing on the missing 
three criteria. In the case of equivalence being claimed for a new device, the question 
is how to obtain sufficient evidence of the benefits of the new device for health and 
health care. Therapeutic support devices used by professionals in a hospital setting, 
such as staplers for closing an incision or new catheters, can enter the market with a 
CE mark without a new clinical investigation. The evaluation can be conducted using 
existing data and comparison of the above nine criteria with equivalent devices or a 
previous version of the same device. Once on the market, these devices are sometimes 
tested in small studies that often are extended over time. An example of such a study is 
given in Appendix 4 (B1.2): a before-after study shows how to investigate the benefits 
of pancreatic stump closure using a reinforced staple line. The study is a second series 
of four years of experience using this technique in a larger sample, following the first 
small group.35 The technique is straightforward and results in reduced morbidity and 
cost. In addition to such studies, the use of registry data on longer-term follow-up or 
linking datasets of different versions of the device are other possibilities for evaluating 
its benefits and risks. 
5. Combination products
Combination products consist of a medical device and a pharmaceutical joined into 
one product, e.g. inhaler devices for asthma and COPD. The primary mode of action 
(or function) of the product dictates how its market access is regulated, so a combi-
nation product can never can be both a medicinal product and possess CE marking 
as a device. Appendix Iv (A4) describes an example of an adaptive trial in healthy 
volunteers intended to optimise the rotacap formulation and ROTAHALER device for 
delivery of Fluticasone Propionate/Salmeterol in COPD patients (ClinicalTrials.gov/ 
NCT01540708). A key element of research on ‘adaptive’ features is that changes in 
design or analyses are guided by an examination of the accumulated data at interim 
points in the trial. Adaptive designs, time series, and linked evidence or synthesis of data 
are more flexible research strategies than the conventional comparative randomised 
trials, which may be particularly useful for the evaluation of medical devices.36
6. Self-management products and online monitoring 
The future of health care delivery is connected to decentralised health care solutions, 
e.g. the continuous monitoring of vital signs (e.g. HbA1c monitoring in patients with 
35  Wallace CL, Georgakis Gv, Eisenberg DP, Macaulay WP, Jimenez RE. Conn Med. 2013 
Apr;77(4):205-10. 
36  Bluhm R. From hierarchy to network: a richer view of evidence for evidence based medi-
cine. Perspective Biol Med 2005;vol 8:535-547; Walach H., Falkenberg T., Fonnebo v., Lewith G., 
Jonas W.B. Circular instead of hierarchical: methodological principles for the evaluation of com-
plex interventions. BMC Med Res Methodol 2006;vol 6:6-29; van de Wetering G., Steuten L.M.G., 
Birgelen von C., Adang E.M.M., IJzerman M.J. Early Bayesian modeling of a potassium lab-on-a-
chip for monitoring of heart failure patients at increased risk of hyperkalaemia. Technological 
Forecasting and Social Change. 2012 Sep;79(7):1268–79.
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diabetes) outside the hospital and the possibility of supervising the functioning of 
devices remotely. The widespread adoption and use of mobile technologies is also 
opening the door to new and innovative ways to improve health and health care 
delivery. Increasingly, these innovations are becoming available for home care and 
for patient self-management. They represent a whole new type of health care inter-
vention, where the benefit is related to user and patient expectations. However, such 
technology also challenges us to define or redefine the risks and benefits associated 
with their use. It involves taking a different approach to introduction, supervision 
and training. It remains unclear what type of clinical investigation is suitable for such 
technology. The FDA recently published a guidance for Mobile Medical Applications 
(September 2013).37 According to industry estimates, 500 million smartphone users 
worldwide will be using a health care application by 2015, and by 2018, 50% of the 
more than 3.4 billion smartphone and tablet users will have downloaded mobile 
health applications. These users include health care professionals, consumers, and 
patients.38
7. Expensive devices and cost-effectiveness 
There should be a balance between added benefit and extra costs; from a cost-ef-
fectiveness perspective, a less advanced but cheaper device that is as accurate as or 
equivalent to the existing care or device can be acceptable. However, new devices 
are often relatively expensive and are used for conditions for which they have not 
necessarily been shown to be beneficial. One example is the da vinci Surgical System, 
a robotic surgical system for complex surgery using a minimally invasive approach, 
controlled by a surgeon from a console.39 Da vinci robots operate in several thousands 
of hospitals worldwide (more than 2,585 da vinci Systems have been installed in over 
2,025 hospitals worldwide at a cost of around USD 2 million).40 The FDA cleared the 
da vinci Surgical System for adult and paediatric use in several laparoscopic surgical 
procedures (e.g. urologic and gynaecologic). Nevertheless, there is criticism that the 
system is difficult for users to learn and that it has not been shown to be more effective 
than traditional laparoscopic surgery. A recent study evaluated outcomes in more than 
a quarter of a million people comparing either laparoscopic or robotically assisted 
hysterectomies in 441 hospitals between 2007 and 2010. Both methods are mini-
mally invasive and involve smaller incisions than open abdominal surgery. No overall 
37 http://www.fda.gov/medicaldevices/productsandmedicalprocedures/connectedhealth/
mobilemedicalapplications/default.htm.
38  http://www.research2guidance.com/500m-people-will -be-using-healthcare-mobile-ap-
plications-in-2015/.
39  The Slow Rise of the Robot Surgeon. MIT Technology Review. 24 March 2010; http://www.
intuitivesurgical.com/products/davinci_surgical_system/.
40  http://www.intuitivesurgical.com/products/products_faq.html#sthash.f1YfH8q2.dpuf.
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difference in complication rates was seen between the two groups.41 There was a big 
difference in costs, however. Robotically assisted hysterectomies cost on average about 
a third more than laparoscopic surgery.
8. The balance between regulation and speed of introduction 
Stricter regulation of clinical investigation poses a dilemma: on the one hand, there 
are considerations of safety and of the benefits for the targeted patients or users; on 
the other hand, there is the potential delay in introducing better technologies. More 
generally, asking for more extensive evidence of the benefits, let alone added benefits, 
of medical devices may increase development costs. This has been recognised by the 
European Council. A Council meeting document explicitly states: ‘An efficient system of 
market access for new products that satisfy the highest possible safety standards is 
crucial in satisfying the needs of patients today and tomorrow. There is certainly a scope 
for improving the current system. Interventions should directly address weaknesses in 
the system, without creating additional barriers for innovation and availability for 
patients. Serious incidents underscore the need for post-market follow-up in evaluating 
the safety of medical devices as they are used in the field.’42 43
Awareness of such barriers can be seen in the field of cell therapy (subject to the 
Advanced Medicinal Therapeutic Products regulation of pharmaceuticals in Europe44). 
While there have been no mesenchymal stem cell (MSC)-based medicine authorisa-
tions in the EU, three MSC products have received marketing approval in other regions 
since 2011. South Korea is leading with two MSC products registered and the first 
authorisation granted in 2011.45 The authorisation seems to be linked to a conditional 
market approval procedure within South Korea’s regulatory framework that allows 
41  Jason D. Wright, MD; Cande v. Ananth, PhD, MPH; Sharyn N. Lewin, MD; William M. Burke, 
MD; Yu-Shiang Lu, MS; Alfred I. Neugut, MD, PhD; Thomas J. Herzog, MD; Dawn L. Hershman, 
MD. Robotically Assisted vs Laparoscopic Hysterectomy Among Women With Benign Gynecolo-
gic Disease. JAMA. 2013;309(7):689-698. doi:10.1001/jama.2013.186.
42  Council of the European Union, meeting document DS1360/1/13, 22 May 2013 on the 
Proposal for a Regulation of the European Parliament and of the Council on Medical Devices, 
and amending Directive 2001/83/EC, Regulation (EC) No178/2002 and Regulation (EC no 
1223/2-009.
43  EU Council conclusions on innovation in the medical device sector; 2011/C 202/03
44  http://ec.europa.eu/health/human-use/advanced-therapies/index_en.htm; Gene therapy, 
somatic cell therapy and tissue engineering are Advanced Therapy Medicinal Products. They are 
included in the medicinal product regulation (Directive 2001/83/EC) and further in Regulation 
(EC) No 1394/2007.  
45  Janis Ancans. Cell therapy medicinal product regulatory framework in Europe and its 
application for MSC-based therapy development. Front Immunol. 2012; 3: 253. Published online 
2012 August 14. doi: 10.3389/fimmu.2012.00253; PMCID: PMC3418507.
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commercial sales in certain instances while pivotal trials are still underway.46 A sim-
ilar regulatory decision has been adopted in Canada.47 The results of clinical studies 
of MSC-based therapy clinical trials in the past ten years have led to the conclusion 
that MSC applications are safe and feasible. However, the benefits of the device itself 
often could not be convincingly demonstrated in single studies, as the therapies also 
advanced along with the development of the MSC products.48 This is also illustrated by 
the absence of MSC-based products in the European market. 
Adaptive licensing, e.g. conditional approvals, could be introduced based on incre-
mental learning in circumstances of acknowledged uncertainty, with iterative phases 
of post-market data gathering and regulatory re-evaluations.49 Adaptive licensing 
requires a different approach from the standardised dichotomous unapproved/
approved CE paradigm, however. Initiatives are under way at the European Medicines 
Agency aimed at facilitating MSC-based medicinal product development and author-
isation in the EU. It is important for the European Commission to monitor the trend 
towards (omics-based) personalised treatments closely and to reflect on how it can 
support this development by regulatory and non-regulatory means.
9. Health technology assessment (HTA)
With regard to HTA and reimbursement discussions, the Health Technology Assess-
ment International (HTAi) Policy Forum supports and promotes ongoing discussions 
and scientific advances in this field. The most recent deliberations (2013) deal with 
HTA and value, but definitions of value vary depending on the stakeholder view 
(patient, societal, health system, industry).50 However, all participating HTA experts 
agree that patient health and benefits are central, and that patient health improvement 
46  Cartistem has become the world’s first allogenic, off-the-shelf MSC-based product (umbili-
cal cord blood (UCB)-derived MSCs for the treatment of traumatic and degenerative osteoarthri-
tis). In 2011 the Korean company FCB PharmiCell received Korean FDA approval for commercial 
sale of HeartiCellgram (autologous bone marrow-derived MSC) indicated for post-acute myocar-
dial infarction treatment.
47  The Osiris Therapeutics Inc. product Prochymal consists of allogenic MSCs. The company 
was granted an authorisation for the treatment of acute graft-vs-host disease (GvHD) in children 
under Health Canada’s Notice of Compliance with conditions (NOC/c) in May 2012.
48  Wang S., Qu X., Zhao R. C. (2012) Clinical applications of mesenchymal stem cells. J. Hema-
tol. Oncol. 5: 19. 
49  Eichler H. G., Oye K., Baird L. G., Abadie E., Brown J., Drum C. L., Ferguson J., Garner S., Ho-
nig P., Hukkelhoven M., Lim J. C., Lim R., Lumpkin M. M., Neil G., O’Rourke B., Pezalla E., Shoda D., 
Seyfert-Margolis v., Sigal E. v., Sobotka J., Tan D., Unger T. F., Hirsch G. (2012). Adaptive licensing: 
taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91 426–437. 
50  Chris Henshall and Tara Schuller, on behalf of the HTAi Policy Forum. HEALTH TECH-
NOLOGY ASSESSMENT, vALUE-BASED DECISION MAKING, AND INNOvATION. International 
Journal of Technology Assessment in Health Care, 29:3 (2013), Cambridge University Press 
2013 doi:10.1017/S0266462313000378.
Background Paper: HTA and Value: Assessing value, making value-based decisions, and sustaining 
innovation. HTAi Policy Forum Meeting 2013, 3-5 February 2013, Barcelona, Spain.
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is considered a core element of value. Wider elements of value include other benefits 
for patients (e.g. less burdensome, improved time to diagnosis, early detection), bene-
fits for caregivers, and benefits for health care and society in general. Although value is 
often defined in economic terms, there are divergent views about whether or not value 
is proportional to cost, i.e. cost-effectiveness thresholds. value measurements (both 
core and wider) can be quantitative and qualitative. There are different approaches 
that health systems take to value-based decision-making. 
The Dutch IMDI (Innovative Medical Devices Initiative, part of the Dutch Life 
Sciences & Health key economic sector) offers another way to approach the HTA of 
medical devices. IMDI is investigating whether it is possible to establish potential clin-
ical use and added benefit in a very early stage of device development. It has defined 
added value along three lines, which takes a system approach instead of an individual 
patient approach:
• Added value in health care/public health, which is further defined as health gains, 
quality of life, safety, self-reliance, and effect on the number of people working in 
health care.
• Added value in industry/economy. The Ministry of Health in the Netherlands does 
not want to limit entrepreneurship in the health care industry by imposing stricter 
controls. Its view is that innovation in health care would benefit from social inno-
vation (such as self-management, informal care, community welfare services) or 
innovation in the organisation of health care, and not so much from regulation. 
• Added value in research. 
In the UK, the National Institute for Health and Care Excellence (NICE) provides guid-
ance to the government on the clinical benefits and cost-effectiveness of selected new 
and established technologies. The Institute provided a guidance document with an 
overview of the principles and methods of health technology assessment, describing 
key principles of appraisal methodology.51 However, despite continuous development 
of technology appraisal methodology, there remain many areas of controversy and 
uncertainty. See also Chapter 5.
Summary
Based on this field survey, it is the opinion of the committee that, in every phase of a 
medical device’s life cycle, it would be of major value to provide more explicit guid-
ance on how to perform studies to assess the benefit or added benefit of the device 
and which type of studies are possible and needed given the type of device and the 
intended context and users. 
51  Guide to the methods of technology appraisal 2013, National Institute for Health and Care 
Excellence (NICE). http://publications.nice.org.uk/guide-to-the-methods-of-technology-ap-
praisal-2013-pmg9.
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Chapter 4 therefore offers an overview of research approaches for collecting 
evidence that is not limited to clinical investigations needed for CE marking, but also 
include guidance on conducting clinical research with CE-certified devices. Chapter 
4 aims to provide detailed guidance on investigating the different clinical benefits of 
medical device use while acknowledging the specific nature and market of medical 
devices. Improved guidance in assessing the clinical benefit or added benefit of medi-
cal devices will lead to more clinical and statistically relevant data that can be used to 
inform CE-marking, uptake and reimbursement discussions.
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4. clinical rEsEarch 
on mEdical dEvicEs: 
principlEs and 
approachEs
A variety of different approaches are available for evaluating the safety, technical/ana-
lytical performance, and clinical benefits/utility/effectiveness (including clinical per-
formance) of a medical device (see also Box 2.1).52,53,54 The field survey (Chapter 3) 
clearly showed that studies meant to substantiate the clinical benefits or effectiveness – 
for example for a patient or user – of a device still raise questions and challenges among 
device manufactures, researchers, care providers, Notified Bodies and policymakers. The 
field survey also indicated that there generally is a good understanding of the types of 
studies required to demonstrate the safety of medical devices as well as their technical 
and analytical performance. 
This chapter therefore does not address approaches for evaluating a device’s safety 
or technical/analytical performance; instead, it provides explicit guidance as to which 
study approach allows for inferences about the clinical benefits/utility/effectiveness (or 
added benefits) – including clinical performance – of a device and to what extent given 
the device specifics and indications. The purpose is to enhance our understanding of 
the evidence on a device, help the parties involved plan future studies (if needed), and 
improve the dissemination, uptake and application of safe and beneficial devices. We 
discuss the essentials of numerous research approaches, and how these can inform us 
about the likelihood that a device will indeed provide the intended benefits for health 
or health care when introduced in regular care. We show that, unlike pharmaceuticals, 
there is no one-size-fits-all approach in the realm of medical device evaluations, simply 
because of the wide variety of medical devices available.
52  Clinical Evidence – Key Definitions and Concepts Study Group 5 Final Document SG5/
N1R8, May 2007. Retrievable from: http://www.imdrf.org/docs/ghtf/final/sg5/technical-docs/
ghtf-sg5-n1r8-clinical-evaluation-key-definitions-070501.pdf.
53  http://www.cdc.gov/genomics/gtesting/ACCE/.
54  Smart A. A multi-dimensional model of clinical utility. Int J Qual Health Care, 2006; 18 (5): 
377-382. doi: 10.1093/intqhc/mzl034.
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Outline of this chapter
The chapter begins by describing its aim and scope (Section 4.1), followed by an 
explanation of the general principle for assessing the performance and benefits or 
added benefits of medical devices (Section 4.2). In Section 4.3 we discuss the overall 
distinction between therapeutic and non-therapeutic (i.e. diagnostic, screening, mon-
itoring or prognostic) devices or test devices. Therapeutic devices commonly inter-
vene with bodily systems and thus may directly benefit the health of targeted users or 
patients. Diagnostic, screening, monitoring or prognostic tests yield information that 
in turn can lead to better, earlier, or enhanced interventions. Hence, such devices have 
different benefits and improve the health of targeted users or individuals indirectly. 
We continue by outlining the optimal research approach for assessing the benefits 
or added benefits of devices, and why this is the case (Section 4.4). In Section 4.5 
we discuss why and when deviations from this optimal research approach may be 
indicated. We also stress how helpful it is to have a mental picture of the theoretical 
optimal research approach when designing or choosing alternative approaches, with 
a view to the validity of such research. In Section 4.6 we describe why it is important 
to define, as early as possible, the pathway or pathways through which the device 
will lead to intended and unintended effects on health or health care. We also provide 
guidance as to which elements should be included in such pathway descriptions, and 
explain that this is a collaborative effort among device developers, manufacturers and 
end-users (e.g. medical professionals and targeted individuals or patients). Section 
4.7 then shows the absence of a one-size-fits-all approach. It describes the three main 
study approaches to generating evidence about the benefits or added benefits of 
device use for the intended individuals, professionals or society at large. These include 
1) studies providing direct evidence and quantification of the benefits/added benefits 
of device use on health or health care (Section 4.7.1); 2) studies providing indirect 
evidence of the benefits/added benefits of device use on health or health care using a 
quantitative linked-evidence approach (Section 4.7.2); 3) studies providing indirect 
evidence of the benefits/added benefits of device use on health or health care using a 
qualitative linked-evidence approach (Section 4.7.3). For each approach, we discuss 
which types of devices can be covered and in which situations, and how each approach 
has its merits and vulnerability to specific forms of bias. Explicit study designs and 
their pros and cons are given for each approach and illustrated with real-life empirical 
examples from a wide range of devices (in Appendix IV). Finally, Section 4.8 provides 
an overall summary of the chapter with a list of key issues that should be consid-
ered by researchers studying the clinical benefits, including clinical performance, of 
devices. Appendix V addresses overarching statistical recommendations. 
This overview and guidance are not based on a formal, systematic literature review, 
but rather survey and summarise the existing methodological literature on assessing 
the performance and benefits/effectiveness of medical devices, supplemented by the 
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expert knowledge of the committee members and interviewees. In relation to this, our 
guidance on choosing research approaches (given the type, context and intended use 
of a device) is not set in stone. It should be seen as a recommendation and option for 
all stakeholders involved in assessing medical devices; it is the start rather than the 
end of a process and a discussion among the stakeholders concerning research meth-
ods for medical devices. 
4.1 Aim and scope
This chapter and accompanying Appendices Iv and v discuss and illustrate the need, 
design, execution and interpretation of available approaches to investigating a device’s 
clinical benefits/added benefits or effectiveness, in view of the wide variety of med-
ical devices available. We illustrate that such variety means there can be no one-size-
fits-all approach. Knowledge of the pros and cons of these different approaches will 
improve the quality and understanding of device evaluations. In the current era of 
evidence-based medicine and accountability, this will increase the uptake and use of 
devices by end-users (patients and care providers), and ultimately result in better 
health or health care for those for whom the device is intended. 
This chapter does not aim to:
• change any government or legal rules or obligations for market access or uptake in 
health insurance systems;
• prescribe at which point in a device’s life cycle – e.g. before or after market access – 
which studies must be performed;
• prescribe which study approaches should specifically be applied for IvDD, AIMDD, 
or MDD devices, or for which risk class. For this we refer to the existing interna-
tional and national guidelines;
• describe methods for evaluating the cost-effectiveness of devices. Some stake-
holders may be specifically interested in methods for such evaluations or in which 
cost-effectiveness thresholds should be used for reimbursement decisions. Such 
methods are rare, however, and are still under development even for drug evalu-
ations, let alone for device evaluations. Moreover, cost-effectiveness-threshold deci-
sions require a political rather than a methodological debate. We briefly address 
the challenges of cost-effectiveness device evaluations in Chapter 5.
4.2 Overarching principle for device evaluations
Medical devices vary greatly in complexity and application and thus in their potential 
unintended (safety) and intended (benefits) effectiveness. Accordingly and perhaps 
arguably, unlike medical drugs, there is no unique optimal study approach to investi-
gating the risks and benefits of a device and its use. Compared to pharmaceuticals, it 
is much more difficult to describe concisely which research methods are applicable 
53clinical research on medical devices: principles and approaches
in which instance. Many factors play a role in choosing the ‘optimal study approach’, 
including:
• phase of the device’s life cycle;
• type of device;
• working mechanism through which a device leads to risks, benefits or less burden-
some care; 
• intended medical context or indication;
• intended users;
• prevailing care in the intended context. 
Nevertheless, as stated in Chapter 1 (and 2), the overarching principle that drives 
the evaluation and regulation of medical drugs, devices or any other health care inter-
vention, is the same: 
To generate and accumulate evidence that the use of an intervention is not only safe 
but also has benefits, preferably added benefits beyond existing care, for the health or 
health care of the intended individuals, patients, professionals or for society at large.
As we stated earlier, this principle is the starting point of this report, the aim being 
to ensure as much as possible the introduction and use of medical devices that are 
‘safe’ and/or ‘necessary’. 
4.3 Therapeutic devices versus non-therapeutic (diagnostic, 
screening, monitoring test) devices
The above principle applies to all types of medical devices, but we can distinguish two 
main categories: therapeutic devices and non-therapeutic devices, including diagnos-
tic, monitoring, screening or prognostic tests. The benefits of both types of devices and 
how these benefits are achieved are markedly different. as we show in Sections 4.5-
4.7, this is in part why there is no one-size-fits-all approach to evaluating the benefits 
and risks of medical devices. 
Therapeutic devices are devices that interfere directly with – often targeted 
– bodily systems and mechanisms. Examples are pacemakers, nerve stimulators, 
prostheses, breast implants and medical robots. Therapeutic devices are beneficial 
because they treat specific diseases (e.g. heart rhythm disorders), alleviate specific 
symptoms or complaints (e.g. pain or tremors), or improve daily activities or quality of 
life directly. Due to their direct interference and thus effects on targeted patients, evi-
dence of the benefits or added benefits of therapeutic devices is much easier to obtain 
directly from a single, properly designed, conducted and analysed clinical study, using 
a variety of study approaches. This may include randomised and non-randomised 
study approaches. This will be explained in detail in Sections 4.5-4.7. 
Diagnostic, prognostic, monitoring or screening devices are devices or rather 
tests that do not by themselves treat or alleviate diseases, symptoms or signs directly, 
but rather do so indirectly. Examples of such test or information-generating devices 
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include imaging tests, companion diagnostics, laboratory tests, point-of-care or bed-
side tests. Diagnostic, prognostic, monitoring or screening tests provide information to 
the users, i.e. professionals, patients or other individuals, which in turn indicates sub-
sequent actions or interventions, such as therapies or lifestyle changes. These inter-
ventions or actions may subsequently lead to benefits in terms of improved health 
outcomes of individuals or patients. Diagnostic, prognostic, monitoring or screening 
tests are information-generating devices rather than therapeutic devices, and there-
fore benefits the health of the targeted patients or individuals indirectly. 
Test devices may also be beneficial by improving the therapeutic actions of medical 
drugs; examples include companion diagnostics, molecular imaging devices or imag-
ing devices to guide surgery. A new diagnostic test may be beneficial because it means 
less invasive detection of disorders, avoiding additional unnecessary testing that is 
more invasive or costly. A new screening or monitoring test that leads to early detec-
tion makes it possible to administer the appropriate treatment at an early stage.
We note that test devices can still be invasive to varying extents (e.g. angiographic 
procedures or imaging techniques requiring radioactive contrast agents), but they are 
often minimally invasive (point-of-care tests requiring blood) or even non-invasive 
(ultrasound techniques). Safety aspects related to these devices are usually related 
directly to the extent of their invasiveness. 
Finally, unlike therapeutic devices, many of the diagnostic, prognostic, monitor-
ing or screening devices have a general purpose (such as imaging techniques, blood 
analysers, point-of-care tests). They are often not intended for one specific medical 
condition or indication. 
All of the above has implications for the type of evidence and study approaches 
that can be used to infer the benefits/added benefits of diagnostic, screening, moni-
toring or prognostic tests for the targeted individuals/patients. This evidence may still 
come from a single clinical (randomised or non-randomised) study. But these devices 
may also profit from network or linked-evidence approaches. This will be explained in 
detail in Sections 4.5-4.7. 
4.4 Optimal clinical study approach 
Given the common goal of medical intervention evaluation, i.e. to accumulate evidence 
that the intended use of a device (therapeutic or non-therapeutic) is safe and has 
positive effects on health or health care beyond what is achieved by current practice, 
it should be possible to design a single study that measures all these aspects directly 
in the most valid and informative way. This is in fact the same optimal study approach 
used to evaluate the effectiveness of medical drugs. The study should:
investigate the device and its use similarly to how it will be used in practice;
• investigate the device in the same clinical context and with the indications as in 
practice;
• use the device by/for the same targeted individuals (e.g. professionals and 
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patients) as in practice;
• compare the device with the prevailing alternative care. Ideally, this would be a 
randomised comparison: the targeted individuals would be allocated randomly to 
either the device use or a comparative care strategy;
• in case of diagnostic, monitoring, screening or prognostic test devices, study their 
use in combination with any therapeutic management actions indicated by the 
test/test information; 
• measures all outcomes/endpoints relevant for the targeted individuals, health care 
professionals, and ideally for society at large. This would include, for example, any 
unintended outcomes, intended health outcomes (for patient and users), burden 
and ease of device use, speed of administering therapeutic decisions (for non-ther-
apeutic devices), and even costs of the device use;
• be sufficiently long to investigate the long-term health care effects of device use; 
• be designed and executed such that it produces valid results, i.e. minimises the risk 
of bias;
• be sufficiently large to obtain precise estimates of the safety and health benefits of 
device use. 
Applying all these main criteria would lead to the design of a large-scale, long-term 
pragmatic or comparative effectiveness randomised trial. For more details on 
this research approach, see Appendix IV, part A.55 The two comparison groups are 
created randomly or by chance splitting. In the index group, the new device is used 
(in combination with subsequent therapeutic actions in the case of diagnostic, screen-
ing, monitoring or prognostic test devices), with the prevailing management being 
applied in the comparison (control) group. Provided they are large enough, then, the 
two groups are ‘the same’ except for the device under study. Any observed differences 
between the two groups in terms of benefits (and risks) of whatever type can then be 
ascribed to the difference in management, and thus to the device use. 
Randomised comparative effectiveness studies compare the use of the device under 
evaluation – combined with subsequent actions in the case of non-therapeutic devices 
– directly with the best alternative strategy in the right population, measuring all 
relevant outcomes (for patients, users, and health care) in the short and long-term, 
and should generate the most direct and valid evidence as to whether the device use 
will indeed produce the intended relevant benefits, at an acceptable level of safety, as 
compared to prevailing care. This approach can even address the cost-effectiveness of 
device use as compared to the alternative care. 
55  Clarke J., Wentz R. Pragmatic approach is effective in evidence based health care. Bmj 
2000;321:566-7; Helms P.J., ‘Real world’ pragmatic clinical trials: what are they and what do 
they tell us? Pediatr Allergy Immunol 2002;13:4-9; Hunink M.G., Krestin G.P. Study design for 
concurrent development, assessment, and implementation of new diagnostic imaging techno-
logy. Radiology 2002;222:604-14; MacRae K.D. Pragmatic versus explanatory trials. Int J Technol 
Assess Health Care 1989;5:333-9; Roland M., Torgerson D.J., What are pragmatic trials? Bmj 
1998;316(7127):285.
56 evaluation of new technology in health care
4.5 Deviation from the optimal study approach: no one-size-
fits-all
In the case of medical devices, both therapeutic and non-therapeutic, such pragmatic 
randomised trials present a greater methodological challenge than in the case of med-
ical drugs. For example, in clinical studies of devices there is often an intricate inter-
play between the technical complexities of the device, its user (often specific skills are 
needed), and ‘user/interpretation learning-curve effects’, compromising intervention 
adherence and sometimes even the possibility of randomised allocation (see also Sec-
tion 4.7.1. and Appendix IV, part A). Indeed, the benefits and risks of a device often 
depend not only on the device itself but are a result of that complex interplay.
Non-randomised or observational studies of therapeutic devices are even more 
challenging, however. Selecting the proper study subjects, choosing a comparison 
group, adjusting for other influential factors, and addressing learning curve issues 
all require the conscious selection of study design, conduct and analysis plan. For 
example, when existing clinical databases or registries are used to obtain evidence of 
the potential benefits and risks of device use in practice, relevant information about 
other influences is often not – or only partially – available. This compromises any valid 
inferences about its true benefits and risks (see Section 4.7.1. and Appendix IV, part 
B). Moreover, for diagnostic, screening, prognostic or monitoring devices, i.e. devices 
without a direct therapeutic effect on patients’ outcomes, a single randomised com-
parative study may even not be indicated or may be very cumbersome.56 Such devices 
may profit from a network or linked-evidence approach instead (see Sections 4.7.2 
and 4.7.3, and Appendix IV, parts C+D). Clearly, there is no one-size-fits-all approach 
to evaluating the benefits of medical devices.
4.5.1 Reminder of optimal clinical study approach and overarching prin-
ciple
The challenge is thus to identify the type of evidence and study approach that is 
required, given the specifics of the device (e.g. therapeutic or information-generat-
ing, invasive or non-invasive, requiring user interference/interpretation or not), its 
intended context, intended indication, and targeted individuals. However, we strongly 
recommend maintaining a mental picture of the optimal randomised comparative 
effectiveness study when designing or choosing any alternative research approaches, to 
56  Bossuyt P.P.M., Lijmer J.G., Mol B.W., Randomised comparisons of medical tests: sometimes 
invalid, not always efficient. Lancet 2000;356:1844-1847; Lord S.J., Irwig L., Simes R.J., When 
is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we 
need randomized trials? Ann Intern Med 2006;144:850-5; Biesheuvel C.J., Grobbee D.E., Moons 
K.G., Distraction from randomisation in diagnostic research. Ann Epidemiol 2006;16:540-4; Li-
jmer J.G., Bossuyt P.M., various randomized designs can be used to evaluate medical tests. J Clin 
Epidemiol 2009;62:364-73.
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allow for valid inferences about the benefits/added benefits of device use for health or 
health care. 
Technical capa-
bilities of the 
device
Intermediate  
effects induced 
by the device
Intended clinical 
benefits for tar-
geted individuals 
or care providers 
by the device
Technical
performance/
Analytical 
performance
Clinical  
performance/ 
Clinical validity
Clinical benefits/
Clinical utility
Role of comparison group
Safety
Figure 4.1 Pathway through which devices may eventually lead to benefits/added be-
nefits for health or health care, and how each step is linked to a specific approach. The 
pathway ranges from the technical or analytical performance of a device through its 
intermediate changes or effects on health or health care outcomes to the final benefits 
for patients, care providers or society at large. 
Indirect versus direct evidence
To obtain direct evidence of the health or health care benefits of a device, alternative 
study approaches may include simpler or more tailored randomised studies and 
non-randomised comparative studies. But there are also approaches that gener-
ate indirect evidence of the device’s intended health or health care benefits. These 
include single study approaches followed by some kind of network or linked-evidence 
approach. For some devices (e.g. devices that are simply a minor modification of an 
existing device), a non-comparative or perhaps even only technical performance 
study can be justified using a network or linked-evidence approach. For other devices, 
direct evidence obtained in randomised comparative effectiveness studies or at least 
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a non-randomised comparative study may be required. This will be discussed and 
illustrated in Section 4.7. 
A clear description of the pathway (see also Section 4.6) through which a device 
may ultimately affect health or health care outcomes, and which type, provides rele-
vant clues for designing the following proper study in the life cycle of a device (see Fig-
ure 4.1). Studies focusing on earlier steps in this pathway generate indirect evidence 
of the benefits of a device for health or health care. This indirectness may relate to 
various sources, including:
• outcomes, e.g. short-term/intermediate rather than long-term outcomes, diagnostic 
accuracy outcomes rather than patient-relevant outcomes, clinical performance 
rather than clinical utility outcomes, care provider rather than patient outcomes;
• use of the device, e.g. by experts in specialised care rather than less experienced 
users in regular care;
• type of device, e.g. a new diagnostic device may lead to better or earlier detection 
of a disorder, whereas its benefits for improved therapeutic decision-making, let 
alone for improved patient health, has not been proven as yet; 
• individuals studied, e.g. investigating a device in a sample of healthy individuals 
rather than in a sample taken from the intended context and patient population.
Bias versus precision 
In addition to the directness or indirectness of a study on the health care benefits of a 
device, there are two other key dimensions of quality to consider in clinical research on 
devices (Figure 4.2). These are:
• risk of bias (invalidity);
• precision of study estimates. 
Every type of clinical study is vulnerable to specific biases, which we discuss in 
detail in Section 4.7 and in the corresponding Appendix IV. Shortcomings in study 
design or execution can produce incorrect or invalid results and thus incorrect infer-
ences about clinical performance, validity, benefits or utility. Minimising such bias is 
the aim of every clinical study. Generally speaking, the more one deviates from the 
optimal study approach, the more challenging it is to draw valid inferences about 
the benefits/added benefits of a device for heath or health care. Awareness of this 
deviation is a major step forward, however. Section 4.7 shows how to make the best 
possible inferences about a device’s benefits or added benefits for health care when 
deviating from the optimal study approach.
Imprecision arises when study results are based on a small study sample. Impre-
cision leads to uncertainty about the study results. Proper statistical analysis can 
describe the uncertainty in study results by using confidence intervals. 
Figure 4.2 integrates the overarching principle and pathway through which 
devices may lead to benefits or added benefits for health or health care, and the three 
main dimensions of quality for evidence obtained from device evaluations (indirect-
ness of evidence; risk of bias; precision of estimates).
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Figure 4.2 Relationship between the pathway through which devices may lead to ben-
efits/added benefits for health or health care and the three dimensions of quality for 
evidence (indirectness of evidence, risk of bias, precision of estimates).
The framework outlined in Figure 4.2 is further discussed in the remaining sections. 
Section 4.6 provides guidance by explaining how and why we must describe the path-
way through which a device leads to benefits (and risks). Section 4.7 then describes 
various research approaches for generating evidence of the benefits of device use for 
the targeted individuals (patients or professionals). Here we focus on two main issues: 
the directness or indirectness of the evidence and the risks of bias (internal invalidity). 
Precision of study results (estimates) is a more straightforward concept for which the 
discussion in Appendix v suffices.
Appendix IV provides a detailed overview of the many different study designs that 
are available for investigating the intended health benefits of a device, either therapeu-
tic, diagnostic, prognostic, screening or monitoring devices. The empirical examples 
are meant to serve as a source of inspiration for both researchers and manufacturers.
4.6 Description of the pathway leading to a device’s benefits:  
a collaborative effort
The variety of devices available is reflected in the variety of pathways through which 
each device leads to intended and unintended effects on health or health care – e.g. 
directly or indirectly. It would be easier to decide which evidence and studies are 
needed to make valid inferences about the benefits or added benefits and risks of a 
device if device developers, manufacturers and end-users (i.e. medical professionals 
and targeted individuals or patients) were to collaborate and describe in detail the 
potential pathways through which benefits and risks are likely to occur. Such working 
pathways or mechanisms address:
60 evaluation of new technology in health care
• the anticipated technical or analytical capabilities of a device;
• the unintended and intended outcomes or effects expected in the targeted context;
• where these effects are likely to occur, e.g. in the targeted individuals/patients, in 
the care providers, other parties, or health care at large (e.g. cost-effectiveness);
• the anticipated mechanisms through which these potential risks and benefits will 
occur or be achieved in the intended context;
• existing care in the targeted context and individuals; 
• the expected time frame in which potential risks and benefits might occur.
4.6.1 Why we must describe the pathways leading to device benefits
The working pathway is ideally defined in a very early stage of a device’s development, 
or even at its conception. When manufacturers/developers provide information on the 
potential technical capabilities of a device and when the targeted end-users indicate 
what is needed in the intended medical context and what can be obtained with the 
prevailing care, the process of designing and – where necessary – altering devices and 
their anticipated studies becomes easier. 
Having a detailed description of the working pathway at an early stage is par-
ticularly useful in situations where the device poses a major risk or is expensive to 
use. This is certainly true for invasive therapeutic devices such as pacemakers, nerve 
stimulators, breast implants, prostheses or medical robots, but it also holds for inva-
sive and non-invasive diagnostic, prognostic, monitoring or screening devices, such as 
clinical chemistry tests to detect specific biomarkers, imaging tests with or without 
radioactive labelled contrast agents, and electrophysiology tests. This is particularly 
useful for the latter type of devices because their effects on health or health care are 
more indirect. For example, they affect health or health care outcomes indirectly by 
diagnosing a disease earlier or in an less burdensome manner, or through early detec-
tion that allows for more timely and effective treatment. 
A detailed description of the above issues can also be used to consider evidence 
taken from different consecutive studies – e.g. technical, safety and clinical studies – in 
a more linked or network of evidence perspective. For instance, if technical perfor-
mance studies fail to provide evidence for the intended technical capabilities of the 
device, further studies are unnecessary. If safety and technical performance studies 
of a new version (modification) of an existing device show that its safety and techni-
cal performance is similar to the preceding version but that it is less burdensome or 
cheaper to use, then subsequent studies may not be needed. 
In summary, a clear description of the pathways through which a device generates 
potential intended and unintended health or health care effects, for whom and in what 
time frame, has the following merits:
• it promotes the logical build-up of a network of evidence leading to an integrated 
portfolio of evidence for a device;
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• it provides a transparent and common starting point for designing the next optimal 
study;
• it leads to improved acceptance and uptake of a device by the medical profession, 
targeted individuals, and other related parties, certainly in the current era of 
evidence-based medicine, accountability and patient rights, and ever-decreasing 
health care resources.
4.7 Direct versus indirect evidence approaches 
There are direct and indirect methods for generating evidence that a therapeutic or 
non-therapeutic device has benefits for health or health care (preferably added ben-
efits beyond existing care) and for the intended individuals, professionals or society 
at large. Based on the level of indirectness, we can distinguish three main research 
approaches: 
1. Studies providing direct evidence and quantification of the benefits or added 
benefits of device use for health or health care (Section 4.7.1).
2. Studies providing indirect evidence of the benefits or added benefits of device 
use for health or health care, via a quantitative linked-evidence approach (Section 
4.7.2).
3. Studies providing indirect evidence of the benefits or added benefits of device 
use for health or health care, via a qualitative linked-evidence approach (Section 
4.7.3).  
Each approach has its own merits, and the vulnerability to specific forms of biases 
also varies across approaches. Below we discuss the essentials of these three research 
approaches, and how they can be informative about the likelihood that a device, 
whether therapeutic or non-therapeutic, will have the intended benefits on health 
or care when introduced in regular care. In this discussion we will be mindful of the 
expected pathways through which benefits (and risks) are generated (Section 4.6). 
In Appendix IV, we provide a detailed overview of the specific study types or designs 
that may be used in each of these three research approaches, along with their pros and 
cons (directness & risk of bias), and we illustrate each one with an example of a trial 
used for medical device evaluation. 
4.7.1 Direct evidence and quantification of the benefits or added benefits 
of a device
As discussed above, a study aimed at providing direct evidence of a device’s benefits 
for the health outcomes of the targeted individuals or for health care at large should 
basically address issues concerning its use in practice, i.e. the intended context, com-
parison strategy, relevant effects, time and size. In Appendix IV (part A), as well as in 
Section 4.4, we discuss why this randomised pragmatic or comparative effectiveness 
design is the optimal, and most valid (lowest risk of bias), study design for a direct 
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evidence approach. This applies both to therapeutic and non-therapeutic devices. 
However, as discussed, this optimal single study approach – in which a device is stud-
ied in a strictly random manner against the best current care in the right population, 
measuring directly all relevant outcomes over a sufficiently long period of time – is not 
always feasible or possible 
We consequently provide numerous alternative study approaches in Appendix 
IV that also produce the desired direct evidence of the benefits or added benefits of 
device use for the relevant and long-term health outcomes of the targeted individuals 
in the intended medical context. These designs may include alternative randomised 
designs, such as cluster (rather than patient level), factorial or cross-over studies, but 
they may also include more modern and efficient designs such as adaptive or N=1 
trials.57 These alternative study types are often as valid as the randomised pragmatic, 
comparative effectiveness trial, only less cumbersome and costly. Appendix IV, part 
A describes the essentials of each of these study types, including their pros and cons, 
and when they may be suitable in device evaluations. 
There are many non-randomised study approaches that may also contribute to 
generating direct evidence about the long-term, comparative benefits or effectiveness 
of the relevant outcomes of a new device. These range from quasi-randomised (or 
quasi-experimental) studies to controlled before-after studies and cohort or case-con-
trol studies.58 These non-randomised studies are more prone to bias due to differ-
ences in demographic and clinical characteristics between the groups being compared. 
Fortunately, there are various approaches to controlling or adjusting for such biases 
(see Appendix V), and these may be possible alternatives to clinical device studies. In 
Appendix IV, part B we survey all these possible alternative, non-randomised designs, 
their advantages and disadvantages, and the possibility of minimizing the risk of bias 
in each design. 
All the study approaches mentioned above can be applied to all types of devices, 
whether therapeutic devices or diagnostic, prognostic, screening or monitoring test 
devices. In Appendix IV, part C3, however, we provide explicit empirical examples in 
which the added health or health care benefits of test devices are studied directly.
57  Pocock SJ. Clinical Trials: a practical approach: John Wiley & Sons, 1984; Friedman L.M., 
Furberg C.D., DeMets D.L., Fundamentals of Clinical Trials. 4th ed: Springer, 2010; Meinert CL. 
Clinical Trials. 2nd ed: Oxford University Press, 2012; Grobbee D.E., Hoes A.W., Clinical Epide-
miology – Principles, Methods and Applications for Clinical Research. London: Jones and Bartlett 
Publishers, 2009; Rothman K.J., Greenland S., Modern epidemiology. Second ed. Philadelphia: 
Lincot-Raven Publishers, 1998.
58  Grobbee D.E., Hoes A.W., Clinical Epidemiology – Principles, Methods and Applications for 
Clinical Research. London: Jones and Bartlett Publishers, 2009; Hennekens C.E., Buring J.E., 
Epidemiology in Medicine. Boston/Toronto: Little, Brown & Co, 1987; Rothman KJ, Greenland 
S. Modern epidemiology. Second ed. Philadelphia: Lincot-Raven Publishers, 1998; Sackett D.L., 
Haynes R.B., Tugwell P. Clinical epidemiology; a basic science for clinical medicine. Boston: Little, 
Brown & Co, 1985; Rosenbaum PR. Design of Observational Studies. 2nd ed: Springer, 2002.
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4.7.2 Indirect or linked evidence approach: Quantitative
Many clinical studies of devices do not measure the device’s effects on the ultimate 
health outcomes for the targeted individuals or health care at large directly. Instead, 
they focus on measuring intermediate effects/outcomes along the working pathway of 
a device (see Figures 4.1 and 4.2 and Section 4.5). However, it possible to undertake 
an explicit – quantitative – exercise that translates the device’s effects on intermediate 
effects/outcomes into its effects on relevant (long-term) health or health care out-
comes. 
Therapeutic devices: short-term and surrogate endpoints
Device studies frequently focus on relatively the short-term effects or benefits of 
device use, rather than on the more relevant long-term outcomes. For example, the 
benefits of a new cardiac synchronisation device for exercise tolerance or quality of 
life improvement are studied in the first three months after implantation, rather than 
after 12 or 24 months. 
Another, related, issue is the decision to measure surrogate or intermediate 
outcomes rather than patient-relevant (often called ‘hard’) endpoints. For example, 
restoring blood flow by inserting a new stent, measured directly after implantation, 
does not mean that it reduces cardiovascular events down the road. A nerve stimulator 
may reduce tremor in Parkinson patients, but not the ability to pick up things with 
their hands or to walk without falling, thus improving their quality of life. 
The key issue when choosing short-term and intermediate outcomes is how 
closely they correlate with long-term and relevant health outcomes. Short-term and 
intermediate outcomes are more valuable if previous studies have repeatedly found a 
close relationship between them and long-term and relevant outcomes. All the study 
approaches discussed in Section 4.7.1 (direct evidence approaches) and in Appendix 
IV parts A and B can also be used to study the benefits of device use for short-term or 
intermediate/surrogate health outcomes, with the same pros and cons. 
The main advantage of using short-term or surrogate/intermediate outcomes is that 
they often require a smaller sample size, shorter follow-up and thus smaller budgets. 
However, it must be acknowledged that the effects or benefits of the device for the 
desired longer term and/or patient relevant endpoints are unobserved in such studies. 
End-users (patients, care providers) as well as health care policymakers are usually 
more interested in the impact (and safety) of devices in the longer term and in par-
ticipant-relevant outcomes, such as quality of life or improvement in daily activities. 
This is particularly so for implantable devices that are implanted for a longer period of 
time, such as breast implants, artificial hips, joints or heart valves, stents, pacemakers, 
and nerve stimulators. 
Linked-evidence method. There are, however, ways to link evidence from differ-
ent device studies quantitatively in order to investigate the benefits of a device for 
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long-term, relevant outcomes (and the safety of that device).59
• First, standard study approaches as discussed in Section 4.7.1 (Appendix IV, parts 
A and B) have documented the benefits of device use on short-term and/or surro-
gate outcomes.
• Second, there are other studies that have quantified the association between short-
term and long-term outcomes or between surrogate outcomes and participant 
relevant outcomes. 
• Third, using decision or Markov modelling approaches, one can (fairly) easy link 
both types of evidence, and actually quantify the benefits (and risks) of device use 
on the long-term and relevant health outcomes. 
• Fourth, these linked-evidence models can include various sensitivity analyses, for 
example accounting for the insecurities involving in using various types of evidence 
taken from different sources (studies). 
In Appendix IV, part D we provide various examples of a quantitative linked-evidence 
approach for many different types of devices. 
Diagnostic, screening, prognostic or monitoring test devices 
A special case of using intermediate outcomes applies to information-generating devices 
such as diagnostic, screening, prognostic, and monitoring tests. As noted in Section 
4.3, their effects on an individual’s health outcomes are usually determined via the 
management or treatments that are initiated based on the information they provide.60 
Studies involving such devices usually begin by examining their predictive, diagnostic or 
screening accuracy and establishing the relationship between the device results and the 
presence/absence of a certain disease or condition. Such studies indicate to what extent 
the information provided and interpreted by the new device accurately predicts or 
detects the presence/absence of a specific disorder. Here, the pure predictive accuracy of 
the device is at stake, and is sometimes compared to the predictive accuracy of another, 
competing device. Despite the obvious relevance of such studies, predictive accuracy is 
still an intermediate endpoint: good predictive accuracy does not guarantee improved 
therapeutic management, let alone improved health outcomes at later stage.
59  Bluhm R. From hierarchy to network: a richer view of evidence for evidence based med-
icine. Perspective Biol Med 2005;vol 8:535-547; Walach H., Falkenberg T., Fonnebo v., Lewith 
G., Jonas W.B., Circular instead of hierarchical: methodological principles for the evaluation of 
complex interventions. BMC Med Res Methodol 2006;vol 6:6-29; Merlin T., Lehman S., Hiller J.E., 
Ryan P., The ‘linked evidence approach’ to assess medical tests: a critical analysis. International 
journal of technology assessment in health care 2013;29(3):343-50; Schaafsma J.D., van der Graaf 
Y., Rinkel G.J., Buskens E. Decision analysis to complete diagnostic research by closing the gap 
between test characteristics and cost-effectiveness. J Clin Epidemiol 2009;62(12):1248-52.
60  Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to eval-
uate a diagnostic test, and when do we need randomized trials? Ann Intern Med 2006;144(11): 
850-5; Bossuyt P.M., McCaffery K. Additional Patient Outcomes and Pathways in Evaluations of 
Testing. Med Decis Making 2009; Bossuyt P.M., Reitsma J.B., Linnet K., Moons K.G., Beyond diag-
nostic accuracy: the clinical utility of diagnostic tests. Clin Chem 2012;58(12):1636-43. 
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Appendix IV, part C provides an overview of the possible approaches to studying 
the predictive accuracy of diagnostic, screening, monitoring or prognostic test devices, 
their essentials and their pros and cons. 
Linked-evidence method. Another option is to apply a similar quantitative 
linked-evidence approach as discussed above that combines evidence from these 
predictive accuracy studies with evidence from therapeutic studies – preferably 
randomised – in order to quantify the potential benefits of a diagnostic, screening, 
prognostic or monitoring device for relevant, long-term health outcomes.61 A key issue 
is whether the additional individuals identified by the diagnostic, screening or prog-
nostic test will benefit from the therapy in the same way as the traditional individuals 
in the existing therapeutic studies.62
In Appendix IV, part D we provide empirical examples of a quantitative linked-ev-
idence approach that quantifies the benefits of a test device for long-term, relevant 
health outcomes. 
4.7.3 Qualitative linked-evidence approach 
As discussed in Section 4.5, indirect evidence that a device has benefits for long-term, 
relevant health outcomes can also come from other sources than those discussed in 
Section 4.7.2. For example:
• Differences in device use (e.g. by experts in specialised care rather than less expe-
rienced users in regular care);
• Differences in the individuals studied (e.g. investigating a device in a sample 
of healthy individuals rather than in a sample from the intended context and 
patients);
• Different indications (e.g. investigating a device for a specific medical context or 
indication and make inferences beyond this context); 
• Differences in the device itself (e.g. a device is a modified version of a previous 
device and only a technical performance study is conducted, without any clinical 
study or evaluation of the newer device). 
In such situations it is clearly much harder to apply a quantitative linked-evidence 
approach. In many cases, we do not know what kind of effects occur when a device is 
used, implanted or interpreted in regular care by less experienced users, or to what 
61  Merlin T., Lehman S., Hiller J.E., Ryan P., The ‘linked evidence approach’ to assess med-
ical tests: a critical analysis. International journal of technology assessment in health care 
2013;29(3):343-50; Schaafsma J.D., van der Graaf Y., Rinkel G.J., Buskens E., Decision analysis 
to complete diagnostic research by closing the gap between test characteristics and cost-effec-
tiveness. J Clin Epidemiol 2009;62(12):1248-52; Koffijberg H., van Zaane B., Moons K.G., From 
accuracy to patient outcome and cost-effectiveness evaluations of diagnostic tests and biomark-
ers: an exemplary modelling study. BMC Med Res Methodol 2013;13:12.
62  Ferrante di Ruffano L., Hyde C.J., McCaffery K.J., Bossuyt P.M., Deeks J.J., Assessing the value 
of diagnostic tests: a framework for designing and evaluating trials. Bmj 2012;344:e686.
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extent these effects are intended and unintended. Similarly, we often do not know to 
what extent the benefits and risks change when a device studied in a specific sample 
of individuals (e.g. in patients with a specific type of cancer) or for a specific med-
ical indication (e.g. stents for coronary arteries) is used for other types of patients 
(another type of cancer) or other indications (e.g. in the carotid arteries). Indeed, 
many devices can be used for several medical indications, which certainly applies to 
various diagnostic, prognostic and screening devices, such as imaging tests. Moreover, 
many devices are merely slightly modified versions or ‘copies’ of existing devices, with 
no testing beyond technical performance studies. 
Quantitative linked-evidence approaches may not be easy in any of these situa-
tions. However, the use of sensitivity and scenario analysis may help assess the impact 
of device use on health or health care, providing a good indication of the need for addi-
tional studies. When this is not feasible, then some kind of qualitative linked-evidence 
approach is indicated to evaluate the risks and benefits for health or health care.63 
Here, evidence concerning the device’s use – e.g. from technical performance studies 
(Figure 4.1) – and evidence of its safety taken from other studies or from studies on 
closely related devices – as well as evidence from studies on the device’s health bene-
fits should be combined and viewed from this perspective. A nice example is the recent 
study on the safety and benefits of stents for treating renal artery stenosis.64 Knowing 
the pathway through which benefits and risks of device use arise (Section 4.6) can be 
extremely helpful in this context. 
We must note that inferences about the relevant and long-term health benefits 
(and risks) of device use derived from qualitative linked-evidence approaches do not 
have the same validity as the direct quantitative approaches discussed in Sections 
4.7.1 and 4.7.2. Nevertheless, qualitative linked evidence is currently often consid-
ered sufficient for market access, and perhaps even for reimbursement decisions.
Summary of linked-evidence approaches
Linked-evidence approaches offer an alternative in situations where direct evaluation 
of a device’s added benefits or effects on long-term, patient-relevant, ‘hard’ health out-
comes is difficult or impossible. Their validity depends on how well the ‘intermediate’ 
outcomes predict the long-term, relevant health or health care outcomes. Linked-evi-
dence approaches can be used to test therapeutic and information-generating devices. 
They may be valuable specifically for devices that are in fact modifications of an 
63  Pope C., Mays N., Qualitative research in health care. 3rd ed: Blackwell Publishing, 2013; 
Bossuyt P.M., Reitsma J.B., Linnet K., Moons K.G., Beyond diagnostic accuracy: the clinical utility 
of diagnostic tests. Clin Chem 2012;58(12):1636-43; Bluhm R. From hierarchy to network: a 
richer view of evidence for evidence based medicine. Perspective Biol Med 2005;vol 8:535-547; 
Walach H., Falkenberg T., Fonnebo v., Lewith G., Jonas W.B., Circular instead of hierarchical: 
methodological principles for the evaluation of complex interventions. BMC Med Res Methodol 
2006;vol 6:6-29.
64  Postma C.T., Spiering W., Kroon A.A., Renal artery stenosis: do not toss the stent aside. Ned 
Tijdschr Geneesk. 2013;157:A6350
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existing device: they can be used to infer to what extent a minor device improvement 
will lead to benefits for the health or health care of the targeted individuals, context 
and users, by combining results from studies (technical and clinical) on the previous 
version or versions of the device. 
The literature provides a wealth of examples of linked-evidence approaches 
applied to medical devices in general, and to diagnostics in particular. The UK Health 
Technology Assessment programme, supervised by the NHS and NICE, offers various 
examples over the past ten years. We cite a few.65 Most linked-evidence approaches 
use general templates methods, generally based on similar approaches for drug 
evaluations.66 There are also general guides on the use of linked-evidence approaches 
65  Riemsma R., Al M., Corro Ramos I., Deshpande S., Armstrong N., Lee Y.C., et al., SeHCAT [tau-
roselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measure-
ment of bile acid pool loss: a systematic review and cost-effectiveness analysis. Health Technol 
Assess 2013;17(61); Meads C., Sutton A., Malysiak S., Kowalska M., Zapalska A., Rogozinska 
E., et al. Sentinel lymph node status in vulval cancer: systematic reviews of test accuracy and 
decision-analytic model-based economic evaluation. Health Technol Assess 2013;17(60); Lord 
J., Willis S., Eatock J., Tappenden P., Trapero-Bertran M., Miners A., et al., Economic modelling of 
diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical 
guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project. Health Technol 
Assess 2013;17(58); Waugh N., Cummins E., Royle P., Kandala N.B., Shyangdan D., Arasaradnam 
R., et al. Faecal calprotectin testing for differentiating amongst inflammatory and non inflam-
matory bowel diseases: systematic review and economic evaluation. Health Technol Assess 
2013;17(55); Sutcliffe P., Connock M., Pulikottil-Jacob R., Kandala N.B., Suri G., Gurung T., et al. 
Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular 
assist devices as either bridge to transplant or alternative to transplant for adults eligible for 
heart transplantation: systematic review and cost-effectiveness model. Health Technol Assess 
2013;17(53); Ward S., Scope A., Rafia R., Pandor A., Harnan S., Evans P., et al. Gene expression 
profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy 
in breast cancer management: a systematic review and cost-effectiveness analysis. Health Tech-
nol Assess 2013;17(44); Simpson E., Stevenson M., Scope A., Poku E., Minton J., Evans P., Echo-
cardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic 
evaluation. Health Technol Assess 2013;17(36); Orlando R., Pennant M., Rooney S., Khogali S., 
Bayliss S., Hassan A., et al., Cost-effectiveness of transcatheter aortic valve implantation (TAvI) 
for aortic stenosis in patients who are high risk or contraindicated for surgery: a model-based 
economic evaluation. Health Technol Assess 2013;17(33); Mowatt G., Scotland G., Boachie C., 
Cruickshank M., Ford J., Fraser C., et al., The diagnostic accuracy and cost-effectiveness of mag-
netic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding 
the localisation of prostate abnormalities for biopsy: a systematic review and economic evalua-
tion. Health Technol Assess 2013;17(20); Meads C., Auguste P., Davenport C., Ma ysiak S., Sundar 
S., Kowalska M., et al., Positron emission tomography/computerised tomography imaging in 
detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of 
subjective probabilities and economic modelling. Health Technol Assess 2013;17(12)
66  Mushlin A.I., Rushlin H.S., Callahan M.A., Costeffectiveness of diagnostic tests. Lancet 
2001;358:1353-55; A. Briggs, M. Sculpher, K. Claxton. Decision Modelling for Health Economic 
Evaluation. Oxford: OUP 2006. Pp. 256; Hunink M., Glasziou P., Siegel J., et al., Decision making in 
health and medicine. Integrating evidence and values. Cambridge: Cambridge University Press, 
2001.
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specifically for medical (diagnostic, screening, monitoring and prognostic) tests, 
obtained from organisations such as NICE, AHRQ and EUNetHTA.67 However, the pre-
vailing view that evidence linkage for medical devices merely requires the application 
of general linked-evidence principles has recently been challenged.68 Much work is 
therefore being carried out on developing linked-evidence methods. 
4.8 Summary: key issues to consider in all clinical studies on 
medical devices
This section summarises the main concepts of this chapter by providing a list of key 
issues that need to be considered by all researchers studying the clinical benefits, 
including clinical performance, of devices, whether therapeutic or non-therapeutic. 
These issues should be addressed regardless of whether the study approach is direct 
or indirect. They are also summarised in Table 4.1.
Device category/type – It is helpful to first specify the type of the device under 
study: a therapeutic device or a test (diagnostic, prognostic, monitoring or screening) 
device (Section 4.3). The intended health or health care benefits of the latter type 
are achieved indirectly because appropriate or more timely therapeutic management 
is subsequently provided, or because potentially harmful or more burdensome or 
costly additional management is avoided. However, undergoing an invasive diagnostic, 
screening, monitoring or prognostic test can still be harmful and may cause side-ef-
fects that negatively affect the benefit/risk ratio.
Pathway of benefits and aim of planned evaluation – Defining the pathways 
through which device use may lead to benefits and risks and determining the device’s 
evaluation phase indicates, directly, what evidence should be produced in the next 
phase. This may range from evidence concerning the device’s safety and technical 
performance to its clinical performance and clinical utility (see Figures 4.1 and 4.2). 
67  http://www.nice.org.uk/media/A0B/97/DAPManualFINAL.pdf; Agency for Healthcare 
Research and Quality. Methods Guide for Medical Test Reviews [posted November 2010]. 
Rockville, MD. Available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-re-
views-and-reports/?pageaction=displayProduct&productID=; http://www.eunethta.eu/
sites/5026.fedimbo.belgium.be/files/HTA%20Core%20Model%20for%20Diagnostic%20Tech-
nologies%201.0r.pdf.
68  Lord J., Willis S., Eatock J., Tappenden P., Trapero-Bertran M., Miners A., et al., Economic 
modelling of diagnostic and treatment pathways in National Institute for Health and Care Excel-
lence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project. 
Health Technol Assess 2013;17(58); Laking G., Lord J., Fischer A., The economics of diagnosis. 
Health Econ 2006 Oct;15(10):1109-20; Sutton A.J., Cooper N.J., Goodacre S., Stevenson M., Inte-
gration of Meta-analysis and Economic Decision Modeling for Evaluating Diagnostic Tests. Med 
Decis Making 2008 28: 650. DOI: 10.1177/0272989X08324036; velasco G.M., Mangiapane S., 
Surrogate outcomes in health technology assessment: an international comparison. Int J Technol 
Assess Health Care 2009 Jul;25(3):315-22. doi: 10.1017/S0266462309990213.
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Specification of the device pathway of effects and its current evaluation phase offers 
direct guidance on the aim and design of the next study. Each planned study should 
describe the current state (phase) of evidence, why the next study is needed, and what 
additional evidence is lacking. This should be linked to the ‘working pathway’ of the 
device (Section 4.6) by indicating what step in the pathway will be evaluated. Focused 
research aims or questions and an explanation of the evidence still lacking are critical 
starting points for discussing the next device evaluation stage. Appropriate choices 
about the type of study design, the intended population, context, use and outcomes 
to be studied (Sections 4.4 and 4.5) all depend on the underlying research aims and 
questions. In the context of diagnostic, prognostic or monitoring test devices, there 
is often a sequence of prior tests still being used in regular practice. Specifying the 
intended role and place of the new test device in this sequence of tests is therefore 
crucial for designing the next study and how to generate the most informative evi-
dence concerning the device’s benefits.
Targeted individuals & setting – The clinical benefit or performance of a device 
clearly depends on the medical setting and targeted users (care professionals) and/
or patients. Hence, it is necessary to determine whether the indications for use and 
diversity of the targeted individuals in the planned study – both defined by the inclu-
sion/exclusion criteria – are as similar as possible to the setting, targeted patients 
and/or users for which the device is intended. A device use may improve the health 
outcomes of the targeted patients or individuals directly, but it may also result in less 
burdensome care with comparable safety and health outcomes for the patient, more 
timely or efficient care by professionals, or more cost-effective care for society at large 
(Section 4.3). Examples include the use of a less invasive laparoscopic surgery device 
that offers the same level of safety and same effectiveness as conventional surgery, or 
the use of a less invasive bed-side diagnostic device that has the same diagnostic per-
formance as the prevailing but more burdensome laboratory or advanced test. 
A device may also be beneficial because it improves the health of care professionals, 
for example the use of patient lifts that assist in lifting and turning patients in bed so 
that nursing personnel can avoid back complaints. 
Other devices address care providers and society at large. Examples include faster 
and thus less costly diagnostic analysers in clinical laboratories that offer the same 
diagnostic performance as prevailing analysers, and thus safety and health effects for 
patients similar to those of prevailing care. Such new devices lead to more efficient or 
cost-effective health care and are thus relevant for care providers, health policymakers 
and indeed society at large. 
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Table 4.1 Key factors to consider in all clinical studies evaluating a medical device.
Key factors Description Implications
Type of device Therapeutic device or test device The benefits of a test device are achieved 
indirectly (informing subsequent health 
care actions), whereas a therapeutic 
device should have a direct effect. This 
difference has major implications for 
decisions related to device design, out-
comes, study subjects and costs. Details 
about research on both types of devices 
are given in Appendix Iv, part A, B and C.
Pathway of benefits Specification of the pathway through 
which a device will generate beneficial 
effects
Researchers can use this pathway to 
indicate what type of evidence their 
study will produce. When evaluating 
devices, it is often efficient to start 
with more simple forms of evaluation. 
Pathway specification greatly improves 
the build-up of a portfolio or network of 
evidence. 
Targeted individu-
als/setting
Indications for use and targeted individ-
uals in the planned study
The clinical benefit or performance of a 
device clearly depends on the targeted 
medical context, individuals and users. 
Ideally, the targeted context, individuals 
and users in the planned study are as 
similar as possible to the ‘real world’ sit-
uation in which the device will be used.
Device use The level of difficulty of device use, the 
user’s required level of expertise, and 
the need for training and level of train-
ing required are all key factors that may 
influence the benefits and risks of the 
device (and its use).
Ideally, the device and the way it is used 
in a clinical study are the same as they 
will be in the ‘real world’ situation.
Comparison group The evaluation of medical devices is in 
essence a comparative process: the new 
intervention is compared with prevail-
ing care.
There are several design, conduct and 
analysis options for generating results 
based on a fair comparison between 
groups. The details of numerous 
research strategies, with their pros and 
cons, are given in Appendix Iv.
Outcome/end-
points
A variety of outcomes can be addressed 
in a device study. These range from: 
in and by whom the outcomes are 
measured, the degree of (in)directness 
of the outcomes, the subjectivity of the 
outcome measurement, and the timing 
of that measurement.
The selection of outcomes to be 
addressed in a device study is crucial 
and should be in line with the type 
of device, the (expected) pathway of 
effects, the device evaluation phase, and 
the type of evidence a study is meant 
to generate. Details about possible 
research approaches and the outcomes 
addressed in each approach are given in 
Appendix Iv.
Device use and user interference – The device and the way it is used in a clinical 
study is ideally the same as will be in the ‘real world’. The level of difficulty of the 
device, the end-user’s required level of expertise, the need for training and the level of 
training required by the end-user are key factors that may influence benefits and risks. 
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However, evidence concerning the benefits (and risks) of devices is often generated in 
an environment quite different from that of real-world use. For example, many clinical 
studies of complex devices are conducted in an environment staffed by highly skilled 
and trained operators. Often there is a learning curve associated with the use of such 
devices, and the results of such studies cannot simply be generalised to expected 
benefits and risks in regular practice. Besides a detailed description of the pathways 
through effects (intended or unintended) may occur, we therefore also need to know 
the conditions for designing a proper clinical evaluation, for example potential user 
variability and learning effects on use or interpretation. If the benefits (and risks) of 
the device depend on how it is used or how its results are interpreted, and are thus 
susceptible to user variation, this should be explicitly defined. 
In clinical investigations, it is advisable to apply the same conditions – training, 
expertise of end-users, etc. – as might be encountered in the targeted context and pop-
ulations. Any deviations from this might compromise the performance/benefits of the 
device when used in practice. Clinical studies can encompass this by including more 
users (to allow for inter-user variation assessment), or by including users other than 
highly experienced ones who have been specifically trained for that purpose (in order 
to better reflect regular practice), and by having the same user use or interpret the 
device (e.g. an imaging test) multiple times (in order to assess intra-user variation and 
learning curve effects). 
Finally, we wish to reiterate that users can be care providers (such as radiologists 
in the case of imaging tests or clinical chemists in the case of laboratory tests), but also 
individuals or patients (e.g. point-of-care tests to detect specific markers in body fluids 
such as the pregnancy test, but also automated blood-pressure measurement devices). 
Comparison strategy & device allocation – Clinical benefits and performance – 
including improved or less burdensome diagnosis, prognosis, screening or monitoring 
– are relative and not absolute features. This in fact applies to any health care inter-
vention. To draw valid inferences about the benefits, performance or accuracy of a 
device, it is important to compare observed benefits, performance or accuracy in the 
device group with those observed in a comparison (control) group. 
This comparison is ideally involves a direct evidence approach (Sections 4.5 and 
4.7.1). The control group individuals may undergo/use an earlier version of the same 
device, a competing device or any other alternative care, including no intervention. 
Ideally, the comparative strategy will offer a realistic alternative. Sham (placebo) 
interventions are less suitable for device studies. They may only be used if they meet 
ethical standards, and then only if there is thought to be a placebo effect.69 Ideally, the 
two groups being compared are created by random (chance) splitting. Accordingly, 
provided the groups are large enough, it is more likely that any observed differences 
69  Kirkley A., Birmingham T.B., Litchfield R.B., Giffin J.R., Willits K.R., Wong C.J., Feagan B.G., 
Donner A., Griffin S.H., D’Ascanio L.M., Pope J.E., Fowler P.J., A randomized trial of arthroscopic 
surgery for osteoarthritis of the knee. N Engl J Med. 2008 ;359:1097-107.
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in benefits, performance, accuracy, risks, etc., can be assigned to the difference in 
management, and thus to the device use. Participants can also serve as controls for 
themselves (e.g. left vs. right hand). This may be indicated when the effects of manage-
ment with the new device and of control management are local. A control group may 
also include non-randomised, concurrent controls, for example individuals who are as 
similar as possible to the individuals in the new device group but managed or treated 
at another centre or in another country that has not used the new device. Controls can 
also be non-concurrent, such as the use of historical control groups. For example, one 
may compare observed benefits, accuracy or performance in a group of individuals at 
the same or another hospital before the new device was used (control group) to the 
same outcome parameters after it was introduced. 
The challenge in all non-randomised comparisons is to ensure that the groups 
being compared are comparable on all other aspects that might influence health out-
comes, e.g. similar characteristics and additional care. Discussions about whether or 
not to include a comparison in a study and how to choose or create these comparison 
groups are the same, whether the devices are therapeutic or test or information-gener-
ating. However, in direct comparative studies of test devices it is often possible to use 
cross-over designs in which each subject is administered the new and alternative tests 
(see Appendix IV, part C).
It is possible to estimate the benefits, accuracy or performance of a new device as 
compared to alternative strategies indirectly using a linked-evidence approach (see 
Sections 4.5 and 4.7.2 and 4.7.3). The observed benefits of a device on intermediate, 
short-term or test accuracy outcomes are extrapolated to long-term effects on the 
relevant individual or patient outcomes using a quantitative modelling approach. This 
is described in detail in Section 4.7.2. The linked-evidence approach can also involve 
qualitative modelling. Here, evidence concerning device use (e.g. taken from techni-
cal performance studies), evidence concerning its safety (taken from other studies 
or from studies on closely related devices) and evidence taken from studies on the 
device’s health benefits for the relevant outcomes are combined and placed into an 
overall working pathway perspective. Inferences about the relevant, and long-term 
health benefits (and risks) of a device obtained by means of qualitative linked-evi-
dence approaches do not have the same validity as direct quantitative approaches.
Outcomes/endpoints – the choice of health outcome parameters (endpoints) is 
dictated by the expected capabilities and working pathway of device use. This involves 
addressing the following issues. 
• Which outcomes may be expected by whom: the patient, care provider (e.g. ease of 
use, less burdensome or more efficient to use), others (e.g. hospital boards, policy-
makers, society at large).
• The type of outcomes: patient-reported endpoints (e.g. perceived pain or quality of 
life), endpoints requiring subjective interpretation (e.g. lesions on imaging, epilep-
tic foci on EEGs), or objective endpoints (all-cause mortality, myocardial infarction 
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based on predefined increase in blood parameters). 
• The timing of outcome measurement: short term or long term, in other words how 
much time should pass between device application and measuring the outcome 
in the participants. This depends on whether there might be a rebound effect, i.e. 
whether a short-term effect will diminish after 12 or 24 months. 
• Surrogate/intermediate versus hard/patient-relevant outcomes. This choice is again 
guided by the pathway through which effects might occur.
• Composite endpoints, i.e. a pre-specified combination of more than one endpoint, 
are sometimes used. This choice should be based on the assumption that the effect 
of the intervention on each of the components will be similar, and is also of similar 
importance.
• A special instance of intermediate outcomes concerns information-generating 
devices such as diagnostic, monitoring, prognostic, and screening tests. Such 
devices are often only studied for their predictive accuracy, which in fact can be 
considered an intermediate outcome between technical performance outcomes 
and clinical effectiveness outcomes (Sections 4.3 and 4.5). 
• Regardless of the types of outcomes, outcomes are measured systematically using 
standardised assessment tools in each patient (for patient-relevant endpoints) or 
for each care provider (for care provider outcomes). 
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5. complEmEntary issuEs 
Although the committee does not intend to prescribe when to use which type of study 
approach in which situation or for which type of device, there are a number of com-
plementary issues that go beyond general guidance for the development of evidence 
strategies from a methodological point of view, as discussed in the previous chap-
ter. These issues are discussed below. They should be seen against the background 
of European policymaking on medical devices, and are referenced here in order to 
improve or highlight the context of medical device evaluation in particular cases. In 
September 2012, the EU published an amended version of the MDD directive, follow-
ing consultations. The new version is meant to tighten up the clinical research require-
ment, combines the MDD and AIMDD into one, and will be turned into a Regulation 
(2015), meaning that the EU guidelines must be implemented in national law (effec-
tive 2020).70 
New clinical data or time series (‘off label’ use)
Assuming that a medical device has a specific indication or targeted population, the 
question remains whether new clinical investigations are needed for each new poten-
tial application, context or target population. It is critical in this context to identify 
when a new device is an incremental development, e.g. the equivalent of a previous 
version or a similar device, whether it is a new device, or an existing device for a 
totally new indication or intended medical context. The equivalence concept is key in 
this discussion (see Appendix III).
70 http://ec.europa.eu/health/medical-devices/documents/revision/index_en.htm and 
http://ec.europa.eu/health/medical-devices/documents/interpretative-documents/index_
en.htm.
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Randomised or non-randomised comparative studies are generally time-consum-
ing. Modifications (e.g. to enhance safety, patient comfort, ease of use) of low-risk 
technologies that already have been available for many years and have been properly 
characterised from a safety, performance and even benefits perspective might not 
require new clinical evidence derived from a newly designed and conducted compar-
ative study. Bench and/or animal testing may be sufficient to substantiate the benefits 
(performance or effectiveness) of the enhanced device. For modifications of high-risk 
and some medium-risk devices, however, new clinical studies – in targeted individuals 
– are basically required. This requirement is even stricter in the amended directives. 
What approach and which specific designs are useful depend on the type of infor-
mation needed, as discussed at length in Chapter 4 and Appendix IV. For example, 
historical controls involving a previous version of the device can be used as a compar-
ison group. 
Linked evidence, notably quantitative, approaches (combining the clinical data of 
small user groups and building evidence by combining data and stratifying for specific 
parameters, see Section 4.7.2) are useful because it is not feasible to require entirely 
new studies for every new target group. Instead, subsequent time series can be col-
lected. This is only possible if the research parameters and possible bias factors are 
well described and if the details of the study are easily accessible for others. 
 
The committee recommends further study of linked-evidence approaches for medical 
device evaluations, as discussed in Sections 4.7.2 and 4.7.3. Appraisal of consecutive 
clinical studies may build on a more holistic perspective, with a more flexible strategy to 
select and synthesise data, an approach known as a network of evidence as opposed to a 
hierarchy of evidence.71 
Registration of the use of medical devices – information in databases
Registration systems and routine care databases used to obtain high-quality data 
that provide a nuanced understanding of safety, performance and clinical benefit in 
71  Lord J., Willis S., Eatock J., Tappenden P., Trapero-Bertran M., Miners A., et al., Economic 
modelling of diagnostic and treatment pathways in National Institute for Health and Care Excel-
lence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project. 
Health Technol Assess 2013;17(58); Laking G., Lord J., Fischer A., The economics of diagnosis. 
Health Econ 2006 Oct;15(10):1109-20; Sutton A.J., Cooper N.J., Goodacre S., Stevenson M., 
Integration of Meta-analysis and Economic Decision Modeling for Evaluating Diagnostic Tests. 
Med Decis Making 2008 28: 650. DOI: 10.1177/0272989X08324036; velasco GM, Mangiapane S. 
Surrogate outcomes in health technology assessment: an international comparison.; A. Briggs, M. 
Sculpher, K. Claxton. Decision Modelling for Health Economic Evaluation. Oxford: OUP 2006. Pp. 
256; Hunink M., Glasziou P., Siegel J., et al., Decision making in health and medicine. Integrating 
evidence and values. Cambridge: Cambridge University Press, 2001. IJzerman M.J., Early Bayesian 
modeling of a potassium lab-on-a-chip for monitoring of heart failure patients at increased risk 
of hyperkalaemia. Technological Forecasting and Social Change. 2012 Sep;79(7):1268–79.
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a broad-based population are difficult and costly. These registrations are, however, 
crucial to assessing the long-term safety, performance and effectiveness of medical 
devices, especially in the case of calamities. The committee wishes to emphasise the 
relevance of such registrations, as well as the need to comply with regulatory post-
marketing surveillance requirements, given the need for continuous monitoring of 
risks and benefits of medical devices.72 Here, unique device identification in the digital 
health infrastructure may prove of value. 
In this respect, the EU is also taking steps: the Global Medical Device Nomencla-
ture (GMDN), now supported by the GMDN Maintenance Agency,73 has developed the 
Nomenclature into what it is today: a comprehensive, regularly updated web-based 
nomenclature accessible to manufacturers for a licence fee. Closer public-private 
partnerships in Europe are needed to combine and connect existing registries and to 
analyse such data in-depth. In addition, these registries require high-quality data for 
proper analysis. Such databases can combine all available data taken from technical 
studies with all clinical investigation and long-term use data. 
The committee realises that the responsibility for lifetime registries of medical devices is 
best placed at the user end, and that this requires transparency from manufacturers and 
regulators. 
User involvement
User needs, user contexts, user outcomes and user evaluation are all aspects of a more 
user-centred world. One of the principles of device development and evaluation is the 
early and continuous focus on users. The modes of involvement range from inform-
ative, through consultative to participative.74 User involvement is needed at an early 
stage of medical device development in order to avoid risks and support benefits. In 
assessing the benefit/risk ratio, patient-reported outcome measures (PROMs) can also 
support the quality of care delivered to patients from a patient perspective.75 
72  A European databank for medical devices has been developed under the name Eudamed 
(under provision of the medical device directives). It is a secure web-based portal acting as a 
central repository for information exchange between national Competent Authorities and the 
Commission and is not publicly accessible. Eudamed use is obligatory since May 2011. The aim 
of Eudamed is to strengthen market surveillance and transparency in the field of medical devic-
es. Eudamed contains (among others) data obtained in accordance with the vigilance procedure 
and also data on clinical investigations.
73  http://www.gmdnagency.com/.
74  Kujala S., User involvement: a review of benefits and challenges. Behaviour & Information 
Technology;2003,vol 22(1): 1-16. DOI: 10.1080/0144929021000055530.
75  Crawford B., Mathias S.D., Sullivan E., Basic principles of patient-reported outcomes 
research. In: Therapeutic and diagnostics device outcomes research; 2011, ISPOR. ISBN 
9780974328928; IJzerman M.J., Steuten L.M.G., Early Assessment of Medical Technologies 
to Inform Product Development and Market Access. Appl Health Econ Health Policy. 2011 
Sep;9(5):331–47.
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User preferences are also relevant in benefit-risk appraisal. Usually the regula-
tor defines what is acceptable, whereas risk tolerance will vary among patients, in 
turn affecting individual patient decisions as to whether the risks are acceptable in 
exchange for a probable benefit. Some patients are willing to take on a very high risk 
to achieve a small benefit, whereas others are more risk averse. The basic principles 
for what constitutes a meaningful benefit and risk may continue to evolve.76
 
Finally, users operate autonomously and are increasingly able to buy tests ‘over the 
counter’. Devices, for instance a genetic test or a blood pressure meter, are offered or 
sold on the internet and the test results are delivered without any advice or interpreta-
tion by a health care professional. A growing number of remote monitoring and mobile 
phone applications are becoming available for homecare and for patient self-manage-
ment. They represent a whole new type of health care intervention whose benefits are 
related to user and patient expectations. However, such technology also challenges 
us to define/redefine the risks and benefits associated with their use. This publicly 
accessible, direct-to-consumer segment beyond any medical control may be one of the 
fastest-growing parts of the market in the near future. Should these devices neverthe-
less meet the same standards as those developed for use by health care professionals?
The committee stresses that these ‘modern’ device use methods should be taken into ac-
count in any further guidance for research into clinical performance and benefit.
End-user training and follow-up on safety issues 
User interference is a crucial factor in the introduction of medical devices and their 
use throughout the entire device life cycle, not only when accessing the market 
through well-trained and properly supported key opinion leaders, but also when 
device use is being extended to other hospitals and users. Untrained use may seriously 
affect device safety and hence negatively impact the device’s risk/benefit ratio. 
The Dutch Order of Medical Specialists (OMS) and the Dutch Health Insurance Board 
(CvZ) therefore defined guidelines for the safe introduction and use by professionals 
of new medical innovations in regular care. By acknowledging the responsibility of 
health care professionals and their institutions for the safety of their patients, OMS 
and CvZ wish to implement a system of back-testing for unintended events. The guide-
line (“Leidraad”) recommends the need for responsible implementation to prevent 
such risks, including extensive end-user training with medical devices and prospec-
tive risk analysis in order to maximise the benefit and minimise the risk when used in 
regular practice. 
76  Hauber, A.B, et al. (2009). Older Americans’ risk-benefit preferences for modifying the 
course of Alzheimer disease. Alzheimer Dis Assoc Disord, 23:23-32; Nigel K. Arden, N.K, et al. 
(2012). How do physicians weigh benefits and risks associated with treatments in patients with 
osteoarthritis in the United Kingdom? J.Rheum, DOI:10.3899.
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When institutions or professionals cannot indicate that they have followed these 
guidelines, the Health Care Inspectorate (IGZ) and/or CvZ may take action (e.g. regard-
ing reimbursement). The new guidelines for the safe introduction of medical devices 
in regular care are currently being discussed with OMS and medical research societies. 
The guidelines will be presented in 2014.77 Of particular interest is that the guidance 
also describes how long-term follow up could be organised.  
The committee endorses the OMS/CvZ plan for guidelines for the safe introduction of 
medical devices in regular care, as they will support the follow-up of medical device use 
and help build and enhance linking evidence. 
Evaluation of cost-effectiveness of devices
Cost-effectiveness analysis aims to provide evidence at the level of the health care sys-
tem and builds upon modelling and standardisation. The international standards are 
more or less established for pharmaceuticals. Standards of research are comparable 
for medical devices, yet their application and implementation in comparable phases of 
development and as part of reimbursement decisions have not received the same level 
of support, i.e. have not yet become standard policy. Standards will inevitably follow 
further advances in health technology assessment, but for medical devices they may 
need to overcome many challenges first.78 
The cost-effectiveness of an individual device depends on our knowing the costs 
and the device’s effectiveness. Both knowledge sets are unstable, so the result of the 
equation is volatile as well, and not yet widely applicable. Costs are not always stable 
because prices are negotiable at the level of the institution. Effectiveness is very often 
not established in terms of health outcomes, although there is a growing demand for 
patient-reported outcomes, and surrogate endpoints are non-informative as primary 
endpoints. 
For example, the National Institute for Health and Care Excellence (NICE,) pro-
vides guidance to the NHS in the UK on the clinical and cost-effectiveness of selected 
new and established technologies. The Institute issues a guidance document with an 
overview of the principles and methods of health technology assessment, describing 
77  Leidraad Introductie van Nieuwe Interventies in de Klinische Praktijk; Draft December 2013. 
Kennisinstituut van medische Specialisten, op initiatief van de orde van Medisch Specialisten en 
College (OMS) voor Zorgverzekeringen (CvZ).
78  Schaafsma J.D., van der Graaf Y., Rinkel G.J., Buskens E., Decision analysis to complete diag-
nostic research by closing the gap between test characteristics and cost-effectiveness. J Clin Epi-
demiol 2009;62(12):1248-52; Koffijberg H., van Zaane B., Moons K.G., From accuracy to patient 
outcome and cost-effectiveness evaluations of diagnostic tests and biomarkers: an exemplary 
modelling study. BMC Med Res Methodol 2013;13:12.
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key principles of appraisal methodology.79 However, despite ongoing advances in the 
methodology of technology appraisal, areas of controversy and uncertainty remain. 
Methods of cost-effectiveness analysis are no exception in terms of ongoing develop-
ment.80 Thus, there will be contributions to our understanding and further develop-
ment of HTA knowledge and expertise both the in the Netherlands and internationally 
(e.g. the HTA international policy forum, HTAi). 
The committee realises that innovative approaches and further research and guidance 
are needed with respect to the cost-effectiveness assessment of medical devices.
79  Guide to the methods of technology appraisal 2013, National Institute for Health and Care 
Excellence (NICE). http://publications.nice.org.uk/guide-to-the-methods-of-technology-ap-
praisal-2013-pmg9.
80  van de Wetering G., Steuten L.M.G., Birgelen von C., Adang E.M.M., IJzerman M.J., Ear-
ly Bayesian modeling of a potassium lab-on-a-chip for monitoring of heart failure patients 
at increased risk of hyperkalaemia. Technological Forecasting and Social Change. 2012 
Sep;79(7):1268-79; IJzerman M.J., Steuten L.M.G., Early Assessment of Medical Technologies 
to Inform Product Development and Market Access. Appl Health Econ Health Policy. 2011 
Sep;9(5):331-47.
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6. concluding rEmarks 
To enable well-informed health care and reimbursement decisions, research is 
required to provide evidence of the risks (safety), performance, benefits (effective-
ness) and even cost-effectiveness of any health care intervention, including medical 
devices. As applies to all medical interventions, medical devices are more likely to be 
used when it is clear that their risk/benefit ratio is more favourable than – or at least 
equal to – current care. Accordingly, this involves studying medical devices in a valid 
scientific manner. 
The committee has discussed the issues presented in this report at length over a 
period of almost two years. During that time, it addressed many viewpoints, ideas, 
comparisons, policy directives, frameworks and designs. It was not easy to find a 
strategy that could build on the committee’s combined scientific expertise in clinical 
research methods without interfering with the current state of affairs and develop-
ments in the regulatory, clinical, academic and industrial sectors. The committee 
explicitly decided to focus on offering guidance for research into the added perfor-
mance and benefits of medical devices, as stakeholders felt that this was notably 
lacking in current research guidelines for medical devices. 
The guidance in this report supports the design, conduct, analysis and reporting of 
suitable, robust, transparent and sustainable device research in order to build evi-
dence of the risks (safety), performance and benefits of medical devices, thereby 
helping to meet the needs of tomorrow. This report can help stakeholders involved in 
the development, use, evaluation and regulation of medical devices choose the proper 
approach when evaluating the benefits and performance of medical devices for health 
care, given the device specifics. The report stresses that there is no one-size-fits-all 
approach possible, given the wide diversity of medical devices available and their spe-
cific characteristics. The report also helps to interpret existing evidence of the risks, 
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performance, and benefits of a device use and put this evidence in perspective so as to 
make more informed decisions regarding the introduction, use, and reimbursement of 
a device. The committee trusts that this report is useful for national and international 
stakeholders, including: 
• researchers and professionals in health care; 
• medical device industry, and SMEs in particular;
• Notified Bodies;
• health insurance companies;
• hospital boards; 
• regulatory agencies;
• funding agencies;
• medical ethical review committees.
The committee appreciates that the guidance in this report is not set in stone. It should 
be regarded as a set of recommendations and options for all stakeholders involved in 
assessing or using medical devices. The guidance ultimately aims to protect society 
and users/end-users against the introduction and use of devices that are ‘unsafe’ or 
‘unnecessary’.
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appEndix iii  
dEfinitions, risk 
classification, and rEgulation 
of mEdical dEvicEs
This appendix provides information on the regulatory requirements for medical 
device innovations and the organisation of market access, which is regulated at inter-
national level. 
Definition of medical device
The term medical device covers a multitude of different items. A few are complex and 
reflect the latest advances in medical technology, e.g. new imaging equipment, vari-
ous implants in heart, vessels, bones and joints, and advanced point-of-care lab tests. 
Most, however, are relatively simple, e.g. thermometers, latex gloves and crutches, to 
mention only a few. There are also numerous ‘me-too’ devices, i.e. different suppliers 
producing similar devices that offer the same performance. The medical device world 
is thus diverse in its nature, applications and user categories. Diversity is also evident 
in the risks involved and in the regulatory systems used to manage those risks; in the 
manufacturing costs and sales prices; in the standards and nomenclature systems; and 
in the various approaches used to determine the effectiveness, cost-effectiveness, and 
safety of devices.1 
The committee decided to take the European Commission definition of a medical 
device as its starting point. The Commission defines a medical device as: 
‘any instrument, apparatus, appliance, software, material or other article, whether 
used alone or in combination, including the software intended by its manufacturer to be 
used specifically for diagnostic and/or therapeutic purposes and necessary for its proper 
application, intended by the manufacturer to be used for human beings’ (Directive 
2007/47/EC). 
Devices are to be used for the purpose of:
• Diagnosis, prevention, monitoring, treatment or alleviation of disease.
• Diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap.
1  Priority Medical Devices, WHO, 2010.
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• Investigation, replacement or modification of the anatomy or of a physiological  
process
• Control of conception
This includes devices that ‘do not achieve its principal intended action in or on the 
human body by pharmacological, immunological or metabolic means, but which may be 
assisted in its function by such means’. The latter refers to products combining medical 
devices and drugs, in which the main mode of action is device-related. 
In fact, Directive 2007/47/EC is the technical revision of the three main directives 
constituting the core legal framework for medical devices. Compliance with Directive 
2007/47/EC became mandatory for manufacturers, Notified Bodies and Competent 
Authorities on 21 March 2010. The three directives aim to ensure a high level of pro-
tection for human health and safety and the proper functioning of the single market. 
The three main directives are:
• Directive 93/42/EEC regarding medical devices (MDD). The MDD covers all 
medical devices that are not regulated by the more specific AIMD Directive or IvD 
Directive (see Box III.1)
• Directive 90/385/EEC regarding active implantable medical devices (AIMDD). 
Active Implantable Medical Devices are devices relying for their functioning on a 
source of electrical energy or any source of power other than that directly gen-
erated by the human body or gravity which are intended to be totally or partially 
introduced, surgically or medically, into the human body or by medical intervention 
into a natural orifice, and which are intended to remain after the procedure.  
A pacemaker is an example of an AIMD.
• Directive 98/79/EC regarding in vitro diagnostic medical devices (IvDD). An in 
vitro diagnostic medical device (IvD) means any medical device which is a rea-
gent, reagent product, calibrator, control material, kit, instrument, apparatus, 
equipment, or system, whether used alone or in combination, intended by the 
manufacturer to be used in vitro for the examination of specimens, including blood 
and tissue donations, derived from the human body, solely or principally for the 
purpose of providing information: on a physiological or pathological state; or on a 
congenital abnormality; or to determine the safety and compatibility with potential 
recipients; or to monitor therapeutic measures.
box iii.1: thE following dEvicEs arE rEgulatEd by thE mdd 1993
• Hospital equipment (e.g. anaesthetic instruments, heart-lung machines, x-ray machines, 
and surgical instruments)
• Dental equipment (e.g. chair, Uv-light apparatus, implants)
• Audiometric devices (e.g. measuring instruments, hearing aids)
• Ophthalmic devices (e.g. diagnostic instruments, glasses and contact lenses)
• Prostheses (both implantable and non-implantable)
• Devices for disabled or impaired persons (e.g. wheelchairs, and rehabilitation devices)
• Devices for single use (e.g. contraceptive rubbers).
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The latest revision of these directives began recently with the publication of two 
Commission proposals (26 September 2012) for two new regulations to replace 
the existing three directives. The new Medical Devices Regulation will integrate the 
MDD and the AIMDD into a single regulation; and the IvDD will be replaced by the In 
vitro diagnostic medical devices regulation. The proposed changes (covered in both 
proposals) include greater transparency, stricter requirements on traceability in the 
supply chain, more scrupulous designation and auditing of notified bodies, additional 
pre-market scrutiny for higher risk devices, more clinical evidence required for higher 
risk (see below) and implantable devices, and the introduction of central reporting of 
serious incidents to a central database. More structured post-marketing surveillance 
activities will also be required.
Risk Classification of medical devices
One key difference across the many different types of medical devices is the wide 
range of risks associated with their use. These risks are particularly relevant when a 
request for market access is filed for new devices. The risk classification system is 
different from that for pharmaceuticals. The EU concept of risk classification depends 
on the intended use (as described by the manufacturer) and distinguishes four classes 
of risks, ranging from low risk to high risk (see box below). This classification system 
is outlined in Annex IX to Directive 93/42/EEC. The classification is based on the risk 
for patients if the medical device were to fail and is set out in a set of rules. The rules 
are broad statements relating to situations, functions, parts of the body treated, 
properties, etc.2 They differentiate between numerous different categories in order to 
offer more flexibility and more easily assess the risk of new developments in medical 
technology. 
The classification is not a list of products, which would require constant updating. 
The rules are designed to minimise any possible ambiguity. The manufacturer can 
assign each new device, or part of a (updated) device, to a risk category, which in 
turn is connected to specific requirements such as how manufacturer are to demon-
strate a device’s performance. The rules work well, with disagreements about risk 
2  European Commission, DG Health and Consumer; Directorate B, Unit B2 ‘Cosmetics and me-
dical devices’. MEDDEv 2.4/1 Rev 9; June 2010. Guidance document – Classification of medical 
devices Guidelines relating to the application of the Council Directives 93/42/EEC on Medical 
Devices.
• Class I – generally regarded as low risk
• Class IIa – generally regarded as medium risk 
• Class IIb – generally regarded as medium risk 
• Class III – generally regarded as high risk 
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classification arising for only ten or so of the 500,000 different devices. The main 
criterion that distinguishes the different classes is whether clinical evaluation requires 
(new) clinical investigations, or whether it can refer to the literature or previous clin-
ical investigations with equivalent devices. Risk classification is particularly relevant 
for new classes of medical devices. It is generally not critical for improvements to a 
device that is based on the same working principles.
The following concepts are used in the legislation governing access to the medi-
cal devices market (see also Box 2.1 in Chapter 2, main text). These concepts are not 
directly comparable to the concepts used for pharmaceuticals, such as efficacy, effec-
tiveness and safety.
• Clinical evidence – Information or clinical data that supports the scientific validity 
and performance (analytical performance and, where applicable, clinical perfor-
mance) of the device when used as intended by the manufacturer;
• Analytical/Technical Performance – The ability of a device to correctly detect or 
measure a particular analyte;
• Clinical evaluation – The assessment and analysis of clinical data pertaining to a 
medical device to verify the clinical safety and performance of the device when 
used as intended by the manufacturer. Clinical evaluation is an ongoing process; 
information about clinical safety and performance (e.g. adverse event reports, 
results from any further clinical investigations, published literature etc.) should be 
monitored routinely by the manufacturer once the device is available on the market 
and the benefits and risks reassessed in light of this additional information;
• Clinical investigation (synonymous with ‘clinical trial’ and ‘clinical study’) – Any 
systematic investigation or study in or on one or more human subjects, undertaken 
to assess the safety and/or performance of a device;
• Clinical utility – A concept generally used for diagnostic devices that refers to the 
likeliness of the test significantly improving the health outcomes of the targeted 
individuals. In other words, the capacity of the test to rule in and/or out the disor-
der of interest, and to facilitate a decision to adopt or to reject a subsequent (e.g. 
therapeutic) action. Clinical utility is an increasingly common concept in health 
care, but one that lacks an agreed formal definition or conceptualisation. The term 
is commonly used as a synonym for clinical effectiveness;
• Clinical Performance – The ability of a device to yield results that are correlated 
with a particular clinical condition or a physiological state in accordance with a 
target population and intended user. Interventional clinical performance is where 
the test results may influence patient management decisions and/or may be used 
to guide treatment.
In the next section we describe the way the regulatory system is organised in the EU 
and in the USA. This is the extended version of the concise regulatory requirements 
presented in Chapter 2 in combination with a diagram. To aid the reader and provide 
an overview, the diagram is reproduced here (see Figure III.1).
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Regulations for market access of medical devices
We begin by comparing the EC regulatory system to that of the USA and then discuss 
international harmonisation activities. 
EU regulatory system
According to the Medical Devices Directives, the government of each Member State 
is required to appoint a Competent Authority (in the Netherlands: the Ministry of 
Health, Welfare and Sport and/or the Health Care Inspectorate/IGZ) responsible for 
medical devices. The Competent Authority (CA) acts on behalf of the government of 
the Member State to ensure that the requirements of the Medical Device Directives are 
transposed into National Law and are applied.
Figure III.1 provides an overview of the regulatory system for medical devices.
The authorisation of medical devices (i.e. market access) is guaranteed by a Decla-
ration of Conformity. This declaration is issued by the manufacturer itself, but for 
products in Class IIa, IIb or III, it must be verified by a Certificate of Conformity 
issued by a Notified Body (in the Netherlands: DEKRA, formerly KEMA). A Notified 
Body is a public or private organisation that has been certified to validate the device’s 
compliance with the European Directive. Medical devices assigned to class I (provided 
that they do not need to be sterilised or are not used to measure a function) can be put 
on the market after self-certification. Manufacturers can choose any Notified Body for 
Conformity assessment. 
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When the Notified Body has approved the Declaration of Conformity, the manufac-
turer is allowed to identify the medical devices with a CE (Conformité Européenne) 
mark. CE marking indicates that the product meets the essential requirements of the 
applicable EU directives (such as safety, health, environmental protection require-
ments). CE marking is compulsory for all medical devices and to sell or use a device 
without it is an economic offence, but CE marking is not compulsory for a device that 
is still subject to clinical research, or for a personally customised product. For a new 
device subject to clinical research, an investigational medical device dossier (IMDD, 
available from the CCMO website) can be given to the medical ethical committees for 
approval. However, in the Netherlands the medical ethical committees prefer a device 
to have a CE marking before they approve clinical research, and the technical instru-
mentation services at hospitals also play an active role in this case. Use of a device 
beyond its intended purpose is considered off-label use.
By and large, then, CE marking refers to the technical quality and safety of the 
product, and compliance with the directives, including risk analysis. Medical devices 
must not only be safe, however, but also function both medically and technically as 
the manufacturer ‘intended’. This is regulated through the ISO system. Of particular 
interest is the recent NEN-EN-ISO 14155:2011 international standard, which provides 
a ‘Good Clinical Practice for medical devices for human use’. ISO 14155:2011 specifies 
general requirements intended to ‘protect the rights, safety and well-being of human 
subjects, ensures the scientific conduct of the clinical investigation and the credibility 
of the results, define the responsibilities of the sponsor and principal investigator, and 
assist sponsors, investigators, ethics committees, regulatory authorities and other 
bodies involved in the conformity assessment of medical devices’, in essentially the 
same way as the ICH GCP applies to medicinal products. ISO 14155:2011 does not 
apply to in vitro diagnostic medical devices. This ISO standard describes the design of 
clinical investigations (A6) and statistical considerations (A7) in largely general terms. 
Clinical evaluation
The Medical Devices directives, as well as the Guidance documents3 that accompany 
the directives, describe the processes and essential requirements in terms of safety 
and clinical evaluation in some detail. One of the essential requirements in the EU is 
to perform a clinical evaluation (see Medical Device Directive Art. 15 and Annex X). 
Performing a clinical evaluation basically means looking at all the available clinical 
data and assessing the safety and performance. Clinical data are derived from: 
• a critical evaluation of the relevant scientific literature currently available and 
relating to the safety, performance, design characteristics and intended purpose of 
the device;
• or a critical evaluation of the results of all clinical investigations made;
3  e.g. MEDDEv 2.7/4 Guideline on Clinical Investigation: A Guide for Manufacturers and Noti-
fied Bodies.
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• or a critical evaluation of the combined clinical data provided. 
The clinical evaluation and its documentation must be actively updated by data 
obtained from the postmarketing surveillance. The update should include not only 
data on the manufacturer’s own medical device but also data on other similar medical 
devices (regardless of their manufacturer). A clinical evaluation report describes the 
data sources, assesses their suitability, and presents an evaluation and conclusions. 
When the available data are not sufficient to draw valid conclusions about the 
device’s safety and performance, additional clinical investigations are required. The 
objectives of such clinical investigations are:
• to verify that, under normal conditions of use, the performance of the devices con-
form to those intended by the manufacturer, and
• to determine any undesirable side-effects, under normal conditions of use, and 
assess whether they constitute risks when weighed against the intended perfor-
mance of the device.
Studies must be conducted in accordance with Article 15, Annex vIII and Annex 
X of the EU MDD. Annex vIII describes what should be submitted to the Competent 
Authority before the start of the study. It also describes what documentation is needed 
for inspection purposes. Pre-approval from a CA is required. 
Guidance from the Medicines and Healthcare Regulatory Agency (MHRA, UK) states 
that clinical investigations should probably be carried out if: 1) it is a Class III device, 
or an implantable device; 2) it is a new design or new application; 3) it contains new 
materials; 4) the device is modified in such a way that it is potentially significantly 
affecting clinical safety and performance; and 5) sufficient data do not exist. A clinical 
investigation is probably not needed (according to the MHRA) if: 1) it is a low-risk 
device; 2) sufficient data exist; and 3) it is an equivalent product. 
The medical devices regulatory process relies heavily on the concept of equiva-
lence, which refers to the fact that data from equivalent devices can be used to support 
the safety and/or performance of the device in question. In order to be equivalent, 
devices should have the same intended use and need to be comparable with respect to 
their technical and biological characteristics. These characteristics should be similar 
to such an extent that there would be no clinically significant difference in the devices’ 
performance and safety. The nine criteria for equivalence depend on:
The intended use relating to: 
• the clinical condition being treated, 
• the severity and stage of disease, 
• the site of application to/in the body and 
• the patient population; 
The technical characteristics relate to: 
• the design, specifications, physiochemical properties including energy intensity, 
• deployment methods, 
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• critical performance requirements, 
• principles of operation and conditions of use. 
Biological characteristics relate to biocompatibility of materials in contact with the 
same body fluids/tissues. 
It is the responsibility of the Notified Bodies to judge whether equivalence has been 
sufficiently shown by the manufacturer. Based on supposed equivalence, a manufac-
turer can build a case for something new on existing data and literature. It is possible 
to show equivalence for some of the criteria; in that case additional investigations are 
only required for the non-equivalent elements of the device. 
To summarise, the critical issue is that Good Clinical Practice for medical devices 
is not supported by a specific process description of how to collect new clinical data 
for every new product. Altogether, the regulatory authorities have neither a basic 
rationale or conceptual framework nor methodological requirements for the clinical 
data needed to provide sufficient evidence of added clinical benefit. This is because 
the range of device products is much larger than in the pharmaceuticals sector and 
because the purpose and role of a device are often low risk, which requires less clin-
ical evidence because manufacturers are allowed to rely on equivalence. But this is 
case-dependent and the more high-risk a device is, the more clinical investigations are 
required. In addition, when a new device enters the market and has a profile similar 
to another, less expensive, device meant for a similar purpose, the more comparative 
effectiveness studies are needed. In the case of medical devices, the critical judgment 
is in the hands of the Notified Bodies, which often take a more technical view than the 
more clinically based European Medicines Agency appraisal. The Notified Bodies are 
under pressure because they are uneven in quality.
US regulatory system
Although there are many similarities between the regulatory process in the United 
States and that in the European Union, there are some important differences that 
impact the time and cost associated with the introduction of a new medical device. 
This is particularly true with regard to the organisation involved in approval, the cri-
teria for approval, and the local institutional review board’s position and negotiation 
options. In the USA, the definition and classification of medical devices is slightly dif-
ferent than in the EU, although Class III devices are the highest-risk ones in the USA as 
well. In addition the USA has a different procedure (see below). The most notable dif-
ference is that the Center for Devices and Radiological Health (CDRH), part of the Food 
and Drug Administration (FDA), is responsible for granting market access instead of 
non-governmental notified bodies regulating the approval and post-approval process.
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For a new medical device, first clinical use is perceived as a key milestone.
1. Clinical testing of an unapproved significant-risk medical device requires FDA 
approval in the form of an Investigational Device Exemption (IDE). The IDE appli-
cation provides the FDA with information on device design and qualification, as 
well as on the study protocol. An IDE may also be required for studies in which an 
approved device is used for a purpose distinct from its approved indication. This 
is typically the case when a trial is sponsored by a company for the purpose of 
expanding a device’s indication or making significant changes in the instructions 
for use.
2. Following FDA approval to initiate clinical studies, subsequent review is required 
by the institutional review board (IRB) at the clinical site. 
3. The regulatory approval process by the FDA’s CDRH is as follows for the different 
risk categories. Note that risk classification in the USA is not exactly the same as in 
the EC: 
3a. Class I (lowest risk) devices are subject to general controls, which are published 
standards pertaining to labelling, manufacturing, postmarketing surveillance, 
and reporting. Formal FDA review is not required for most class I devices before 
their market introduction. This correlates with the EU self-certification process.
3b. Class II devices are those higher-risk devices for which general controls alone 
are insufficient to provide reasonable assurance of safety and effectiveness. 
They require special controls that may include performance standards, design 
controls, and postmarketing surveillance programmes. In addition, most class 
II devices require FDA clearance of a premarket notification application (PMA or 
510[k]) before the device may be marketed. In the 510(k) application, the med-
ical device manufacturer must provide data to demonstrate that the new device 
is ‘substantially equivalent’ to a legally marketed device. Although substantial 
equivalence can usually be demonstrated on the basis of bench and animal 
testing alone, approximately 10% of 510(k) applications include clinical data. 
In other words, the concept of equivalence is a dominant principle in the USA as 
well.
3c. Class III devices (such as heart valves and coronary artery stents) are judged 
to pose the highest potential risk. Most class III devices require FDA approval 
of a PMA before they can be legally marketed. Approval of the PMA generally 
requires clinical data demonstrating reasonable assurance that the device is 
safe and effective in the target population.
The PMA process typically involves a series of studies starting with first clinical use 
and culminating in a multicentre, prospective (randomised) control trial (pivotal 
trial). The complexity and extent of the clinical testing programme is dictated by the 
nature of the device and its proposed use. The clinical study programme is developed 
by the company in conjunction with clinician investigators, all in close collaboration 
with FDA/CDRH. Even when the FDA has authorised early US clinical trials, clinical 
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testing must pass significant additional hurdles at each clinical site in terms of IRB 
and contract approvals. This difference has a profound impact on the size and scope 
of the clinical studies for regulatory approval.4 When few data on existing standards 
are available, the FDA typically requires randomised rather than single-arm studies, 
in which the new device is compared against concurrent controls treated with current 
best medical practice. That comparison may be powered to show that the new treat-
ment is superior to prior approaches, or that it is non-inferior (equivalent or better) 
compared with a previously approved treatment/device.
For new high-risk devices, US regulatory requirements are more extensive and 
require more time and resources than those of other countries. It is estimated that 
obtaining FDA approval to initiate clinical studies in the United States adds 3 to 6 
months to the process of device development. In addition, subsequent review by the 
institutional review board (IRB) at the clinical site can add an additional 3 to 6 months 
to this timeline. Because of these factors, most initial clinical device testing has shifted 
to outside the United States. It is estimated that more than 75% of first clinical use 
of cardiovascular device testing now takes place outside the United States. However, 
high-profile new devices that require new clinical data for approval are the exception 
rather than the rule. Most devices currently in testing are similar to well-characterised 
approved devices. When FDA/CDRH has substantial data on the device class metrics, 
comparisons may be made to historical data or objective performance criteria. The 
vast majority of device clinical trials are case series that carefully document product 
performance. 
To summarise, the USA is generally more stringent and the innovation climate in 
the EU is more favourable in the case of new and innovative devices, but for subse-
quent versions of previously approved devices, USA practice is less stringent. The 
510K procedure is currently under review and the requirements for in vitro diagnostic 
tests (high risk in the USA, medium risk in the EU) have been circumvented by the 
application of ‘lab developed tests’, which do not require extensive clinical data. 
Harmonisation
The reason that the EU and the USA (and the rest of the world, for that matter) differ 
with regard to medical devices is that the international harmonisation of legislation 
has not been concluded. One example of the lack of harmonisation is the ISO 14155 
(2011),5 which has not been accepted by the FDA; it currently works with CFR 820 but 
may accept ISO 14155 in the near future. However, regulatory authorities and indus-
try from all over the world joined forces in 1992 to respond to the growing need for 
4  Medical Device Development: from Prototype to regulatory approval. Kaplan et al. (2004). 
Circulation 109: 3068-3072.
5  ISO 14155 (2011) Clinical investigation of medical devices for human subjects – Good Clini-
cal Practice.
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international harmonisation by creating the Global Harmonization Task Force (GHT-
F),6 which worked on definitions and concepts for medical devices. Since its inception, 
the GHTF has consisted of the representatives of five founding members (Australia, 
Japan, USA, EU, Canada) grouped into three geographical areas – Europe, Asia-Pacific 
and North America – each of which actively regulates medical devices using their own 
unique regulatory framework. Chairmanship of the GHTF is rotated among the regula-
tory representatives of the five founding members. Japan is the current chair.
The purpose of the GHTF is to encourage convergence in regulatory practices 
related to ensuring the safety, effectiveness/performance and quality of medical 
devices, promoting technological innovation and facilitating international trade. The 
primary way in which this purpose is accomplished is via the publication and dissem-
ination of harmonised documents on basic regulatory practices. These documents, 
which are developed by five different GHTF Study Groups, provide a model for the 
regulation of medical devices that can then be adopted/implemented by national reg-
ulatory authorities. The GHTF study groups have delivered working documents. The 
Group on clinical safety and performance has delivered reports on Clinical evidence7. 
The other study groups have documented their agreements. All the guidance docu-
ments are discussed in the ASEAN harmonization working party to expand global cov-
erage. GHTF is now in the process of liquidation. In collaboration with the WHO, a new 
forum is being created: the International Medical Devices Regulatory Forum (IMDRF),8 
which started in 2011. IMDRF will further continue to develop the documents, to 
prepare for worldwide implementation in national law at a global scale. The medical 
device industry has achieved this harmonisation in almost 20 years. 
Use in wider populations – Postmarketing surveillance
The realities of logistics, time, and resources restrict the size and duration of most new 
device trials to 800-1500 patients, thereby limiting the power of these trials to detect 
events with an occurrence rate of <1%. In addition, the most experienced physicians at 
medical centres with sufficient research infrastructure and patients to recruit usu-
ally carry out the pivotal trials. The need to extrapolate the results to the real-world 
post approval is equally or even more pressing than in the case of pharmaceuticals 
(because of user interference), since the degree of generalizability to a wider popu-
lation is much smaller. This cannot be captured in randomised clinical trials (RCT), 
but requires follow-up studies. There is therefore a need for stricter postmarketing 
surveillance data that are accurate and timely, both in the US and Europe. 
Several systems for obtaining high-quality data are available that provide a 
nuanced understanding of safety, performance and clinical benefit in a broad-based 
6  http://www.ghtf.org/.
7  Key definitions and concepts, June 07 (N1); Clinical evaluation, June 07 (N2); Clinical inves-
tigations April 10 (N3).
8  http://www.imdrf.org/.
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population. These are difficult and costly. In the US there is:
• The Medical Device reporting (MDR) system (the EU has a similar system). The 
MDR system relies mainly on manufacturers, importers and user facilities comply-
ing with mandatory reporting requirements. It is easy and relatively inexpensive 
for monitoring, but not suitable for detecting rare (but serious) adverse events. 
This is due to underreporting and inadequate characterisation of the patient popu-
lation at risk. 
• Claims-based data drawn from health insurance companies or other third parties 
that can combine admission and diagnosis-related groupings with adverse events. 
These databases may be useful but are not designed for postmarketing surveil-
lance. Moreover, there is a substantial delay between reporting and the event, and 
coverage may be poor. 
• Regional databases. These allow for follow-up of in-hospital complications, for 
example, but are not structured for following outcomes associated with a specific 
device. 
• Multicentre registries (disease-oriented). They may examine practice patterns and 
the outcomes of procedures in specific medical disciplines. The data are limited in 
that these databases are not designed to track specific devices.
• Device-specific registries. They are often established by manufacturers as part 
of their postmarketing surveillance programmes. They typically contain larger 
amounts of data, but numbers frequently remain below the number (>5,000 or so) 
required to detect and quantify a 1 in 200 adverse event frequency with adequate 
statistical power. 
New approaches would need to do at least the following:
• assign device-related complications, distinguishable from spontaneous events 
related to disease natural history;
• sample the entire population;
• establish a frequency threshold.
Requirements for reimbursement in The Netherlands
Unlike the authorisation process for medical devices in the EU, which all Member 
States (the Competent Authority and Notified Body) follow to a greater or lesser 
extent, the reimbursement procedures for medical devices vary significantly from 
country to country. The health care policy of a country largely determines whether 
and how a medical device is eligible for reimbursement. In the Netherlands the health 
care policy, including the rules and measures for compensation, is developed and 
controlled by the Ministry of Health, Welfare and Sport. The Dutch reimbursement 
policy for medical devices is based on diagnosis-related groups (DRGs). The system is 
called the Diagnosis Treatment Combination (DBC) and it is used for patient classifica-
tion, cost containment and Health Technology Assessment (HTAs), which quantify the 
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cost-effectiveness of interventions (including devices). On the basis of established pro-
cedures (see below), the Health Insurance Board in The Netherlands (CvZ) assesses 
whether drugs, medical devices and other devices are part of the basic insurance pack-
age. Most medical devices are included (in part) in the basic health insurance package 
for specific indications. Some reimbursement instruments are available that are based 
on other than health insurance schemes, such as the Exceptional Medical Expenses Act 
(AWBZ) and the Social Support Act (WMO).
Medical care must meet at least two criteria: it must be care that ‘professionals 
tend to offer’ and the care must reflect ‘the state of science and practice’. For some 
types of care, additional conditions or limitations apply. Care must also be delivered in 
a way that professionals consider up to professional standards. CvZ usually determines 
whether this is the case on the basis of guidelines and professional standards. To 
determine whether care meets ‘state of science and practice ‘standards, CvZ adheres 
to the principles of evidence-based medicine. This method involves the careful, explicit 
and judicious use of the best available evidence on the effectiveness, cost-effectiveness 
and safety of the care in question. CvZ’s premise is that there must be a ruling based 
on medical-scientific data that meet the highest possible standards for evidence. CvZ 
basically uses only published and peer-reviewed literature in its assessments.
In essence, care must comply with the principles of effectiveness, cost-effective-
ness, necessity and feasibility. For the effectiveness principle, CvZ makes a distinction 
between health-related and welfare-related tools. CvZ has made this distinction to 
clarify the level of proof required. The Assessment Framework Tools report (for out-
patient medical devices) is especially elaborating on the principles of necessity and 
effectiveness.
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appEndix iv  
ovErviEw of clinical study 
approachEs for mEdical 
dEvicEs
The huge variety of medical devices available calls for a flexible but integrated approach 
to accumulating evidence that a device is safe and will produce relevant benefits for 
health or health care. There are numerous study approaches available for building 
a portfolio of evidence for a device. One key difference between these approaches is 
whether the study will provide 1. direct evidence; 2. indirect quantitative evidence (e.g. 
short-term outcomes, intermediate/surrogate outcomes, accuracy measures) or 3. 
indirect qualitative evidence (e.g. results from different patient population or when the 
device tested differs from the device of interest). Whether a direct or indirect (linked) 
evidence approach is used, it is still possible to choose from a wide range of different 
study types or designs that can be used in each of these three research approaches. Each 
of these study types has its pros and cons (e.g. risks of bias). 
In this appendix we describe traditional and novel study types and designs – 
everything from traditional randomised studies to novel, more tailored randomised stud-
ies, to semi-randomised and non-randomised designs – which can all be used in medical 
device evaluations that are aimed at providing evidence of the benefits of a device (or 
its use) for health or health care. The advantages and drawbacks of each study type are 
given, and they are illustrated by examples of medical device evaluations taken from 
many different areas of medicine and many different types of devices. For background 
literature, see the references cited in the main text, which are complemented by some 
additional references (without being exhaustive) where deemed necessary.
A. Randomised (direct evidence) study approaches9
Randomisation ensures that the groups being compared – one in which the device 
is used and one (or more) in which not the device but some alternative, compara-
tive management (including placebo or sham management) is used – are created by 
random or chance splitting. Provided they are large enough, the groups are ‘the same’ 
9  This section builds upon the extensive literature and books written on these topics, some of 
them referred to in the main text of chapter 4, and on the report Alternatieven voor Randomized 
Clinical Trials in onderzoek naar de effectiviteit van interventies. M. Langendam, L. Hooft, R. 
Scholten, P. Bossuyt. Dutch Cochrane Centre (DCC), Academisch Medisch Centrum, Amsterdam, 
februari 2013.
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except for the device under study. All other modifying factors – the ‘confounders’ 
– are equally distributed across the comparison groups. Accordingly, any observed 
differences in benefits (and risks) between the groups can be assigned with a larger 
measure of likelihood to the actual difference in management, and thus to the device 
use; all other modifying (confounding) factors are ruled out due to the randomisation. 
Provided it is successful, randomisation allows researchers to draw conclusions about 
true cause-and-effect relationships between the device use and the health or other 
outcomes.
A randomised clinical trial (RCT) can have varying sample sizes, ranging from small 
trials to very large (mega) trials..10 Randomisation can be executed on the individ-
ual or patient level, where the usual aim is to compare the effects of device use on 
patient-related endpoints, intermediate or long term. It can also be executed at the 
practitioner or end-user level, where the endpoints are user-relevant, such as a differ-
ence in ease of use, efficiency, time-to-diagnosis, etc.
Device companies often struggle to fund and organise such trials. Randomised 
designs, especially the more novel and tailored approaches (see below under B), still 
can play a role by providing high-level evidence (low risk of bias) for the comparative 
safety, performance, benefits or effects, and even cost-effectiveness of devices. 
A1. Pragmatic or comparative effectiveness randomised trials
The best randomised design for direct evaluation of a medical device’s benefits or 
added benefits is the parallel randomised pragmatic design. This applies both to 
therapeutic and test devices, i.e. diagnostic, monitoring, screening or prognostic 
tests (see Chapter 4.3). Targeted individuals or clusters of individuals are allocated 
randomly, concurrently and in parallel to either the new intervention or the compar-
ative (control) strategy. A large-scale, long-term pragmatic or comparative effec-
tiveness randomised trial compares the use of the device in question directly with 
the best alternative care in the right population, measuring all relevant outcomes 
over the long term and with use as it would be in everyday practice. Of course in the 
case of diagnostic, screening or monitoring devices, the therapeutic actions dictated 
by the results of such devices are also part of the intervention. 
Such a design would produce the most direct and valid evidence of whether the 
device will indeed produce the intended relevant health benefits, at an acceptable 
level of safety, as compared to prevailing care. Even the cost-effectiveness of the 
device use can be addressed. This is true both for devices that interfere with bodily 
systems in order to treat or alleviate specific health conditions (therapeutic devices) 
and for test devices such as diagnostic, prognostic, monitoring or screening tests 
that rather generate information based on which therapeutic actions are adminis-
tered (see Chapter 4.3, main text).
10  Charlton B.G., Mega-trials: methodological issues and clinical implications. J R Coll Physi-
cians Lond 1995;29:96-100.
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Pragmatic randomised trials are a specific and – for device evaluations – argua-
bly the best form of a parallel RCT. The key feature of the pragmatic trial is that the 
comparison is not a placebo intervention (see below) but an alternative intervention, 
usually best current practice, with no restrictions on their application. Pragmatic trials 
are designed to evaluate the effectiveness of the index intervention (e.g. device use) 
under routine practice conditions, as opposed to placebo controlled trials, which test 
whether a specific intervention-aspect (in drugs this is referred to as the ‘pharmaco-
logical agent or substance’) is effective under optimal ‘experimental’ conditions. The 
pragmatic aspects of a trial may include, among others:
• the use of broad eligibility criteria to specifically select participants with heteroge-
neous characteristics, conform daily care; 
• having flexible strategies for the use of the device; 
• include a variety of practicioners with different expertise regarding the device use;
• include a variety of clinical settings;
• assess a variety of clinically meaningful or patient relevant outcomes. 
Accordingly, the outcomes of pragmatic randomised trials are considered to have 
greater relevance for clinical practice and health policy makers. 
The main disadvantage of pragmatic trials is that the participants and the practi-
tioners are commonly not blinded, potentially obscuring the net effects of the index 
device. Their advantage, however, is that results are often directly applicable to daily 
care. The benefits (and risks) found in such trials are highly generalizable because 
pragmatic trials usually include participants who will be dealing with the intervention 
in the real world, recruit patients from a broader range of study sites (not only aca-
demic or highly experienced medical centres and professionals), and have outcomes 
that often represent a full range (not only short-term or intermediate outcomes) of 
relevant patient and professional health outcomes. 
A2. Randomised placebo-controlled trials 
A placebo or sham-controlled parallel randomised design is the most traditional 
randomised design, and comes from the pharmaceutical domain. The major advantage 
of this design is that all possible influences from any source – patient and professional 
interpretation influences and other confounding factor influences – are controlled for 
due to the double-blinded, placebo-controlled randomised character of the study. This 
design is much less straightforward for the evaluation of medical devices than it is for 
medicines, mainly because devices are part of complex interventions where, for exam-
ple, double blinding, and thus a full placebo or sham-management control group can 
be extremely difficult. Moreover, traditional randomised placebo-controlled studies 
are often conducted in an environment staffed by highly skilled and trained operators 
and by high-volume medical centres, with very specific patient inclusion and exclusion 
criteria. As a result, these trials deliver evidence in an environment that can be quite 
different from real-world, pragmatic use. 
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In the medical device sector, the comparative strategy often involves alternative, 
prevailing management or even no management (wait-and-see), see under A1. Sham 
or placebo-device interventions as comparison exist but are rare in device evaluations. 
When they do take place, they are almost always for therapeutic devices, and not for 
diagnostic, screening or monitoring devices.
ExamplEs of pragmatic trials usEd for mEdical dEvicE  
Evaluation
Title: Clinical evaluation of silicone hydrogel lens wear with a new multipurpose disin-
fection care product.
Registration number: Not reported.
Source: MEDLINE (through PubMed)
Reference: Zigler L, Cedrone R, Evans D, Helbert-Green C, Shah T. Eye Contact Lens. 2007 
Sep;33(5):236-43.
Abstract:  PURPOSE: To evaluate subjective symptoms and clinical signs in silicone hydro-
gel contact lens wearers with three different multipurpose solution (MPS) lens care reg-
imens. METHODS: In a double-masked, randomized, concurrently controlled study, 233 
subjects from 12 clinical sites wore one of two silicone hydrogel lens brands (ACUvUE 
Advance or Focus NIGHT & DAY) for 1 month on a daily-wear basis supported by a new 
reconditioning multipurpose disinfecting solution (MPDS) preserved with POLYQUAD 
and ALDOX, regimen 1 (OPTI-FREE RepleniSH Multi-Purpose Disinfecting Solution), or by 
one of two MPSs preserved with polyhexamethyl biguanide, regimen 2 (ReNu MultiPlus 
Multi-Purpose Solution No Rub Formula) or regimen 3 (Complete MoisturePLUS Mul-
ti-Purpose Solution). RESULTS: Significant differences in favor of regimen 1 were found 
in subjective responses of subjects wearing ACUvUE Advance lenses. For Focus NIGHT & 
DAY lens wearers, regimen 1 was associated with significantly less corneal staining (se-
verity [P=0.0019], area [P=0.0077]) than regimen 2 was. The average number of times 
per day that rewetting drops were used was significantly higher for subjects randomized 
to regimen 3 than for subjects using regimen 1. CONCLUSIONS: The clinical performance 
of the new MPDS product with silicone hydrogel lenses was generally as good as or better 
than the two comparative polyhexamethyl biguanide-preserved MPSs. Clinical differenc-
es were evident between the products. Practitioners should be aware that MPS product 
choice for use with silicone hydrogel lenses may lead to different clinical outcomes, par-
ticularly in regard to stress on the ocular surface, as evidenced by the corneal staining 
response.
Title: Safety and efficacy of gravitational shunt valves in patients with idiopathic normal 
pressure hydrocephalus: a pragmatic, randomised, open label, multicentre trial (SvASONA).
Registration number: ISRCTN51046698
Source: MEDLINE (through PubMed)
Reference: Lemcke J, Meier U, Müller C, Fritsch MJ, Kehler U, Langer N, Kiefer M, Eymann 
R, Schuhmann MU, Speil A, Weber F, Remenez v, Rohde v, Ludwig HC, Stengel D. J Neu-
rol Neurosurg Psychiatry. 2013 Aug;84(8):850-7. doi: 10.1136/jnnp-2012-303936. Epub 
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2013 Mar 1.
Abstract: OBJECTIvES: To investigate whether gravitational valves reduce the risk of 
overdrainage complications compared with programmable valves in ventriculoperitoneal 
(vP) shunt surgery for idiopathic normal pressure hydrocephalus (iNPH). BACKGROUND: 
Patients with iNPH may benefit from vP shunting but are prone to overdrainage compli-
cations during posture changes. Gravitational valves with tantalum balls are considered 
to reduce the risk of overdrainage but their clinical effectiveness is unclear. METHODS: 
We conducted a pragmatic, randomised, multicentre trial comparing gravitational with 
non-gravitational programmable valves in patients with iNPH eligible for vP shunting. 
The primary endpoint was any clinical or radiological sign (headache, nausea, vomiting, 
subdural effusion or slit ventricle) of overdrainage 6 months after randomisation. We also 
assessed disease specific instruments (Black and Kiefer Scale) and Physical and Mental 
Component Scores of the Short Form 12 (SF-12) generic health questionnaire. RESULTS: 
We enrolled 145 patients (mean (SD) age 71.9 (6.9) years), 137 of whom were available 
for endpoint analysis. After 6 months, 29 patients in the standard and five patients in the 
gravitational shunt group developed overdrainage (risk difference -36%, 95% CI -49% to 
-23%; p<0.001). This difference exceeded predetermined stopping rules and resulted in 
premature discontinuation of patient recruitment. Disease specific outcome scales did not 
differ between the groups although there was a significant advantage of the gravitational 
device in the SF-12 Mental Component Scores at the 6 and 12 month visits. CONCLUSIONS: 
Implanting a gravitational rather than another type of valve will avoid one additional 
overdrainage complication in about every third patient undergoing vP shunting for iNPH.
ExamplEs of placEbo-controllEd rcts usEd for mEdical  
dEvicE Evaluation 
Title: A novel nasal expiratory positive airway pressure (EPAP) device for the treatment 
of obstructive sleep apnea: a randomized controlled trial.
Registration number: NCT00772044
Source: MEDLINE (through PubMed)
Reference: Berry RB, Kryger MH, Massie CA. Sleep. 2011 Apr 1;34(4):479-85.
Abstract: STUDY OBJECTIvES: Investigate the efficacy of a novel nasal expiratory positive 
airway pressure (EPAP) device as a treatment for obstructive sleep apnea (OSA). DESIGN: 
A prospective, multicenter, sham-controlled, parallel-group, randomized, double-blind 
clinical trial. SETTING: 19 sites including both academic and private sleep disorder 
centers. PATIENTS: Obstructive sleep apnea with a pre-study AHI ≥10/hour. INTERvEN-
TIONS: Treatment with a nasal EPAP device (N=127) or similar appearing sham device 
(N=123) for 3 months. Polysomnography (PSG) was performed on 2 non-consecutive 
nights (random order: device-on, device-off) at week 1 and after 3 months of treatment. 
Analysis of an intention to treat group (ITT) (patients completing week 1 PSGs) (EPAP 
N=119, sham N=110) was performed. MEASUREMENTS AND RESULTS: At week 1, the 
median AHI value (device-on versus device-off) was significantly lower with EPAP (5.0 
versus 13.8 events/h, P<0.0001) but not sham (11.6 versus 11.1 events/h, P=NS); the 
decrease in the AHI (median) was greater (-52.7% vs. -7.3%, P<0.0001) for the ITT group. 
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At month 3, the percentage decrease in the AHI was 42.7% (EPAP) and 10.1% (sham), 
P<0.0001. Over 3 months of EPAP treatment the Epworth Sleepiness Scale decreased (9.9 
± 4.7 to 7.2 ± 4.2, P<0.0001), and the median percentage of reported nights used (entire 
night) was 88.2%. CONCLUSIONS: The nasal EPAP device significantly reduced the AHI 
and improved subjective daytime sleepiness compared to the sham treatment in patients 
with mild to severe OSA with excellent adherence.
Title: Evaluating the Effect of Tooth Cleaning Devices on Oral Health
Registration number: NCT01250769
Source: ClinicalTrials.gov
Reference: Not published (yet).
Protocol: This is a study to evaluate the safety and the efficacy of tooth and interproximal 
cleaning modalities on oral health. Study Design: Allocation: Randomized; Endpoint Clas-
sification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Sin-
gle Blind (Outcomes Assessor); Primary Purpose: Treatment. Condition: Dental Plaque. 
Intervention: Device: Manual Toothbrush; Device: Interproximal Cleaning Device. Prima-
ry Outcome Measures: Residual Protein Concentration [Time Frame: 14 days] [Designat-
ed as safety issue: No], Residual protein concentration of interproximal plaque samples. 
Secondary Outcome Measures: Residual Protein Concentration [Time Frame: 28 days] 
[Designated as safety issue: No], Residual protein concentration of interproximal plaque 
samples, Modified Gingival Index [ Time Frame: 14 days ] [ Designated as safety issue: No 
], Gingival inflammation evaluation on an ordinal scale of 0 to 4 (0 is best ; 4 is worst), 
Modified Gingival Index [ Time Frame: 28 days ] [ Designated as safety issue: No ], Gingi-
val inflammation evaluation on an ordinal scale of 0 to 4 (0 is best ; 4 is worst), Gingival 
Bleeding Index [ Time Frame: 14 days ] [ Designated as safety issue: No ], Gingival bleeding 
evaluation using an ordinal scale of 0 to 3; (0 is best; 3 is worst), Gingival Bleeding Index 
[ Time Frame: 28 days ] [ Designated as safety issue: No ], Gingival bleeding evaluation 
using a ordinal scale of 0 to 3; (0 is best; 3 is worst).
Enrollment: 170 patients
Study Start Date: April 2010 
Study Completion Date: June 2010 (Final data collection date for primary outcome 
measure)
A3. Cross-over trials 
In addition to RCTs involving parallel groups, pragmatic or placebo-controlled, there 
are other approaches in which subjects can serve as self-controls. In a randomised 
controlled paired or cross-over design (in contrast with parallel comparison), 
participants still undergo randomisation but also serve as their own control. They can 
retrieve the device (e.g. nerve stimulator) and the alternative treatment simultane-
ously, with the new intervention being assigned to, for example, the left leg or arm and 
the control treatment to the right leg or arm. In a cross-over design, the participants 
receive both interventions, although consecutively in a randomly assigned order. This 
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design is possible when the target disease/condition is chronic and regresses – in due 
time – to the original baseline status when the first assigned intervention ceases. Cross-
over trials are also recommended when the new device and control intervention have 
relatively local effects that do not overlap after a ‘washout period’. 
Paired or cross-over approaches have two major advantages over parallel designs. 
First, they are less susceptible to imbalances between other modifying factors (con-
founders) because each patient serves as his or her own control. Second, these trials are 
very efficient and require smaller sample sizes because they produce within-participant 
comparisons (whereas parallel designs produce between-participants comparisons).11 
Cross-over trials are sometimes infeasible, however, and they have their disadvan-
tages. As we said, this approach is generally performed in patients with chronic or 
incurable diseases. For curative treatments or rapidly changing (instable) conditions, 
cross-over trials may be infeasible or unethical. The effects of both interventions should 
also have rapid onset, be of short duration and be administered after a sufficiently long 
‘washout period’ to avoid ‘carry-over effects’ between the two intervention periods. In 
practice, however, planning a sufficiently long wash-out period requires expert knowl-
edge of the treatment dynamics, which are often unknown. Related to this problem is 
the issue of ‘order effects’, because the order in which treatments are administered may 
affect the endpoints under study. 
ExamplE of a cross ovEr trial usEd for mEdical dEvicE  
Evaluation
Title: A comparison of the Supreme laryngeal mask airway with the Proseal laryngeal 
mask airway in anesthetized paralyzed adult patients: a randomized crossover study.
Registration number: Not reported.
Source: MEDLINE (through PubMed)
Reference: Tham HM, Tan SM, Woon KL, Zhao YD. Can J Anaesth. 2010 Jul;57(7):672-8. 
doi: 10.1007/s12630-010-9312-6. Epub 2010 Apr 22.
Abstract:  PURPOSE: The Supreme laryngeal mask airway (SLMA) is a new single-use 
advanced form of the Proseal laryngeal mask airway (PLMA). This study tested the hy-
pothesis that the SLMA is equally as effective as the PLMA as a supraglottic ventilato-
ry device in anesthetized paralyzed adult patients. METHODS: Size 4 SLMAs and PLMAs 
were compared in a randomized crossover study involving 60 patients aged 21-75 yr and 
American Society of Anesthesiologists physical status I and II. Once the patients were 
anesthetized and paralyzed, the SLMA and the PLMA were inserted into each patient in 
random order. The primary outcome measure was the laryngeal seal pressure (LSP) at 
an intracuff pressure of 60 cm H(2)O. Secondary outcome measures included the ease of 
inserting the laryngeal mask airway devices (LMADs) and the fibreoptic position of the 
airway tube. RESULTS: There was no statistically significant difference in LSP between the 
11  Louis T.A., Lavori P.W., Bailar J.C. III, Polansky M. ‘Crossover and self-controlled designs in 
clinical research’. In: Bailar J.C. III, Mosteller F., eds. Medical uses of statistics, 2nd edn. Boston, 
MA: New England Medical Journal Publications, 1992:83-104.
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SLMA and the PLMA. The mean LSP was 19.6 +/- 5.8 cm H(2)O and 20.9 +/- 6.7 cm H(2)
O for the SLMA and the PLMA, respectively. There was a similarity between the SLMA and 
the PLMA regarding the number of attempts required and the duration for insertion. How-
ever, fibreoptic positioning was better with the PLMA than with the SLMA (P < 0.0001). 
CONCLUSION: The clinical performance of the SLMA as a ventilatory device is comparable 
with that of the PLMA, as illustrated by the similar LSPs. The inferior position of the SLMA 
airway tube compared with that of the PLMA does not affect its ease of ventilation.
A4. Adaptive trials 
This novel approach is defined as ‘a clinical study design that uses accumulating data 
to decide how to modify aspects of the study as it continues, without undermining 
the validity and integrity of the trial.’12 The randomisation ratio is changed during the 
course of the trial; these changes should not be ad hoc but by design. In general, there 
are two main approaches: monitoring the balance of baseline covariates in the rando-
misation during the continuing trial; and a response-adaptive treatment allocation. 
An example of the latter is that, based on observed benefits (or absence of benefits) 
in particular subgroups in the first series of randomised subjects, one continues the 
randomisation (or discontinues the trial) in those subgroups only. Another version of 
an adaptive design is a sequential trial. In this approach, the number of participants is 
not pre-specified. Instead, participants are recruited until intervention differences are 
observed (or can be dismissed). These trials are designed with the idea that the accu-
mulated evidence at – pre-specified – interim analyses is sufficient to draw appropri-
ate inferences about the benefits (and risks) of the device. Particularly in these adap-
tive trials, the use of Bayesian methods has been on the rise; that has also been true of 
clinical trials of medical devices over the past decade, as it may offer many advantages 
when it comes to evaluating more invasive, implantable medical devices.13 In Bayesian 
approaches, estimates of the benefits (and risks) are made based on prior informa-
tion, which is complemented by and weighted against empirical observations taken 
from new studies. Accordingly, inferences about the benefits and risks of a device are 
not based solely on the empirical studies but on the weighted evidence of previous 
knowledge and new evidence. Prior information can come from previous studies or 
informative registries. 
The major advantage of adaptive trial designs is that they can suffice with consider-
ably smaller sample sizes and are very efficient compared to typical randomised trials 
12  U.S. Food and Drug Administration: Draft Guidance for Industry: adaptive design clinical 
trials for drugs and biologics. http:// www.fda.gov/downloads/DrugsGuidanceComplianceReg-
ulatoryIn formation/Guidances/ UCM201790.pdf.
13  Bonangelino P. et al., ‘Bayesian Approaches in Medical Device Clinical Trials: A Discussion 
with Examples in the Regulatory Setting’. Journal of Biopharmaceutical Statistics 2011; 21:5, 
938-953; Pibouleaua L, Chevreta S. Bayesian statistical method was underused despite its ad-
vantages in the assessment of implantable medical devices. Journal of Clinical Epidemiology 64 
(2011) 270e279.
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with fixed numbers of participants, thereby shortening the device evaluation process. 
As for Bayesian modelling, the combined use of existing data could further improve 
the efficiency of the evaluation process by potentially decreasing costs and shorten-
ing the timelines for device evaluation. Adaptive designs also have greater flexibility. 
Another advantage is the possibility of recalculating and adjusting the required sam-
ple sizes, with more real data (beyond assumptions) on differences in benefits (and 
risks) and variation between the groups while the trial is ongoing. Finally, there is the 
built-in possibility of stopping a trial prematurely in the presence of unexpected risks, 
or even in the clear presence (or absence) of major benefits.
A disadvantage of these designs is that not all outcomes or devices lend themselves 
to early discontinuation. Interim analyses may not be feasible when the primary 
endpoint cannot be measured relatively soon after start of the trial. Trials may also be 
discontinued prematurely in error. Moreover, sufficient experience using a superior 
device may be lacking if the trial is discontinued prematurely in the presence of clear 
benefits and the device is subsequently introduced to the medical profession. Finally, 
this design requires trained statisticians with specialist knowledge to conduct the 
analyses and interpret the results.
ExamplEs of adaptivE trial dEsigns usEd for mEdical dEvicE 
Evaluation
Title: A Single Centre Study in Healthy volunteers to Optimise the Rotacap Formulation 
and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol
Registration number: NCT01540708
Source: ClinicalTrials.gov
Reference: Not published (yet)
Protocol: The purpose of this study is to optimise the device and/or formulation of the 
Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to 
achieve drug delivery characteristics comparable to the Fluticasone propionate /salmet-
erol DISKUS inhaler. The indication is asthma and chronic obstructive pulmonary disease. 
The study is an open-label, randomised, cross-over, single centre study in healthy volun-
teers and will be conducted in a maximum of 3 parts, A, B and C. The design is adaptive 
and pharmacokinetic (PK) data analysis follows each part to enable a decision on whether 
progression to the subsequent parts is required. Part A of the study will test an alternative 
version of the Rotahaler with a low airflow resistance. The study will then test one or 
more of the following options depending on the outcome of part A. If progressed, part B 
will test modified Rotacap formulations including: (1) modified blend formulation, (2) re-
duced capsule fill weights, (3) different capsule types. Part B will also test other versions 
of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength 
FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). A total 
of 36 subjects will be enrolled in each part to ensure 32 complete. In each cross-over 
arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following ad-
ministration of the 7th dose. A three-day minimum wash-out period will separate each 
cross-over arm.
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Enrolment: 36
Start date: January 2012
Study completion date: September 2012
Title: Prospective evaluation of elastic restraint to lessen the effects of heart failure 
(PEERLESS-HF) trial.
Reference: Costanzo MR, Ivanhoe RJ, Kao A, Anand IS, Bank A, Boehmer J, Demarco T, 
Hergert CM, Holcomb RG, Maybaum S, Sun B, vassiliades TA Jr, Rayburn BK, Abraham WT.
J Card Fail. 2012 Jun;18(6):446-58. 
Registration number: Not reported
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Left ventricular (Lv) remodeling predicts poor outcomes in 
heart failure (HF) patients. The HeartNet(®) cardiac restraint device (Paracor Medical 
Inc., Sunnyvale, CA) may reduce Lv remodeling and improve functional capacity, quality of 
life, and outcomes in HF patients. To evaluate the safety and efficacy of the HeartNet ven-
tricular Support System in HF patients receiving optimal medical therapy. METHODS AND 
RESULTS: Prospective, randomized, controlled, multicenter trial in patients with symp-
tomatic HF and Lv ejection fraction ≤35% on optimal medical and device therapy. The 
primary efficacy end points were changes in peak vO(2), 6-minute walk (6MW) distance, 
and Minnesota Living with Heart Failure (MLWHF) quality of life score at 6 months. The 
primary safety end point was all-cause mortality at 12 months. Because the planned adap-
tive interim analysis of the first 122 subjects with a completed 6-month follow-up indicat-
ed futility to reach the peak vO(2) end point, trial enrollment was suspended. Hence, the 
results on the 96 treatment and 114 control subjects are reported. Groups were similar at 
baseline. At 6 months, responder frequency for a prespecified improvement was similar 
between groups for peak vO(2) (P = .502) and MLWHF score (P = .184) but borderline 
higher for improvement in 6MW distance in the treatment compared with the control 
group (33 [38%] vs. 25 [25%]; P = .044). At 6 months, the treatment group had a signif-
icantly greater improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) (P < 
.001) and decrease in Lv mass (P = .032), Lv end-diastolic diameter (P = .015), Lv end-sys-
tolic diameter (P = .032), and Lv end-diastolic volume (P = .031) as compared with con-
trols. At 12 months, all-cause mortality and responder rates were similar in the 2 groups. 
Success rate for the HeartNet implantation was 99%. CONCLUSION: Enrollment in the 
trial was stopped because an interim analysis showed futility of reaching the peak vO(2) 
end point. However, because of the device safety and favorable signals for Lv remodeling 
and quality of life, further investigation of this device is warranted.
TwO ExAMPLES OF SUCCESSFUL USE OF BAyESIAN METHODS IN DEVICE TRIALS 
ARE*: 
TRANSCAN (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.
cfm?num=p970033). Prior information was used to incorporate results from previous 
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studies, resulting in a reduced sample size for demonstration of effectiveness. 
INTERFIx (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.
cfm?num=p970015). An interim analysis was performed; based on Bayesian predictive 
modeling of the future success rate, the trial was stopped early. No prior information was 
used. 
*FDA: Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. Document 
issued on: February 5, 2010
A5. Cluster trials 
In cluster trials, aimed at quantifying the effects of device use on patient outcomes, 
randomisation takes place at a higher level; with practitioners, general practices, 
hospitals, villages or families being randomised to the index device and alternative 
intervention or management rather than individual participants.14
Motivation for performing a cluster trial may be to avoid contamination. This can 
happen – for example – when evaluating the effects of new diagnostic or monitoring 
devices on treatment decisions. The physician may learn from patients randomised to 
the index device group. Subsequent control patients, in whom the device is not used, 
may be treated differently based on experiences in similar patients from the index 
group. Another advantages of cluster-randomised trials over individually randomised 
trials include the ability to study interventions that cannot be randomly assigned to 
individuals, as discussed above. 
The main disadvantage, compared with individually randomised trials, is that clus-
ter randomised trials are more complex to design and require more complex analysis 
because, for example, two different units of measurement (the cluster and the patient) 
are used. In addition, this approach commonly requires a larger number of partic-
ipants to obtain enough statistical power. Finally, selection bias can occur because 
informed patient consent is requested after randomisation of the clusters, such that 
specific patients may selectively refuse (or consent) to participate. 
ExamplEs of clustEr trials usEd for thE Evaluation of mEdi-
cal dEvicEs
Title: Integrated community case management of fever in children under five using rapid 
diagnostic tests and respiratory rate counting: a multi-country cluster randomized trial. 
Registration number: NCT00720811. 
Source: MEDLINE (through PubMed)
Reference: Mukanga D, Tiono AB, Anyorigiya T, Källander K, Konaté AT, Oduro AR, Tiben-
derana JK, Amenga-Etego L, Sirima SB, Cousens S, Barnish G, Pagnoni F. Am J Trop Med 
Hyg. 2012 Nov;87(5 Suppl):21-9. 
Abstract: Evidence on the impact of using diagnostic tests in community case management 
14  Puffer S. et al., ‘Evidence for risk of bias in cluster randomised trials: review of recent trials 
published in three general medical journals‘. BMJ 2003; 327: 785–9.
112 evaluation of new technology in health care
of febrile children is limited. This effectiveness trial conducted in Burkina Faso, Ghana, 
and Uganda, compared a diagnostic and treatment package for malaria and pneumonia 
with presumptive treatment with anti-malarial drugs; artemisinin combination therapy 
(ACT). We enrolled 4,216 febrile children between 4 and 59 months of age in 2009-2010. 
Compliance with the malaria rapid diagnostic test (RDT) results was high in the interven-
tion arm across the three countries, with only 4.9% (17 of 344) of RDT-negative children 
prescribed an ACT. Antibiotic overuse was more common: 0.9% (4 of 446) in Uganda, 
38.5% (114 of 296) in Burkina Faso, and 44.6% (197 of 442) in Ghana. Fever clearance 
was high in both intervention and control arms at both Day 3 (97.8% versus 96.9%, P = 
0.17) and Day 7 (99.2% versus 98.8%, P = 0.17). The use of diagnostic tests limits overuse 
of ACTs. Its impact on antibiotic overuse and on fever clearance is uncertain.
Title: Field evaluation of permethrin long-lasting insecticide treated nets (Olyset(®)) for 
malaria control in an endemic area, southeast of Iran.
Registration number: Not reported.
Source: MEDLINE (through PubMed)
Reference: Soleimani-Ahmadi M, vatandoost H, Shaeghi M, Raeisi A, Abedi F, Eshraghian 
MR, Madani A, Safari R, Oshaghi MA, Abtahi M, Hajjaran H. Acta Trop. 2012 Sep;123(3):146-
53. Epub 2012 May 9.
Abstract: Long lasting insecticide treated nets (LLINs) have been advocated as an ef-
fective tool for prevention and control of malaria. Olyset net was the first LLINs which 
became commercially available and obtained WHO approval. According to the national 
strategic plan on evaluation of Olyset net, a field trial was conducted to determine the 
efficacy of these nets against malaria vectors in an endemic area in the southeast of Iran. 
Fourteen villages with similar topographical and epidemiological situations were selected 
and randomly assigned to two clusters of the study: Olyset net and untreated net. Distri-
bution of nets was carried out to cover 100% of the population in Olyset net and untreated 
net cluster. Anopheline mosquitoes were collected monthly using different WHO standard 
methods in both areas to determine their abundance, feeding pattern and resting behav-
iour. Human blood index was determined using ELISA test. Additionally, Olyset nets were 
evaluated for their biological activity using WHO cone bioassay test by susceptible colo-
ny of Anopheles stephensi (Beech strain) and then for insecticide residues by employing 
high performance thin layer chromatography. Malaria incidence was measured by passive 
and active case detection from all study population. In total 2115 adult anopheline mos-
quitoes were collected and identified using morphological characters. They comprised of 
seven species: Anopheles dthali (Liston), A. culicifacies (Giles), A. stephensi (Liston), A. 
superpictus (Grassi), A.fluviatilis (James), A. moghulensis (Christophers) and A. turkhudi 
(Liston). A. dthali, A. culicifacies and A. stephensi were most prevalent species in both 
areas. In the Olyset net study area, there was a significant reduction of 41.1%, 54.4%, 
59.39% and 64.1% in the indoor-resting density of A. culicifacies, A. stephensi, A. dthali 
and A. superpictus, respectively, with an overall reduction of 39.3% in total mosquitoes in 
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comparison with untreated net area. A significant reduction was also observed in human 
blood index of vector species in the Olyset net villages. Bioefficacy test results of Olyset 
nets showed that the median knockdown time was 1.48 and 3.25min, while the average 
mortality rate was 100% and 72.3%±7.07 in baseline and after 1 year of intervention, 
respectively. The average permethrin content reached to 68.31% (683.1mg/m(2)) of the 
initial insecticide dose of 937±21.69mg/m(2) (nearly 1000mg/m(2)) at the end of in-
tervention. Malaria incidence was reduced by 96.6% and 64.8% in the village with Oly-
set nets and in the villages with untreated nets, respectively. During intervention period, 
there was a reduction of 93.2% in malaria incidence in Olyset net area as compared to 
the untreated area. This study indicated that Olyset nets have a major impact on malaria 
vectors and disease burden; therefore it could be recommended as an effective personal 
protection tool for malaria control in malarious areas.
A6. Factorial designs 
In a factorial randomised design, each participant is randomly assigned to a group that 
receives a particular combination of interventions or non-interventions.15
The advantages of this approach over parallel comparison are its ability to effi-
ciently investigate multiple interventions and detect interaction between different 
treatments. It also requires fewer patients and is less costly than conducting multiple 
parallel group trials.
The main disadvantage is that most actual trials are underpowered to detect signif-
icant treatment interactions because they are often designed on the assumption that 
interaction will be absent and, additionally, that interactions can only be determined 
at the end of the study. If such an effect is present, analysing the results by ignoring the 
other treatment assignments becomes invalid. It follows that one of the main advan-
tages, i.e. the smaller required sample size, is also invalidated.
ExamplE of a factorial dEsign usEd for thE Evaluation of 
mEdical dEvicEs
Title: A randomized controlled trial comparing the effects of counseling and alarm device 
on HAART adherence and virologic outcomes.
Registration number: NCT00273780
Source: MEDLINE (through PubMed)
Reference: Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, Simoni JM, Over-
baugh J, Attwa M, John-Stewart GC. PLoS Med. 2011 Mar;8(3):e1000422. doi: 10.1371/
journal.pmed.1000422. Epub 2011 Mar 1.
Abstract: BACKGROUND: Behavioral interventions that promote adherence to antiretro-
viral medications may decrease HIv treatment failure. Antiretroviral treatment programs 
in sub-Saharan Africa confront increasing financial constraints to provide comprehensive 
15  Daniel B. Efficient Designs: Factorial Randomized Trials. J Bone Joint Surg Am, 2012 Jul 
18;94(Suppl 1(E)):34-38.
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HIv care, which include adherence interventions. This study compared the impact of coun-
seling and use of an alarm device on adherence and biological outcomes in a resource-lim-
ited setting. METHODS AND FINDINGS: A randomized controlled, factorial designed trial 
was conducted in Nairobi, Kenya. Antiretroviral-naïve individuals initiating free highly 
active antiretroviral therapy (HAART) in the form of fixed-dose combination pills (d4T, 
3TC, and nevirapine) were randomized to one of four arms: counseling (three counseling 
sessions around HAART initiation), alarm (pocket electronic pill reminder carried for 6 
months), counseling plus alarm, and neither counseling nor alarm. Participants were fol-
lowed for 18 months after HAART initiation. Primary study endpoints included plasma 
HIv-1 RNA and CD4 count every 6 months, mortality, and adherence measured by month-
ly pill count. Between May 2006 and September 2008, 400 individuals were enrolled, 362 
initiated HAART, and 310 completed follow-up. Participants who received counseling 
were 29% less likely to have monthly adherence <80% (hazard ratio [HR] = 0.71; 95% 
confidence interval [CI] 0.49-1.01; p = 0.055) and 59% less likely to experience viral failure 
(HIv-1 RNA ≥5,000 copies/ml) (HR 0.41; 95% CI 0.21-0.81; p = 0.01) compared to those 
who received no counseling. There was no significant impact of using an alarm on poor 
adherence (HR 0.93; 95% CI 0.65-1.32; p = 0.7) or viral failure (HR 0.99; 95% CI 0.53-1.84; 
p = 1.0) compared to those who did not use an alarm. Neither counseling nor alarm was 
significantly associated with mortality or rate of immune reconstitution.
CONCLUSIONS: Intensive early adherence counseling at HAART initiation resulted in sus-
tained, significant impact on adherence and virologic treatment failure during 18-month 
follow-up, while use of an alarm device had no effect. As antiretroviral treatment clin-
ics expand to meet an increasing demand for HIv care in sub-Saharan Africa, adherence 
counseling should be implemented to decrease the development of treatment failure and 
spread of resistant HIv.
A7. Preferences trials
Preferences trials are variations of RCTs in which participants’ preferences – i.e. 
whether or not to receive the new device or the control treatment – are taken into 
account.16 The primary purpose is to minimise refusals at the recruitment stage owing 
to the reluctance of some participants to be randomised. The best-known preferences 
trial is probably the comprehensive cohort design. Here, all patients who meet the 
eligibility criteria can be recruited regardless of their informed consent to randomisa-
tion. This trial includes at least one group in which the (eligible, but non-randomised) 
participants are allowed to choose their own preferred treatment from several options 
offered. The second group is designed as a common parallel RCT, with participants 
being randomly allocated to either the treatment or the control.
Other well-known versions of preferences trials are the Zelen’s design or the 
16  Kao L.S. et al., Clinical Research Methodology I: Introduction to Randomized Trials. J Am 
Coll Surg. 2008 February; 206(2): 361–369. Silverman W.A., Altman D.G., Patients’ preferences 
and randomised trials. Lancet 1996;347:171-4.
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Wennberg’s design. In the Zelen’s design, participants are randomised to either the 
treatment (new device) or control group before giving informed consent, instead of 
prior to randomisation. In this design, participants that give their informed consent 
are certain of receiving the new device. Participants who do not consent (for other 
than privacy reasons) can receive the control treatment – often care as usual – in the 
clinical trial. In the Wennberg’s design, participants are randomised to either a pref-
erence group or a randomisation group. Participants in the randomisation group are 
assigned to either the new device or the control treatment, and patients in the prefer-
ence group are offered their treatment of choice.
The main advantage of these designs is that eligible patients who normally would 
refuse to participate in trials, either because they do not want to be randomised to 
placebo or because they have strong preferences for a particular intervention, will 
now participate in clinical research. Often patients in a randomised trial only rep-
resent a small proportion of the patients eligible for the trial in the real world. This 
design allows the applicability of trial results to be assessed by comparing the RCT 
group with the cohort of patients who met the eligibility criteria but did not consent to 
randomisation. On average, the outcomes of the patients who normally would not par-
ticipate in randomised trials and those who participate and have strong preferences 
may differ.
A disadvantage of this design is that the trials must be open, thereby introducing 
the possibility of a ‘placebo’ effect (performance bias), and that the statistical power 
of the study may be affected if a high proportion of participants choose to receive the 
same treatment.
ExamplEs of prEfErEncE trials usEd for thE Evaluation of 
mEdical dEvicEs
Title: Effectiveness of nurse delivered endoscopy: findings from randomised multi-insti-
tution nurse endoscopy trial (MINuET).
Reference: Williams J, Russell I, Durai D, Cheung WY, Farrin A, Bloor K, Coulton S, Richard-
son G. BMJ. 2009 Feb 10;338:b231. doi: 10.1136/bmj.b231.
Registration number: ISRCTN82765705.
Source: MEDLINE (through PubMed)
Abstract: OBJECTIvE: To compare the clinical effectiveness of doctors and nurses in un-
dertaking upper and lower gastrointestinal endoscopy. DESIGN: Pragmatic trial with Zel-
en’s randomisation before consent to minimise distortion of existing practice. SETTING: 
23 hospitals in the United Kingdom. In six hospitals, nurses undertook both upper and 
lower gastrointestinal endoscopy, yielding a total of 29 centres. PARTICIPANTS: 67 doc-
tors and 30 nurses. Of 4964 potentially eligible patients, we randomised 4128 (83%) and 
recruited 1888 (38%) from July 2002 to June 2003. INTERvENTIONS: Diagnostic upper 
gastrointestinal endoscopy and flexible sigmoidoscopy, undertaken with or without se-
dation, with the standard preparation, techniques, and protocols of participating hospi-
tals. After referral for either procedure, patients were randomised between doctors and 
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nurses. MAIN OUTCOME MEASURES: Gastrointestinal symptom rating questionnaire (pri-
mary outcome), gastrointestinal endoscopy satisfaction questionnaire and state-trait anx-
iety inventory (all analysed by intention to treat); immediate and delayed complications; 
quality of examination and corresponding report; patients’ preferences for operator; and 
new diagnoses at one year (all analysed according to who carried out the procedure). 
RESULTS: There was no significant difference between groups in outcome at one day, one 
month, or one year after endoscopy, except that patients were more satisfied with nurses 
after one day. Nurses were also more thorough than doctors in examining the stomach and 
oesophagus. While quality of life scores were slightly better in patients the doctor group, 
this was not statistically significant. CONCLUSIONS: Diagnostic endoscopy can be under-
taken safely and effectively by nurses.
Title: Designs for mechanical circulatory support device studies.
Reference: Neaton JD, Normand SL, Gelijns A, Starling RC, Mann DL, Konstam MA. J Card 
Fail. 2007 Feb;13(1):63-74.
Registration number: not reported 
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: There is increased interest in mechanical circulatory support 
devices (MCSDs), such as implantable left ventricular assist devices (LvADs), as ‘destina-
tion’ therapy for patients with advanced heart failure. Because patient availability to eval-
uate these devices is limited and randomized trials have been slow in enrolling patients, 
a workshop was convened to consider designs for MCSD development including alter-
natives to randomized trials. METHODS AND RESULTS: A workshop was jointly planned 
by the Heart Failure Society of America and the US Food and Drug Administration and 
was convened in March 2006. One of the panels was asked to review different designs 
for evaluating new MCSDs. Randomized trials have many advantages over studies with 
no controls or with nonrandomized concurrent or historical controls. These advantages 
include the elimination of bias in the assignment of treatments and the balancing, on av-
erage, of known and unknown baseline covariates that influence response. These advan-
tages of randomisation are particularly important for studies in which the treatments may 
not differ from one another by a large amount (eg, a head-to-head study of an approved 
LvAD with a new LvAD). However, researchers have found it difficult to recruit patients to 
randomized studies because the number of clinical sites that can carry out the studies is 
not large. Also, there is a reluctance to randomize patients when the control device is con-
sidered technologically inferior. Thus ways of improving the design of randomized trials 
were discussed, and the advantages and disadvantages of alternative designs were con-
sidered. CONCLUSIONS: The panel concluded that designs should include a randomized 
component. Randomized designs might be improved by allowing the control device to be 
chosen before randomisation, by first conducting smaller vanguard studies, and by al-
lowing crossovers in trials with optimal medical management controls. With use of data 
from completed trials, other databases, and registries, alternative designs that include 
both a randomized component (eg, 2:1 allocation for new device versus control) and a 
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nonrandomized component (eg, concurrent nonrandomized control, historical control, 
or a comprehensive cohort design) should be evaluated. This will require partnerships 
among academic, government, and industry scientists.
A8. N=1 trials 
Basically, N=1 trials (or individual patient trials) are cross-over trials in which one 
participant receives both the experimental and the control interventions; this single 
case study is the entire trial.17 Usually, the number of treatments is not specified in 
advance, so that the clinician and the patient can decide to stop when they observe 
important differences between the interventions.
The major advantage of this design is that it can be very effective in confirming cau-
sality between an achieved effect and the administered treatment. This is very useful 
when it is not clear whether a treatment will help a particular patient and it can guide 
clinical decisions, for example when there is little evidence from trials supporting 
which treatment to use in the event of rare diseases or in a particular patient popula-
tion (children, elderly). In addition, the costs of the N=1 trial are considerably lower 
than those of other randomised designs.
The main disadvantages are that these trials provide individual outcomes rather 
than generalizable results, and that they are time-consuming.
ExamplEs an n=1 trial usEd for thE Evaluation of mEdical 
dEvicEs
Title: High AC/A accommodative esotropia strabismus treated with contact lenses: a sin-
gle case design (N=1) study.
Registration number: Not reported.
Reference: Gonzalez E, Barra F, Sanchez I, Antona B, Barrio A. Binocul vis Strabismus Q. 
2007;22(2):90-5.
Abstract:  PURPOSE: The purpose was to determine the efficacy of two types of contact 
lenses (spherical disposable and aplanatic) as treatment in a patient with esotropia with 
a high Accommodative Convergence/Accommodation Ratio (AC/A). Due to the possibility 
of the appearance of accommodative insufficiency in this kind of patient, (i.e., following 
many years of bifocal glasses use), the elimination of the plus addition lens is advisable. 
Nevertheless, in some patients, this change leads to the appearance of a residual angle 
of esodeviation in near vision. It was expected that monofocal aplanatic contact lenses 
could achieve, due to their optical characteristics, an accurate and orthotropic binocular 
alignment, without aggravating an undesirable manifestation of the accommodative in-
sufficiency. METHODS: An experimental design of a single case (N=1) was used in which 
17  Guyatt G.H., Sackett D., Taylor D.W., Chong J., Roberts R.S., Pugsley S. Determining optimal 
therapy – randomized trials in individual patients. N Engl J Med 1986;314:889-92; Guyatt G.H., 
et al., The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. 
Ann. Intern. Med. 1990; 112 (4): 293–9.
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the subject acted as his own control. With bifocal glasses the subject displayed stability 
in his binocular and accommodative system at every distance of vision for the past three 
years. We compared the efficacy of two different types of hydrophilic contact lenses to 
control the angle of deviation, both at distance and at near vision. RESULTS: Neither of the 
two contact lenses produced the results of stability and the correct binocular alignment 
that had been achieved with bifocal glasses. This subject experienced a worse manifest 
esodeviation in distance vision with aplanatic lenses than with the disposable ones. CON-
CLUSIONS: These monofocal contact lenses did not create acceptable binocular alignment 
and stability in a subject with a high AC/A accommodative esotropia.
B. Non-randomised (direct evidence) study approaches 
Non-randomised studies (NRS) may be important alternative approaches to study-
ing the benefits of devices. However, ensuring proper selection of the subjects and 
a comparison group, adjusting for other influential factors, and addressing learning 
curve issues all require even more fine-tuning of the specific study design, conduct and 
analysis plan. In the absence of randomisation, conclusions as to whether an observed 
difference in benefits between the two groups is indeed due to the device are compro-
mised (e.g. higher risk of bias). The main challenge of NRS in device evaluations is to 
correct for such biases – technically known as correcting for confounding factors – and 
thus to reach valid (unbiased) conclusions about the benefits of device use. There are 
various ways to address this confounding in NRS for devices (see Appendix v).18
Non-randomised studies can be divided into semi- or quasi-experimental trials 
(experimental is used here as a synonym for randomisation) and observational studies:
• Quasi-experimental studies are very similar to RCTs, but they specifically lack the 
element of random assignment (and thus concealed allocation) of participants to 
groups.19 Instead, quasi-experimental research allows the investigator to assign 
the participants to either the device or the control group using other allocation 
methods, including date of birth, the number of the hospital record or the day of 
invitation. These allocation methods are not regarded as ‘purely random’; these 
trials are therefore called quasi-experimental or pseudo-randomised trials. Ill luck 
may also make them more susceptible to (confounding) bias than RCTs and they 
may therefore require one of the adjustment methods described in Appendix v.
• Observational studies (comparative and non-comparative) use neither randomi-
sation nor any pseudo-randomisation. Study participants are only observed on 
their received interventions (e.g. device use versus other intervention) and their 
18  Cousens S. et al., Alternatives to randomisation in the evaluation of public-health interven-
tions: statistical analysis and causal inference. J Epidem Community Health 2011;65:576-581; 
McNamee R., Regression modelling and other methods to control confounding. Occup Environ 
Med 2005;62:500-506 doi:10.1136/oem.2002.001115
19  Grimshaw J., Campbell M., Eccles M., Steen N., Experimental and quasi-experimental de-
signs for evaluating guideline implementation strategies. Fam Pract. 2000 Feb;17 Suppl 1:S11-6.
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outcomes. In general these designs can be divided into (retrospective or prospec-
tive) comparative and (retrospective or prospective) non-comparative observa-
tional studies.
B1. Quasi-experimental studies
B1.1 Non-randomised controlled study 
This is an experimental study in which people are allocated to different interventions 
using one of the semi-randomisation methods described above, e.g. the number of the 
hospital record, the day of hospital admission, the day of invitation, etc. 
Advantages of the quasi-experimental approach are that the results are more rep-
resentative for routine clinical practice, such designs are easier to set up, and to some 
extent the allocation is still random and there is thus less potential for (confounding) 
bias compared to other NRS. This design can be used when randomisation is not feasi-
ble or in longitudinal research that involves a longer time horizon. 
B1.2 Controlled before-and-after study 
This approach involves making and measuring observations before and after imple-
menting an intervention, both in a group that receives the device and in a control 
group that does not. The control group usually has similar characteristics (matching) 
to the group of participants receiving the (new) device. Outcomes of interest are meas-
ured in both groups before the intervention is introduced and again after the interven-
tion has been introduced. 
Even though these two designs use some form of pseudo-randomisation or well-
matched controls, their main disadvantage is that any differences in outcomes may 
still be explained (in part) by other differences between the control and device use 
group. To correct for this, one of statistical methods described in Appendix v can and 
should be used. 
ExamplE of a controllEd bEforE-aftEr study usEd for thE 
Evaluation of mEdical dEvicEs
Title: Further experience with pancreatic stump closure using a reinforced staple line.
Reference: Wallace CL, Georgakis Gv, Eisenberg DP, Macaulay WP, Jimenez RE. Conn Med. 
2013 Apr;77(4):205-10.
Registration number: not reported
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: We previously demonstrated that pancreatic transection with a 
reinforced staple line results in significantly lower fistula rates than when stapling with-
out reinforcement. (J Gastrointest Surg. 2007;11:345-349). Criticism of this initial study 
focused on the small size of the treated group (N = 13). We report four more years of ex-
perience with this technique with a larger sample size. METHODS: This was a before-after 
trial. Patients included had distal pancreatectomies with stapled stump closure. The main 
intervention analyzed was staple-line reinforcement with Seamguard. The experimental 
120 evaluation of new technology in health care
group consisted of a consecutive series of stapled pancreatectomies with reinforcement 
performed from 2005 to 2010. The control group was a consecutive series of stapled 
pancreatectomies without reinforcement performed between 2003 and 2005 (previous-
ly published). The main outcome measure was pancreatic fistula. RESULTS: 54 patients 
were included; 36 in the experimental group and 18 in the control group. Mean age was 
62; 50% were males. The most common diagnoses were adenocarcinoma (31%), cystic 
neoplasm (24%), and neuroendocrine tumor (22%). There were no mortalities. Postop-
erative pancreatic leak rate was 39% in the control group, and 8% in the experimental 
group (P = 0.01). Seven of ten patients with leak required additional drain placement. 
Development of pancreatic leak resulted in prolonged hospital stays (12 vs eight days, P 
< 0.007). CONCLUSION: We demonstrate sustained success of reinforced stapling for pan-
creatic stump closure. Our technique is straightforward and results in reduced morbidity 
and cost. Our results suggest that surgical drains may not be needed when this technique 
is applied.
B1.3 Interrupted time series study (ITS)
This approach is a kind of a before-after study and observes a group of targeted 
individuals (and their outcomes) at multiple time points before the index intervention 
(i.e. device) is used or introduced in daily care; after the index intervention is intro-
duced and used, the observations are compared to those of another group of individ-
uals – preferably in the same setting or location as the control group (the ‘interrup-
tion’/‘pseudo-randomisation by time’). The design attempts to detect whether the 
intervention has had an effect significantly greater than any underlying trend over 
time: the multiple time points before the intervention allow the underlying trend to be 
estimated, the multiple time points after the intervention allow the intervention effect 
to be estimated. Any differences may be attributed to the intervention, accounted for 
by a time trend. 
This approach measures the effect of an intervention when randomisation or iden-
tification of an appropriate concurrent control group is impractical.
A disadvantage of any time series study – i.e. when control and index group are 
split by time – is that the measured effect observed in the index, the device-use period, 
can be the effect of other events or changes in care occurring at the same time as the 
study intervention, or other differences between the two groups that occurred over 
time. To correct for this, one of the above methods should be used. Another limitation 
is that it is often difficult to collect sufficient data points during both the control and 
index periods, unless such studies are carefully planned, designed and conducted, or 
conducted in practices where comprehensive routine data sources or registries are 
available to allow for proper adjustment of other influential (confounding) factors. 
Many published interrupted time series have not been analysed correctly, so that the 
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effects of interventions are frequently overestimated.20
ExamplE of an intErruptEd timE sEriEs study usEd for thE 
Evaluation of mEdical dEvicEs
Title: Helmet legislation and admissions to hospital for cycling related head injuries in 
Canadian provinces and territories: interrupted time series analysis.
Reference: Dennis J, Ramsay T, Turgeon AF, Zarychanski R. BMJ. 2013 May 14;346:f2674. 
doi: 10.1136/bmj.f2674.
Reference number: Not reported
Source: MEDLINE (through PubMed)
Abstract: OBJECTIvE: To investigate the association between helmet legislation and ad-
missions to hospital for cycling related head injuries among young people and adults in 
Canada. DESIGN: Interrupted time series analysis using data from the National Trauma 
Registry Minimum Data Set. SETTING: Canadian provinces and territories; between 1994 
and 2003, six of 10 provinces implemented helmet legislation. PARTICIPANTS: All admis-
sions (n=66,716) to acute care hospitals in Canada owing to cycling related injury between 
1994 and 2008. MAIN OUTCOME MEASURE: Rate of admissions to hospital for cycling re-
lated head injuries before and after the implementation of provincial helmet legislation. 
RESULTS: Between 1994 and 2008, 66,716 hospital admissions were for cycling related 
injuries in Canada. Between 1994 and 2003, the rate of head injuries among young people 
decreased by 54.0% (95% confidence interval 48.2% to 59.8%) in provinces with helmet 
legislation compared with 33.1% (23.3% to 42.9%) in provinces and territories without 
legislation. Among adults, the rate of head injuries decreased by 26.0% (16.0% to 36.3%) 
in provinces with legislation but remained constant in provinces and territories without 
legislation. After taking baseline trends into consideration, however, we were unable to 
detect an independent effect of legislation on the rate of hospital admissions for cycling 
related head injuries. CONCLUSIONS: Reductions in the rates of admissions to hospital for 
cycling related head injuries were greater in provinces with helmet legislation, but injury 
rates were already decreasing before the implementation of legislation and the rate of 
decline was not appreciably altered on introduction of legislation. While helmets reduce 
the risk of head injuries and we encourage their use, in the Canadian context of existing 
safety campaigns, improvements to the cycling infrastructure, and the passive uptake of 
helmets, the incremental contribution of provincial helmet legislation to reduce hospital 
admissions for head injuries seems to have been minimal.
20  Grilli R., Freemantle N., Minozzi S., Domenighetti G., Finer D., Impact of Mass Media on 
Health Services Utilisation (Cochrane Review). In The Cochrane Library, Issue 3 Oxford: Update 
Software; 1998.
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B2. Observational study approaches: comparative and non-comparative 
studies
B2.1 Comparative observational studies
Cohort study – In a cohort study on the benefits of a specific intervention (device), a 
defined group of people with common characteristics is tracked over time in order to 
examine associations between different interventions that they have received and subse-
quent outcomes. Some in the cohort have received or used the device under evaluation 
and others have not; the observed outcomes of the two are then compared.
In a prospective cohort study (B2.1.1), the investigator recruits participants before 
any intervention has started or been used and tracks them into the future to observe 
their outcomes. A predefined comparison of outcomes can be made between interven-
tions, e.g. a sub-cohort that received/used the device versus a sub-cohort that did not 
receive/use the device but some other form of care, including no care at all. 
The design is a valid alternative in situations where randomisation is not ethical. The 
prospective manner allows the investigator to pre-specify and collect all necessary data, 
e.g. on the outcomes and other influential (cofounding) factors. However, a major disad-
vantage is that any differences in observed outcomes can be explained by other differ-
ences between the two sub-cohorts. This is even more so than for the quasi-experimen-
tal designs. Hence, one of the correction methods (see above) always need to be applied 
in order to isolate the effects of the device as much as possible from any confounding 
effects. As we said, however, the investigator has full control over which data to collect so 
as to ensure that all potentially known influential factors are defined and measured in all 
participants. This is in contrast to retrospective cohort studies (see below). 
ExamplEs of prospEctivE cohort study usEd for thE Evalua-
tion of mEdical dEvicEs
Title: Transversus abdominis plane (TAP) catheters inserted under direct vision in the 
donor site following free DIEP and MS-TRAM breast reconstruction: a prospective cohort 
study of 45 patients.
Reference: Zhong T, Wong KW, Cheng H, Ojha M, Srinivas C, McCluskey SA, Clarke H, 
Jacks L, Hofer SO. J Plast Reconstr Aesthet Surg. 2013 Mar;66(3):329-36. doi: 10.1016/j.
bjps.2012.09.034. Epub 2012 Nov 9.
Registration number: not reported
Source: MEDLINE (through PubMed)
Abstract: INTRODUCTION: The transversus abdominis plane (TAP) block is a peripheral 
nerve block of T6-L1 intercostal nerves of the abdominal wall. The purpose of this study 
was to evaluate the usefulness of intermittent TAP blockade for the first two postoperative 
days following free muscle sparing-transverse rectus abdominis muscle (MS-TRAM) or 
deep inferior epigastric perforator (DIEP) flap reconstruction of the breast. Therapeu-
tic-Level II evidence. MATERIAL AND METHODS: This prospective cohort consisted of 45 
consecutive patients who underwent DIEP or MS-TRAM free-flap breast reconstruction. 
123appendices
Intra-operatively, a multi-orifice epidural catheter was inserted under direct vision into 
the TAP. Ten millilitres of 0.25% bupivacaine was injected into each TAP catheter every 
12 h until removal on day 3. The control group consisted of 80 consecutive patients who 
underwent free MS-TRAM or DIEP free-flap breast reconstructions by the same two sur-
geons without TAP block. Postoperatively, both groups had patient-controlled analgesia 
(PCA) and the primary outcome was intravenous (Iv) PCA opioid consumption in the 
first 48 h. RESULTS: There were no complications associated with using TAP catheters. 
The 48-h PCA-delivered opioid requirement was significantly less (p<0.001) in the TAP 
block group (17.10±17.23 mg Iv morphine equivalent) compared to the control group 
(48.44±39.53 mg). CONCLUSION: Intermittent delivery of bupivacaine through the TAP 
block significantly reduced postoperative parenteral opioid requirements following free 
MS-TRAM or DIEP flap reconstruction of the breast. This is the first report of the TAP block 
being inserted under direct vision to provide postoperative analgesia at the abdominal 
flap donor site following microsurgical breast reconstruction.
Title: Risk of revision for fixed versus mobile-bearing primary total knee replacements.
Reference: Namba RS, Inacio MC, Paxton EW, Ake CF, Wang C, Gross TP, Marinac-Dab-
ic D, Sedrakyan A. J Bone Joint Surg Am. 2012 Nov 7;94(21):1929-35. doi: 10.2106/JB-
JS.K.01363.
Registration number: not reported
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Mobile-bearing total knee arthroplasty prostheses were devel-
oped to reduce wear and revision rates; however, these benefits remain unproven. The 
purposes of this study were to compare the short-term survivorship and to determine risk 
factors for revision of mobile-bearing and fixed-bearing total knee replacements. METH-
ODS: A prospective cohort study of primary total knee arthroplasties performed from 
2001 to 2009 was conducted with use of a community total joint replacement registry. 
Patient characteristics and procedure details were identified. Cox regression models were 
used. Bearing type was investigated as a risk factor for revision while adjusted for other 
risk factors such as age, American Society of Anesthesiologists (ASA) score, body mass 
index, sex, race, diagnosis, bilateral procedures, cruciate-retaining versus posterior-stabi-
lized components, surgical approach, fixation, patellar resurfacing, hospital and surgeon 
volumes, and fellowship training. RESULTS: The study cohort consisted of 47,339 total 
knee arthroplasties, with 62.6% of the procedures in women. Fixed bearings were used in 
41,908 knees (88.5%) and mobile bearings in 4830 (10.2%). Rotating-platform designs 
were used in all mobile-bearing total knee arthroplasties (3112 had a Rotating-Platform 
Press-Fit Condylar posterior-stabilized design; 1053, a Low Contact Stress [LCS] design; 
and 665, a Rotating-Platform Press-Fit Condylar cruciate-retaining design). Patients who 
received fixed-bearing total knee arthroplasty systems were older (mean age, 68.1 years) 
than those who received mobile-bearing total knee arthroplasty systems (mean age, 62.2 
years); the difference was significant (p < 0.001). Overall, 515 knees (1.1%) were revised 
for reasons other than infection. The survival rate was 97.8% (95% confidence interval 
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[CI], 97.4% to 98.0%) at 6.7 years. The adjusted risk of aseptic revision for the LCS total 
knee replacements was 2.01 times (95% CI, 1.41 to 2.86) higher than that for fixed-bear-
ing total knee replacements (p < 0.001).There was no significant revision risk for the other 
mobile-bearing total knee arthroplasty systems. There was no association with surgeon 
and hospital case volumes and the risk of revision total knee arthroplasty. CONCLUSIONS: 
Our study suggests the benefit of potential long-term wear reduction with the LCS im-
plant may not be realized in a community-based setting, where a variety of surgical skills, 
surgical experience, and diverse patient demographic factors may affect early outcomes.
A specific form of prospective cohort study is the prospective unpaired before- 
after study (B2.1.2). Here, participants act as self-controls or self-comparisons. Their 
outcomes are first measured before they receive/use the device, and once again after 
the device has been received/used (non-randomised (unpaired) cross-over trial). An 
advantage over the two-group cohort design is that smaller sample sizes are often 
needed because they produce within-participant comparisons (whereas parallel designs 
produce between-participant comparisons). But as with paired (randomised) cross-
over trials, the problem with using participants as their own controls is that they may 
improve for unknown reasons unrelated to the device (e.g. regression to the mean or 
placebo effect). This design is also only possible when the target condition is chronic, 
and non-progressive. For rapidly changing (instable) conditions, either self-limiting or 
progressive, such designs are infeasible, as the true effects of the device can hardly be 
isolated from the natural course. 
A retrospective cohort study (B2.1.3) uses an existing cohort (e.g. database from 
a previous study or existing registry) and selects from the same cohort a sub-cohort of 
participants that had received the intervention in the past and another sub-cohort that 
had not. Thus the use of the device and comparative interventions had both taken place 
in the past, relative to the starting point of the study. Then the outcomes of both groups 
– measured after the device has been used – are taken from that same database or per-
haps even measured by the investigator at the present time. 
The advantage of this cohort design over the prospective variants is that it is more 
efficient as it makes use of data collected earlier. It does require that the device and 
target condition were properly understood and used in the past, have not changed much 
over time, and also that the comparison group or current best practice has not changed 
much over time either. 
The disadvantage is that, as in all observational studies, confounding correction 
methods must be applied to draw the most valid possible inference about whether the 
device has in fact caused the differences in outcomes observed between the two sub-co-
horts. However, unlike the prospective cohort study designs, the use of earlier data 
means that the investigator has no control over the data and must rely on data that were 
collected previously and thus on data availability. Important confounding factors could 
therefore have been missed or not collected, making it impossible to make valid infer-
ences about the benefits of the device. Moreover, existing databases or registries often 
lack data, which can also lead to bias. 
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ExamplE of a rEtrospEctivE cohort study usEd for thE Evalu-
ation of mEdical dEvicEs
Title: A Retrospective Study Evaluating the Use of Permacol Surgical Implant in the Repair 
of Abdominal Wall Defects.
Registration number: NCT01214252
Source: ClinicalTrials.gov
Reference: Not published (yet).
Protocol: Purpose: To evaluate short, mid and long term clinical outcomes associated 
with the use of Permacol in the treatment of abdominal wall defects. Study Population: Pa-
tients who have undergone surgical repair of their abdominal wall defects with Permacol 
Surgical Implants with at least 12 months(-30days)follow-up. Inclusion Criteria:•Equal or 
over 18 years of age; •Had undergone surgical repair or reconstruction of abdominal wall 
defects, ventral hernias or incisional hernias using Permacol Surgical Implant; •At least 
12 months of follow-up post date of surgery (-30 days); •Undergone open or laparoscopic 
repairs. Exclusion Criteria: •Had undergone inguinal, parastomal, diaphragmatic or par-
aesophageal/hiatal hernia repair; •Any prior use of Permacol in abdominal wall repair.
Enrollment: 472
Start date: October 2010
Study completion date: January 2012
In a non-randomised historically controlled study (B2.1.4), a group of partici-
pants who have received/used the device is compared – often with prospective data 
collection – with a group of individuals who have not received/used the device but 
some form of alternative management. This control group can be taken from existing 
registries, or from a previous cohort or trial conducted in similar individuals. This is 
a common design for device evaluations and it is more efficient than a prospective 
cohort study. In addition, it shares the same advantages as a retrospective cohort study 
(B2.1.3). 
Unfortunately, it also shares the same disadvantages as the retrospective cohort 
study, and may in fact have one more disadvantage, because the index (device) group 
and control group are by definition not selected from the same underlying total 
cohort. The risk of incomparability between the two groups is thus much larger. This 
incomparability can be due to changes over time (device group very different from the 
historical control group; they may not have received current best practice, and there-
fore have other outcomes by definition); not all relevant confounding factors have 
been documented in the historical control group; and the methods used for outcome 
evaluation might not be similar or appropriate in both groups. 
ExamplE of a historically controllEd study usEd for thE  
Evaluation of mEdical dEvicEs
Title: Comparison Study of Two Different Surgical Clips During Laparoscopic Urologic 
Surgery
Registration number: NCT01008709
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Source: ClinicalTrials.gov
Reference: Not published (yet)
Protocol: Purpose. Intracorporeal suturing and knot tying during robotic prostatectomy 
and laparoscopic and robotic renal surgery have historically been considered the most 
technically challenging and time consuming aspects of these procedures. With improved 
operative technique as well as the use of innovative surgical devices, vascular control dur-
ing these surgeries is often less cumbersome as compared with traditional techniques. 
Current standard methods of hemostasis include the use of clips, of which the most pop-
ular design is the Hemolock, a locking, nonabsorbable plastic clip, or the use of the very 
expensive endomechanical stapler. Unfortunately while they are associated with time 
savings in the operating room, there is a great deal of disposable costs associated with 
these various devices as well as a not insignificant device malfunction rate reported in the 
literature. The aim of this case-controlled study is to evaluate the Aesculap U-clip device 
compared to our current technique of vascular control using the Teleflex Hemolock clip 
device during minimally invasive genitourinary surgery.
Enrolment: 20
Start date: October 2009
Study completion date: October 2012
The case-control study (B2.1.5) compares people with a specific outcome of interest 
(‘cases’) with people from the same source population but without that outcome (‘con-
trols’), and then studies differences in the interventions they have undergone. Unlike 
cohort studies, where subjects are selected for having or not having undergone/used 
the device, here the subjects are selected for having or not having the outcome of 
interest. 
This design is particularly useful for investigating the development (causes) of rare 
outcomes. It can be a useful for assessing the association of a particular event – often a 
particular rare outcome or unintended effect – with a specific device use.
A disadvantage is that case-control studies are generally considered to have a 
larger risk of bias than cohort studies, mainly because data collection on device use in 
the past is often retrospective, leading to incomplete data collection. As in the case of 
retrospective cohort studies, information on many confounders is also often missing. 
Moreover, data re-collection to determine previous exposure to possible causes of the 
relevant outcomes may differ depending on whether the subjects had or had not expe-
rienced the outcome under study (recall bias). 
B2.2 Non-comparative observational studies
Case series (uncontrolled longitudinal study; B2.2.1) are descriptive studies in 
which observations are made on a series of individuals, usually all receiving the same 
intervention, before and after the intervention but with no control group. It can be retro-
spective or prospective, consecutive or non-consecutive, and usually involves a smaller 
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number of patients than case-control studies or randomised controlled trials.21 
A disadvantage of case series is that they may be confounded by selection bias, 
which limits the strength of conclusions concerning the causality of correlations 
observed.
ExamplEs of casE-sEriEs usEd for thE Evaluation of mEdical 
dEvicEs
Title: Cardiovascular implantable electronic device replacement infections and preven-
tion: results from the REPLACE Registry.
Reference: Uslan DZ, Gleva MJ, Warren DK, Mela T, Chung MK, Gottipaty v, Borge R, Dan D, 
Shinn T, Mitchell K, Holcomb RG, Poole JE. Pacing Clin Electrophysiol. 2012 Jan;35(1):81-7. 
doi: 10.1111/j.1540-8159.2011.03257.x. Epub 2011 Nov 11.
Registration number: NCT00395447
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Infection following cardiovascular implantable electronic de-
vice (CIED) replacement is a serious complication, and rates of infection have increased. 
Analysis of procedural and clinical data from device replacement procedures collected 
by the REPLACE Registry may provide insights into infection prevention strategies and 
outcomes.
METHODS: We prospectively evaluated procedural complications in patients undergo-
ing CIED replacement over 6 months from 72 U.S. sites. Major and minor infections were 
predefined and adjudicated by an independent blinded clinical events committee. Data 
regarding infection prevention strategies and infectious outcomes were analyzed for their 
potential relationships.
RESULTS: A total of 1,744 patients were included in REPLACE. All patients received pre-
operative intravenous antibiotics and 68.7% received postoperative systemic antibiotic 
therapy. CIED infection developed in 22 patients (1.3%), of which 14 cases were major 
(0.8%, 95% confidence interval [CI] 0.4%-1.3%) and eight were minor (0.5%, 95% CI 
0.2%-0.9%). Patients with infections were more likely to have had postoperative hemato-
mas (five of 22 [22.7%] vs 17 of 1,722 [0.98%], P = 0.002). Participating sites experiencing 
infection rates >5% were more likely to use povidone-iodine for topical antisepsis, had 
lower implantation volume, and had patients with higher Charlson Comorbidity Index 
(2.79 vs 2.32, 95% CI for difference 0.08-0.86, P = 0.019).
CONCLUSIONS: In this multicenter prospective study with 6 months of follow-up, infec-
tions associated with CIED replacements were surprisingly infrequent, possibly due to 
the use of preoperative antibiotics. Patients with infections were more likely to have had 
a postoperative hematoma, and sites with higher infection rates had sicker patients and 
lower overall procedural volume.
21  Dekkers O.M., Egger M., Altman D.G., vandenbroucke J.P., Distinguishing case series from 
cohort studies. Ann Intern Med. 2012 Jan 3;156(1 Pt 1):37-40. doi: 10.7326/0003-4819-156-1-
201201030-00006.
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Title: Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator.
Reference: Not published (yet).
Registration number: NCT01026805
Source: ClinicalTrials.gov
Protocol: Purpose. This study assesses the effectiveness of intrauterine fibroid and pol-
yp removal using the Interlace Medical 1st generation hysteroscopic morcellator device 
based on a retrospective review of medical records of women who have been treated with 
the device. Case series: 11 women previously receiving hysteroscopic myomectomy or 
polypectomy using the hysteroscopic morcellator device.
Enrollment: 11
Start date: February 2009
Study completion date: March 2009
Device-based registries (B2.2.2) can be useful not only for long-term surveillance 
and postmarketing but also for evaluating medical devices outcomes. The main 
advantage is that registry data reflects the use of devices in routine practice (in the 
real-world setting) over time. Because registries contain date on large numbers of par-
ticipants, subgroup analyses are possible. Moreover, by linking device exposures and 
long-term outcomes, registries permit follow-up that can span decades.
Special challenges related to the construct (and use) of a medical device registry 
include the need for unique identification of devices and the need for follow-up to 
collect all relevant information on outcomes, patient factors, device factors, user inter-
face, experience and learning curves, device modifications, and the ability to combine 
all multiple components within a device. 
ExamplEs of rEgistriEs usEd for thE Evaluation of mEdical 
dEvicEs 
Title: The international registry infrastructure for cardiovascular device evaluation and 
surveillance.
Reference: Marinac-Dabic D, Holmes DR. JAMA. 2013 Jul 17;310(3):257-9. doi: 10.1001/
jama.2013.7133 (http://www.ncbi.nlm.nih.gov/pubmed?term=Sedrakyan%20A%5BAu-
thor%5D&cauthor=true&cauthor_uid=23860981)
Source: MEDLINE (through PubMed)
Abstract: Since the creation of the US Food and Drug Administration (FDA) Medical De-
vice Epidemiology Network (MDEpiNet),1 there has been an increasing FDA commitment 
to support the development of a global medical device research and surveillance infra-
structure. The FDA’s new postmarket surveillance plan2 strengthens this commitment and 
highlights the importance of national and international registries, and multi-stakeholder 
involvement for ensuring this commitment is fulfilled. This viewpoint summarizes the po-
tential for development of an International Consortium of Cardiovascular Registries, mod-
eled on a consortium established for orthopedic devices, as an initial project in the realm 
of cardiovascular devices with the focus on transcatheter aortic valve replacement (TAvR).
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Summary: Modeling after the orthopedic ICOR initiative, a global consortium of cardio-
vascular device registries has great potential to improve the public health, facilitate and 
strengthen regulatory processes, and advance clinical practice using innovative approach-
es. The exploration of the new International Consortium of Cardiovascular Registries fo-
cused on the novel technology of TAvR has multiple potential scalable positive outcomes 
for a larger cardiovascular initiative. The initiative may improve collaboration of the dif-
ferent stakeholders and enhance efficiency of registries and could facilitate the evaluation 
of the safety and efficacy of new devices and approaches, thereby reaching the goal of 
harnessing the global knowledge.
Title: Kaiser Permanente implant registries benefit patient safety, quality improvement, 
cost-effectiveness.
Reference: Paxton EW, Kiley ML, Love R, Barber TC, Funahashi TT, Inacio MC. Jt Comm J 
Qual Patient Saf. 2013 Jun;39(6):246-52.
Source: MEDLINE (through PubMed)
Abstract BACKGROUND: In response to the increased volume, risk, and cost of medical 
devices, in 2001 Kaiser Permanente (KP) developed implant registries to enhance patient 
safety and quality, and to evaluate cost-effectiveness. 
METHODS: Using an integrated electronic health record system, administrative databases, 
and other institutional databases, orthopedic, cardiology, and vascular implant registries 
were developed in 2001, 2006, and 2011, respectively. These registries monitor patients, 
implants, clinical practices, and surgical outcomes for KP's 9 million members. Critical to 
registry success is surgeon leadership and engagement; each geographical region has a 
surgeon champion who provides feedback on registry initiatives and disseminates regis-
try findings. RESULTS: The registries enhance patient safety by providing a variety of clin-
ical decision tools such as risk calculators, quality reports, risk-adjusted medical center 
reports, summaries of surgeon data, and infection control reports to registry stakehold-
ers. The registries are used to immediately identify patients with recalled devices, eval-
uate new and established device technology, and identify outlier implants. The registries 
contribute to cost-effectiveness initiatives through collaboration with sourcing and con-
tracting groups and confirming adherence to device formulary guidelines. Research stud-
ies based on registry data have directly influenced clinical best practices. CONCLUSIONS: 
Registries are important tools to evaluate longitudinal device performance and safety, 
study the clinical indications for and outcomes of device implantation, respond promptly 
to recalls and advisories, and contribute to the overall high quality of care of our patients
Title: Comparison of 21-gauge and 22-gauge aspiration needle in endobronchial ultra-
sound-guided transbronchial needle aspiration: results of the American College of Chest 
Physicians Quality Improvement Registry, Education, and Evaluation Registry.
Reference: Yarmus LB, Akulian J, Lechtzin N, Yasin F, Kamdar B, Ernst A, Ost DE, Ray 
C, Greenhill SR, Jimenez CA, Filner J, Feller-Kopman D; American College of Chest Phy-
sicians Quality Improvement Registry, Education, and Evaluation (AQuIRE). Chest. 2013 
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Apr;143(4):1036-43. doi: 10.1378/chest.12-1205.
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Endobronchial ultrasound-guided transbronchial needle as-
piration (EBUS-TBNA) is a minimally invasive procedure originally performed using a 
22-gauge (22G) needle. A recently introduced 21-gauge (21G) needle may improve the di-
agnostic yield and sample adequacy of EBUS-TBNA, but prior smaller studies have shown 
conflicting results. To our knowledge, this is the largest study undertaken to date to de-
termine whether the 21G needle adds diagnostic benefit. METHODS: We retrospective-
ly evaluated the results of 1,299 patients from the American College of Chest Physicians 
Quality Improvement Registry, Education, and Evaluation (AQuIRE) Diagnostic Registry 
who underwent EBUS-TBNA between February 2009 and September 2010 at six centers 
throughout the United States. Data collection included patient demographics, sample ade-
quacy, and diagnostic yield. Analysis consisted of univariate and multivariate hierarchical 
logistic regression comparing diagnostic yield and sample adequacy of EBUS-TBNA spec-
imens by needle gauge. RESULTS: A total of 1,235 patients met inclusion criteria. Sample 
adequacy was obtained in 94.9% of the 22G needle group and in 94.6% of the 21G needle 
group (P = .81). A diagnosis was made in 51.4% of the 22G and 51.3% of the 21G groups 
(P = .98). Multivariate hierarchical logistic regression showed no statistical difference in 
sample adequacy or diagnostic yield between the two groups. The presence of rapid ons-
ite cytologic evaluation was associated with significantly fewer needle passes per proce-
dure when using the 21G needle (P < .001). CONCLUSIONS: There is no difference in spec-
imen adequacy or diagnostic yield between the 21G and 22G needle groups. EBUS-TBNA 
in conjunction with rapid onsite cytologic evaluation and a 21G needle is associated with 
fewer needle passes compared with a 22G needle.
Performance goals (B2.2.3) – In a performance goal study, participants are enrolled 
through databases, registers or surveys only to receive the device under investigation. 
The performance of a device can be evaluated by comparing it to a numerical target 
value that pertains to a safety or effectiveness endpoint. Developing performance 
goals requires good historical data or publications, and a-priori agreement on who 
should develop the goals in question. 
A performance goal study has limitations comparable to that of a non-randomised 
historically controlled study. In addition, since there is no control group, such studies 
cannot demonstrate either superiority or non-inferiority to another management, 
device or intervention. 
ExamplE of a pErformancE goal study usEd for thE 
Evaluation of mEdical dEvicEs
Title: GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects  
(EMBOLDEN)
Reference: Not published (yet)
Registration number: NCT00766493
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Source: ClinicalTrials.gov
Protocol: Purpose: Compare the 30-day safety and efficacy of the GORE® Embolic Filter 
used in conjunction with FDA-approved carotid stents to a performance goal obtained 
from carotid stent studies utilising distal embolic protection.
Enrollment: 250 
Start Date: January 2009 
Study Completion Date: July 2010
C. Study approaches to evaluating diagnostic, screening,  
monitoring and prognostic test devices 
As described in Chapter 4.3 main text, non-therapeutic devices include diagnostic, 
screening and prognostic test devices. Test devices commonly have no direct thera-
peutic effects on the health outcomes of the intended population; instead, they are 
tests that generate information which in turn directs health care professionals (or 
sometimes patients themselves – depending on the type of device) to guide clinical 
management (see Figure 1). The health of the targeted individuals will thus improve 
indirectly because they receive more appropriate or earlier treatment, and because 
they can avoid potentially harmful additional tests. 
Researchers of such devices should consider carefully whether they will focus on 
the results generated by the device often referred to as (predictive) accuracy studies 
– or also measure the down-stream consequences of test use, for example changes 
in the management of health care professionals or even in the health effects induced 
by combining the use of the device and follow-up treatment (device test-treatment 
evaluations). 
Medical test Test result
Clinical action
Treat No treat
Patient outcomePatient
No direct effect 
Side effect possible
Patient outcome
Figure 1. Possible working pathways of diagnostic, screening, monitoring, prognostic test 
devices.
Example of non-therapeutic devices:
relation between tests and patient outcomes
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C1. Diagnostic and screening device accuracy designs
Diagnostic and screening test accuracy studies aim to measure the relationship 
between the results of the test and the presence or absence of a certain disease or con-
dition (e.g. disease or any other health state) of interest at the same time. This leads 
to a cross-sectional (though time) design where subjects will undergo both the index 
device (test) under evaluation and the reference standard. The reference standard 
is the best available method – usually more invasive, burdensome or costly than the 
index device – for determining whether a subject in fact (‘truly’) has or does not have 
the condition of interest. Because the interest is in the cross-sectional relationship, 
the device and the reference standard should ideally be performed within a short time 
interval. Sometimes it is not possible or ethical to establish the presence or absence of 
a target condition at the moment when the index device is used. Follow-up can then be 
used as a means of confirming or refuting the true presence or absence of the target 
condition. This is frequently applied in studies on the accuracy of screening devices for 
detecting early stages of a certain disease, e.g. breast cancer. Several accuracy meas-
ures can be used to express the agreement between the index device/test under evalu-
ation and the true presence or absence of disease, for example sensitivity & specificity, 
positive and negative predictive values, likelihood ratios, and the diagnostic odds ratio. 
Test accuracy studies are vulnerable to some specific types of biases, as described 
at length in the literature (see e.g. references in Chapter 4).22 For example, in diagnos-
tic accuracy studies, the individuals of interest are often defined by their presenting 
symptoms, signs and setting. Using patients already diagnosed with the condition 
or disease of interest and a separate group of control subjects without the disease 
can lead to overoptimistic measures of accuracy, because patients with the disease 
are more typical or advanced cases of the target condition. Also, the selected con-
trol group can be atypical, for instance when a healthy control group has been used. 
Such case-control designs (see above) using healthy controls may indeed be used to 
examine whether there a device test holds any promise. However, the results of such 
designs and the accuracy (agreement) found between the index device and the ref-
erence test cannot simply be generalised to the device accuracy that would be found 
when the device is used in the targeted clinical population in routine practice. For 
diagnostic and screening test accuracy studies, it is crucial to think about the targeted 
individuals and setting beforehand (see Chapter 4.5). Another key quality item of such 
studies is that all patients will undergo the same (best available) reference standard. 
Finally, the results of the index diagnostic or screening test device should be deter-
mined or interpreted without knowing the outcome of the reference standard; other-
wise, there is the risk of producing overoptimistic estimates of accuracy for the device 
under evaluation.
22  Bossuyt P.M., Irwig L., Craig J., Glasziou P., Comparative accuracy: assessing new tests 
against existing diagnostic pathways. BMJ. 2006 May 6;332(7549):1089-92.
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C1.1 Single (non-comparative) device test accuracy studies
The aim in single device test accuracy studies is to determine the accuracy of a specific 
device test (see Figure 2). This leads to a cross-sectional diagnostic or screening 
device study where the targeted individuals (ideally a consecutive series of such indi-
viduals) undergo both the index device test and the reference standard. A key qual-
ity item of such studies is that all patients will undergo the same optimal reference 
standard. The results of the index test should be determined or interpreted without 
knowing the outcome of the reference standard; otherwise, there is the risk of produc-
ing overoptimistic estimates of accuracy. 
Single device test accuracy studies are not suitable for determining whether a 
specific test leads to improved accuracy beyond what is achieved with available test 
results, or which order of testing is to be preferred (see C1.2); neither are they suita-
ble for determining whether the use of the diagnostic or screening device will lead to 
actual (additional) health benefits in individuals (see C.3).  
ExamplE of a singlE dEvicE tEst accuray study (1)
Title: A Prospective Study to Determine the Role of 2-[18F]Fluoro-2-Deoxy-D-Glucose 
(FDG)Positron Emission Tomography (PET)in the Assessment of Regional Nodal Spread 
of Disease in Breast Cancer Patients
Registration number: NCT00201942
Source: ClinicalTrials.gov
Protocol: Patients will have histologic confirmation of invasive breast cancer and will 
have a FDG-PET scan prior to axillary node assessment. All patients will have a sentinel 
node biopsy if any sentinel nodes can be located. Patients with a positive sentinel node 
will have an axillary node dissection. The results of the PET will be compared to the refer-
ence standard of histologic examination of all excised (sentinel and non-sentinel) axillary 
lymph nodes which will be referred to as axillary node assessment. Sensitivity, specificity, 
positive and negative predictive values for PET-FDG will be determined.
ExamplE of a singlE dEvicE tEst accuray study (2)
Title: Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating in-
tracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. 
Reference: Foerch C, Niessner M, Back T, Bauerle M, De Marchis GM, Ferbert A, Gre-
hl H, Hamann GF, Jacobs A, Kastrup A, Klimpe S, Palm F, Thomalla G, Worthmann H, 
Sitzer M; BE FAST Study Group. Clin Chem. 2012 Jan;58(1):237-45. doi: 10.1373/
clinchem.2011.172676. Epub 2011 Nov 28.
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Glial fibrillary acidic protein (GFAP) is a biomarker candidate 
indicative of intracerebral hemorrhage (ICH) in patients with symptoms of acute stroke. 
GFAP is released rapidly in the presence of expanding intracerebral bleeding, whereas a 
more gradual release occurs in ischemic stroke. In this study the diagnostic accuracy of 
plasma GFAP was determined in a prospective multicenter approach.
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METHODS: Within a 1-year recruitment period, patients suspected of having acute (symp-
tom onset<4.5 h before admission) hemispheric stroke were prospectively included into 
the study in 14 stroke centers in Germany and Switzerland. A blood sample was collected 
at admission, and plasma GFAP was measured by use of an electrochemiluminometric 
immunoassay. The final diagnosis, established at hospital discharge, was classified as ICH, 
ischemic stroke, or stroke mimic.
RESULTS: The study included 205 patients (39 ICH, 163 ischemic stroke, 3 stroke mimic). 
GFAP concentrations were increased in patients with ICH compared with patients with 
ischemic stroke [median (interquartile range) 1.91 μg/L (0.41-17.66) vs 0.08 μg/L (0.02-
0.14), P<0.001]. Diagnostic accuracy of GFAP for differentiating ICH from ischemic stroke 
and stroke mimic was high [area under the curve 0.915 (95% CI 0.847-0.982), P<0.001]. 
A GFAP cutoff of 0.29 μg/L provided diagnostic sensitivity of 84.2% and diagnostic speci-
ficity of 96.3% for differentiating ICH from ischemic stroke and stroke mimic.
CONCLUSIONS: Plasma GFAP analysis performed within 4.5 h of symptom onset can dif-
ferentiate ICH and ischemic stroke. Studies are needed to evaluate a GFAP point-of-care 
system that may help optimize the prehospital triage and management of patients with 
symptoms of acute stroke.
C1.2 Comparative test accuracy studies
In medical practice, professionals are commonly interested in the accuracy of a new 
test device for a specific target condition as compared to the accuracy of other existing 
tests, rather in than the accuracy of a single test device. Comparing tests within the 
same study – where all the subjects undergo both the new and existing test devices 
and the same reference standard – is likely to produce more valid results than com-
paring accuracy estimates taken from different studies, each evaluated as a separate 
test.23 In the latter situation, many factors other than the use of a different device 
test may be responsible for a difference in accuracy, for example differences in the 
setting, population, observers or users of the device, and reference standard protocol. 
Comparative test device accuracy studies are thus similar to the cross-over design in 
therapeutic designs (see above). 
Comparative test accuracy studies also allow us to study the accuracy of combi-
nations of diagnostic tests, whether a new device can lead to improved classification 
or accuracy for patients beyond what current tests have already achieved, in which 
order different tests may be conducted, and at which point in time a specific new test 
device may be best suited. Often, the focus in such comparative studies is on assessing 
whether a certain test adds information to previous test results in terms of improved 
accuracy or classification. 
Comparative accuracy designs are attractive in any test device research (diagnos-
tic, screening or prognostic tests) because it is often easy to meet the requirements 
that the first index test does not influence the result of the second index test (due to 
23  Takwoingi Y., Leeflang M.M., Deeks J.J., Empirical evidence of the importance of compara-
tive studies of diagnostic test accuracy. Ann Intern Med. 2013 Apr 2;158(7):544-54.
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learning effects, for example) and that the targeted disease (stage) should not change 
between the first and second index test. If these requirements are violated or if it is too 
burdensome for subjects to receive all index test devices, subjects can be randomised 
to receive either one of the test devices under evaluation. However, cross-over designs 
are more efficient as they require only half the number of patients (or even fewer) 
than needed in a parallel randomised design. An additional benefit of cross-over 
comparative test studies is that such studies reveal whether index tests tend to make 
errors in the same subjects (correlated errors). The different test accuracy designs are 
outlined in Figure 2.
Series of patients
Index test
Reference standard
Accuracy measures
Series of patients
Index test A
Reference 
standard
Comparing accuracy
Series of patients
Index test A or index test B
Reference standard
Comparing accuracy
R
Index test B
Reference 
standard
Index test A or index test B
Single test design Parallel randomised design Cross-over design
Comparative studies
Figure 2. Single test and comparative diagnostic or screening test accuracy designs
ExamplE of a comparativE dEvicE tEst accuray study (cross-
ovEr dEsign)
Title: Comparative study of automated breast 3-d ultrasound and handheld B-mode ultra-
sound for differentiation of benign and malignant breast masses.
Reference: Chen L, Chen Y, Diao XH, Fang L, Pang Y, Cheng AQ, Li WP, Wang Y. Ultrasound 
Med Biol. 2013 Oct;39(10):1735-42. doi: 10.1016/j.ultrasmedbio.2013.04.003. Epub 
2013 Jul 9.
Source: MEDLINE (through PubMed)
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Abstract: The automated breast volume scanner (ABvS) represents a new technology 
for diagnosing breast masses. In this study, a total of 219 breast masses in 175 patients 
underwent both conventional handheld B-mode ultrasound (HHUS) and ABvS examina-
tions, and the differences in the diagnostic values of the two modalities for benign and 
malignant breast masses were compared with the final pathologic findings. In addition, 
the diagnostic accuracy for breast masses with features including retraction phenome-
non and hyperechoic rim in the coronal plane of the ABvS was evaluated. There were 
no differences between the ABvS and HHUS in terms of sensitivity (92.5% vs. 88.0%), 
specificity (86.2% vs. 87.5%), accuracy (88.1% vs. 87.2%), false-positive rate (13.8% vs. 
12.5%), false-negative rate (11.8% vs. 7.5%), positive predictive value (74.7% vs. 75.6%) 
and negative predictive value (96.3% vs. 94.3%) (p > 0.05 for all). However, there were 
significant differences between the malignant and benign masses with respect to retrac-
tion phenomenon and hyperechoic rim in the coronal plane of the ABvS. For retraction 
phenomenon, both the specificity and positive predictive value of a malignant diagnosis 
reached 100%, and the accuracy and false-positive rate were 96.8% and 0, respectively; 
for the hyperechoic rim, the specificity, negative predictive value and accuracy of a benign 
diagnosis were 92.8%, 95.3% and 95.9%, respectively. 
Conclusion: Overall, ABvS is a promising modality for the clinical diagnosis of breast 
masses with retraction phenomenon and hyperechoic rim in the coronal plane, although 
the ABvS and HHUS do not differ in diagnostic accuracy for the differentiation of malig-
nant or benign breast masses.
ExamplE of a comparativE dEvicE tEst accuray study  
(parallEl randomisEd dEsign)
Title: Acetic acid compared with i-scan imaging for detecting Barrett’s esophagus: a ran-
domized, comparative trial.
Reference: Hoffman A, Korczynski O, Tresch A, Hansen T, Rahman F, Goetz M, Murthy S, 
Galle PR, Kiesslich R. Gastrointest Endosc. 2013 Aug 13. pii: S0016-5107(13)02129-9. doi: 
10.1016/j.gie.2013.07.013. [Epub ahead of print]
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Traditional surveillance in patients with Barrett’s esophagus 
(BE) has relied on random biopsies. Targeted biopsies that use advanced imaging modali-
ties may significantly improve detection of specialized columnar epithelium (SCE).
OBJECTIvE: We compared the efficacy of targeted biopsies that used i-scan or acetic acid 
to random biopsies in the detection of SCE.
DESIGN: Patients with visible columnar lined epithelium or known BE were randomized 
at a 1:1 ratio to undergo acetic acid application or i-scan with targeted biopsies.
SETTING: Targeted biopsies were performed based on surface architecture according to 
the Guelrud classification followed by 4-quadrant biopsies.
PATIENTS: A total of 95 patients were randomized.
INTERvENTION: A total of 46 patients underwent acetic acid staining, and 49 underwent 
i-scan imaging. Random biopsies were performed in 86 patients.
MAIN OUTCOME MEASUREMENTS: The primary outcome was the yield of SCE as 
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confirmed by histologic assessment.
RESULTS: The diagnostic yield for SCE was significantly higher with targeted biopsies 
than with random biopsies in both groups combined (63% vs 24%; P = .0001). The yield 
of targeted biopsies was significantly greater with both i-scan (66% vs 21%; P = .009) and 
acetic acid (57% vs 26%; P = .012) technologies and did not differ between these groups. 
The accuracy for predicting SCE was 96% (k = .92) for i-scan and 86% (k = .70) for acetic 
acid analysis.
LIMITATIONS: No dysplastic lesions were found.
CONCLUSION: The i-scan or acetic acid-guided biopsies have a significantly higher diag-
nostic yield for identifying SCE, with significantly fewer biopsies, as compared with a pro-
tocol of random biopsies. Acetic acid and i-scan showed comparable results diagnosing 
SCE in our study. (Clinical trial registration number: NCT01442506.).
C2. Prognostic (and monitoring) device accuracy studies
In accuracy studies for prognostic and monitoring test devices (or biomarkers), the 
interest is in the relationship between the information from the index test device and 
the occurrence of an health outcome (or health event) in the future – in other words, 
how information from the index test device can predict a future health outcome. 
Such outcomes can be an objective event such as a particular disease progression or 
recurrence, a new event, or a treatment response, but can also include more subjective 
measures such as decreased pain experience or improved quality of life. The future 
may be measured in hours or days (e.g. devices to measure blood loss during surgery 
in order to predict the need for postoperative blood transfusion), weeks, months or 
even years. 
The time sequence between the index test device and outcome occurrence requires 
a different type of study design than diagnostic or screening device accuracy studies. 
The biggest difference between diagnostic and screening device accuracy studies and 
prognostic device accuracy studies is time. More specifically, the time interval between 
the index test result and the outcome of interest. In prognostic test accuracy studies, 
subjects must undergo the test device and are tracked for a certain amount of time 
to establish whether or not they develop the targeted study outcome(s) in the future. 
This time may range from hours, days, weeks, months or even years, depending on 
the working mechanism of the device. Such prognostic test device study thus have 
to follow a longitudinal design, such as a prospective or retrospective observational 
cohort study (see above). Also, data from randomised studies may be used to evaluate 
the predictive accuracy of prognostic test devices.
In studies of prognostic test devices, the population of interest can be patients 
diagnosed with a particular condition for whom a particular future health outcome 
is to be predicted, but may also involve predicting whether healthy individuals will 
develop diabetes type 2, for example. The overall question in such studies is whether 
the information provided by the test device is helpful in labelling or stratifying 
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patients by their risk of developing a certain outcome in the future. Study individuals 
or patients should again be representatives of the intended spectrum of individuals 
(patients) and not only a specific small subgroup. Important choices must be made 
about which relevant health outcomes to predict and thus observe in a study, and what 
the relevant duration of the follow-up is. Studies with longer follow-ups are usually 
more relevant for patients, professionals and society at large, but they are also more 
time-consuming, expensive, and run a higher risk of losing the study individuals. The 
accuracy of a prognostic device can be expressed in terms of how well the device pre-
dicts actual observed outcomes and how well it differentiates between those who do 
or do not experience the health outcome.  
C2.1 Single prognostic device studies
Like single diagnostic and screening test device accuracy studies, prognostic test 
devices can also be evaluated individually (in isolation) for their predictive prognos-
tic accuracy. Such studies often apply the classic cohort design, with follow-up of the 
subjects using the prognostic test device until the predefined time period for devel-
oping the health outcome. One important quality item of any prognostic device study, 
whether single or comparative (see next section), is the completeness of the follow-up; 
ideally, all the study follow up all the subjects for the predefined time period. Like 
single diagnostic and screening test accuracy studies (C1.1), the main result of a 
single prognostic test device study is the strength of the association between the test 
device information and the occurrence of the health outcome of interest. And like 
single diagnostic and screening test accuracy studies, single prognostic test accuracy 
studies are not suitable for determining whether a new prognostic device has added 
predictive value beyond the accuracy already obtained by existing prognostic tests or 
factors; they are also not suitable for identifying the order in which prognostic devices 
can best be used (see C.2.2) or for determining whether actual use of the prognostic 
device or use of the diagnostic or screening device will lead to actual (or added) health 
benefits in individuals (see C.3). 
ExamplE of a comparativE dEvicE tEst accuray study  
(parallEl randomisEd dEsign)
Title: Acetic acid compared with i-scan imaging for detecting Barrett’s esophagus: a ran-
domized, comparative trial.
Reference: Hoffman A, Korczynski O, Tresch A, Hansen T, Rahman F, Goetz M, Murthy S, 
Galle PR, Kiesslich R. Gastrointest Endosc. 2013 Aug 13. pii: S0016-5107(13)02129-9. doi: 
10.1016/j.gie.2013.07.013. [Epub ahead of print]
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Traditional surveillance in patients with Barrett’s esophagus 
(BE) has relied on random biopsies. Targeted biopsies that use advanced imaging modali-
ties may significantly improve detection of specialized columnar epithelium (SCE).
OBJECTIvE: We compared the efficacy of targeted biopsies that used i-scan or acetic acid 
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to random biopsies in the detection of SCE.
DESIGN: Patients with visible columnar lined epithelium or known BE were randomized 
at a 1:1 ratio to undergo acetic acid application or i-scan with targeted biopsies.
SETTING: Targeted biopsies were performed based on surface architecture according to 
the Guelrud classification followed by 4-quadrant biopsies.
PATIENTS: A total of 95 patients were randomized.
INTERvENTION: A total of 46 patients underwent acetic acid staining, and 49 underwent 
i-scan imaging. Random biopsies were performed in 86 patients.
MAIN OUTCOME MEASUREMENTS: The primary outcome was the yield of SCE as con-
firmed by histologic assessment.
RESULTS: The diagnostic yield for SCE was significantly higher with targeted biopsies 
than with random biopsies in both groups combined (63% vs 24%; P = .0001). The yield 
of targeted biopsies was significantly greater with both i-scan (66% vs 21%; P = .009) and 
acetic acid (57% vs 26%; P = .012) technologies and did not differ between these groups. 
The accuracy for predicting SCE was 96% (k = .92) for i-scan and 86% (k = .70) for acetic 
acid analysis.
LIMITATIONS: No dysplastic lesions were found.
CONCLUSION: The i-scan or acetic acid-guided biopsies have a significantly higher diag-
nostic yield for identifying SCE, with significantly fewer biopsies, as compared with a pro-
tocol of random biopsies. Acetic acid and i-scan showed comparable results diagnosing 
SCE in our study. (Clinical trial registration number: NCT01442506.).
ExamplE of a singlE prognostic dEvicE study (2)
Title: High-sensitivity troponin T is a prognostic marker for patients with aortic stenosis 
after valve replacement surgery.
Reference: Saito T, Hojo Y, Hirose M, Ikemoto T, Katsuki T, Kario K. J Cardiol. 2013 
May;61(5):342-7. doi: 10.1016/j.jjcc.2013.01.005. Epub 2013 Mar 6.
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Aortic stenosis (AS) is recognized as a cause of sudden cardi-
ac death. Recently, the measurement of high-sensitivity troponin T (hs-TnT) has become 
possible. Several studies have clarified that hs-TnT is a marker to indicate mortality of 
cardiovascular diseases.
OBJECTIvES: To examine whether hs-TnT can be used as a prognostic marker to predict 
the operative outcome of AS.
METHODS: We enrolled 60 patients with AS (mean age=68.7 ± 9.6 years, male/fe-
male=30/30). Cardiac catheterisation and echocardiography were performed to evaluate 
the severity of AS. Aortic valve replacement surgery was performed in all patients. We 
defined major adverse cardiac events (MACE) as composite events of heart failure, fatal 
arrhythmia, and all causes of death.
RESULTS: We followed up the patients for 922 ± 800 days. Mean left ventricular ejection 
fraction was 60.0 ± 1.8%. Mean aortic valve area was 0.61 ± 0.03 cm(2). MACE occurred 
in 11 patients (18%), including 5 sudden cardiac deaths. We divided the patients into 
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three groups based on the percentile of the plasma levels of hs-TnT. Kaplan-Meier curve 
revealed a statistically significant difference in MACE rate among the groups (log-rank 
test, χ(2)=13.0, p=0.002). We conducted a Cox proportional hazard analysis with a model 
including age, sex, estimated glomerular filtration rate, and hs-TnT tertile as explanatory 
variables to predict MACE. We found that hs-TnT tertile to be a significant factor to predict 
MACE (hazard ratio: 3.71, p=0.03).
CONCLUSIONS: hs-TnT can be a prognostic marker for patients with AS after valve re-
placement surgery.
C2.2 Comparative prognostic device studies
As in the case of comparative diagnostic and screening test accuracy studies (C1.2), 
professionals in medical practice are generally interested in the predictive accuracy of 
any new prognostic device as compared to or beyond the accuracy of existing prog-
nostic test devices. Comparing prognostic tests devices within the same study – where 
all the subjects undergo the existing and new test devices – is likely to produce more 
valid results than comparing the accuracy estimates from different studies, each one 
evaluating a separate prognostic test device. As discussed under C.1.2, in the latter 
case many factors other than the use of a different device test may be responsible for a 
difference in accuracy, for example differences in the setting, population, and observ-
ers or users of the device. 
Like comparative diagnostic or screening test device studies, comparative prognos-
tic device studies allow us to study whether a new device improves prediction beyond 
what current tests already achieve, what the predictive accuracy is of combinations 
of different prognostic devices, in which order different prognostic tests should be 
conducted, and at which time point a specific new prognostic test device may be most 
suitable.
The advantages of comparative diagnostic and screening test accuracy studies (see 
C.1.2) also apply for prognostic comparative accuracy studies. 
ExamplE of a comparativE prognostic dEvicE study (addEd 
valuE study)
Title: Does coronary CT angiography improve risk stratification over coronary calcium 
scoring in symptomatic patients with suspected coronary artery disease? Results from the 
prospective multicenter international CONFIRM registry.
Reference: Al-Mallah MH, Qureshi W, Lin FY, Achenbach S, Berman DS, Budoff MJ, Callister 
TQ, Chang HJ, Cademartiri F, Chinnaiyan K, Chow BJ, Cheng vY, Delago A, Gomez M, Had-
amitzky M, Hausleiter J, Kaufmann PA, Leipsic J, Maffei E, Raff G, Shaw LJ, villines TC, Cury 
RC, Feuchtner G, Plank F, Kim YJ, Dunning AM, Min JK. Eur Heart J Cardiovasc Imaging. 
2013 Aug 21. [Epub ahead of print]
Source: MEDLINE (through PubMed)
Abstract: AIMS: The prognostic value of coronary artery calcium (CAC) scoring is well 
established and has been suggested for use to exclude significant coronary artery disease 
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(CAD) for symptomatic individuals with CAD. Contrast-enhanced coronary computed to-
mographic angiography (CCTA) is an alternative modality that enables direct visualisation 
of coronary stenosis severity, extent, and distribution. Whether CCTA findings of CAD add 
an incremental prognostic value over CAC in symptomatic individuals has not been exten-
sively studied.
METHODS AND RESULTS: We prospectively identified symptomatic patients with suspect-
ed but without known CAD who underwent both CAC and CCTA. Symptoms were defined 
by the presence of chest pain or dyspnoea, and pre-test likelihood of obstructive CAD was 
assessed by the method of Diamond and Forrester (D-F). CAC was measured by the meth-
od of Agatston. CCTAs were graded for obstructive CAD (>70% stenosis); and CAD plaque 
burden, distribution, and location. Plaque burden was determined by a segment stenosis 
score (SSS), which reflects the number of coronary segments with plaque, weighted for 
stenosis severity. Plaque distribution was established by a segment-involvement score 
(SIS), which reflects the number of segments with plaque irrespective of stenosis severity. 
Finally, a modified Duke prognostic index-accounting for stenosis severity, plaque distri-
bution, and plaque location-was calculated. Nested Cox proportional hazard models for 
a composite endpoint of all-cause mortality and non-fatal myocardial infarction (D/MI) 
were employed to assess the incremental prognostic value of CCTA over CAC. A total of 
8627 symptomatic patients (50% men, age 56 ± 12 years) followed for 25 months (inter-
quartile range 17-40 months) comprised the study cohort. By CAC, 4860 (56%) and 713 
(8.3%) patients had no evident calcium or a score of >400, respectively. By CCTA, 4294 
(49.8%) and 749 (8.7%) had normal coronary arteries or obstructive CAD, respectively. At 
follow-up, 150 patients experienced D/MI. CAC improved discrimination beyond D-F and 
clinical variables (area under the receiver-operator characteristic curve 0.781 vs. 0.788, P 
= 0.004). When added sequentially to D-F, clinical variables, and CAC, all CCTA measures 
of CAD improved discrimination of patients at risk for D/MI: obstructive CAD (0.82, P < 
0.001), SSS (0.81, P < 0.001), SIS (0.81, P = 0.003), and Duke CAD prognostic index (0.82, 
P < 0.0001).
CONCLUSION: In symptomatic patients with suspected CAD, CCTA adds incremental dis-
criminatory power over CAC for discrimination of individuals at risk of death or MI.
C3. Clinical utility of diagnostic, screening, monitoring and 
prognostic test devices: direct evidence 
The clinical utility (impact or effectiveness) of a test device is commonly defined as the 
degree to which actual use of the test device will lead to the intended benefits, ideally 
added benefits, in the relevant health outcomes of the targeted patients and setting. 
This is similar to therapeutic devices, as discussed in Chapter 4.2 and 4.3, and above. 
The main difference between a clinical utility study of a test device versus the same 
study of a therapeutic device is that the latter may impact health outcomes directly, 
either in the short term or the long term, whereas test devices do this indirectly. Test 
devices provide information or results that change or guide therapeutic decisions and 
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management, which in turn lead to benefits or added benefits. Hence, when studying 
the added benefits of test devices for the relevant health outcomes in the targeted indi-
viduals and context, we not only study the test device but the test device in combina-
tion with subsequent treatments/management – also known as test-treatment studies 
(see also Figure 3, left panel). 
The study designs discussed above under parts A and B can thus also be used – 
subject to the same pros and cons – to evaluate the clinical benefits or added benefits 
of using a certain test device combined with the treatment of choice. Here as well, a 
randomised design – notably a comparative effectiveness or pragmatic randomised 
design – is the preferred choice of design. Depending on how the test device is used, 
however, the type of randomisation may vary, as described in various papers (see 
references in Chapter 4). Also, the results of a test device and the subsequent thera-
peutic management decisions must be clearly linked. Without this, the results of a trial 
become more difficult to interpret. The link is needed when using a traditional ran-
domised design, a novel randomised design (both part A) or a non-randomised design 
(part B). All the issues mentioned in part A and B apply equally when evaluating the 
clinical utility of non-therapeutic devices. 
ExamplE of a clinical utility study to documEnt thE impact 
of using a tEst dEvicE on patiEnt outcomEs 
Title: Cardiac computed tomography guided treatment strategy in patients with recent 
acute-onset chest pain: Results from the randomised, controlled trial: CArdiac cT in the 
treatment of acute CHest pain (CATCH).
Reference: Linde JJ, Kofoed KF, Sørgaard M, Kelbæk H, Jensen GB, Nielsen WB, Hove JD. nt 
J Cardiol. 2013 Aug 14. pii: S0167-5273(13)01545-3. doi: 10.1016/j.ijcard.2013.08.020. 
[Epub ahead of print]
Source: MEDLINE (through PubMed)
Abstract: OBJECTIvES: In patients admitted on suspicion of acute coronary syndrome, 
with normal electrocardiogram and troponines, we evaluated the clinical impact of a Cor-
onary CT angiography (CCTA)-strategy on referral rate for invasive coronary angiography 
(ICA), detection of significant coronary stenoses (positive predictive value [PPv]) and 
subsequent revascularisations, as compared to a function-based strategy (standard care). 
Secondarily we assessed intermediate term clinical events.
METHODS AND RESULTS: We randomised 600 patients to a CCTA-guided strategy (299 
patients) or standard care (301 patients). In the CCTA-guided group referral for ICA re-
quired a coronary stenosis >70% or >50% in the left main, and for intermediate stenoses 
(50-70%), a stress test was used. A significant stenosis on ICA was defined as a stenosis 
≥70% or reduced FFR ≤0.75 in intermediate stenoses (50-70%). Referral rate for ICA was 
17% with CCTA vs. 12% with standard care (p=0.1). ICA confirmed significant coronary 
artery stenoses in 12% vs. 4% (p=0.001), and 10% vs. 4% were subsequently revascu-
larised (p=0.005). PPv for the detection of significant stenoses was 71% with CCTA vs 
36% with standard care (p=0.001). Clinical events (cardiac death, myocardial infarction, 
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unstable angina pectoris, revascularisation and readmission for chest pain), during 
120days of follow-up, were recorded in 8 patients (3%) in the CCTA-guided group vs. 15 
patients (5%) in the standard care group (p=0.1).
CONCLUSION: In patients with recent acute-onset chest pain, a CCTA-guided diagnostic 
strategy improves PPv for the detection of significant coronary stenoses, and increases the 
frequency of revascularisations, when compared to a conventional functional approach.
D. Linked-evidence approaches for both therapeutic and non-
therapeutic (test) devices
In the main text, we described how linked-evidence approaches can be used to evalu-
ate the clinical benefits or added benefits for the relevant, long-term health outcomes 
in the targeted individuals and context of medical devices. That is the case for both 
therapeutic and test devices. Whether quantitative or qualitative in nature (see main 
text), the linked-evidence approach is often a key component when building evidence 
for the clinical benefits of devices. In linked-evidence approaches, the results of stud-
ies on the impact of device use on short-term outcomes or surrogate/intermediate 
outcomes, or of test accuracy studies can be linked to the results of other studies – e.g. 
long-term therapeutic studies on the relevant health outcomes – in order to make 
inferences about the long-term effectiveness (and cost- effectiveness) of a medical 
device. Figure 3 below shows the difference between linked-evidence and direct 
evidence approaches for evaluating test devices, notably diagnostic and screening 
devices. 
Linked-evidence approaches, preferably quantitative, may be justified if there is 
clear evidence that, for example, short-term or surrogate/intermediate outcomes are 
indeed associated with clinically meaningful outcomes – in other words, if there is 
sufficient confidence that indirect outcomes can predict clinical meaningful outcomes. 
For test devices (Figure 3) for which only a test accuracy study has been performed, 
a linked-evidence approach may be justified if evidence from longitudinal studies has 
shown that treatment of the condition of interest has a positive impact on relevant, 
long-term health outcomes in the same targeted individuals as those in which the new 
test device was studied. 
Bear in mind that a linked-evidence approach is basically inferior to a direct evidence 
approach. For details about these approaches, we refer to Chapter 4, main text. Here 
we provide a few examples of linked-evidence approaches of different kinds (inferring 
from short-term outcomes to long-term outcomes, from surrogate to ‘hard’, relevant 
outcomes, and from test accuracy parameters to relevant health outcomes and even 
cost-effectiveness) and from different types of devices (therapeutic, diagnostic, and 
screening devices).
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Figure 3. The use of direct evidence compared with linked evidence in the evaluation of 
test devices24
ExamplEs linkEd EvidEncE approachEs usEd for thE Evalua-
tion of mEdical dEvicEs 
Title: The long-term cost-effectiveness of cardiac resynchronisation therapy with or with-
out an implantable cardioverter-defibrillator.
Reference: Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. Eur Heart J. 
2007 Jan;28(1):42-51. Epub 2006 Nov 16.
Source: MEDLINE (through PubMed)
Abstract: AIMS: Cardiac resynchronisation therapy (CRT-P) is an effective treatment for 
24  Lord S., Ghersi D., Simes J., Irwig L., (2005) Medical Services Advisory Committee: Guidelines 
for the assessment of diagnostic technologies. Canberra: Commonwealth of Australia). Note that 
the right panel – the linked-evidence approach – may be quantitative or qualitative in nature.
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patients with heart failure and cardiac dyssynchrony with moderate or severe symptoms 
despite pharmacological therapy. The addition of an implantable cardioverter-defibrilla-
tor (ICD) function may further reduce the risk of sudden death. We assessed the cost-ef-
fectiveness of CRT-P compared with medical therapy (MT) alone, and the cost-effective-
ness of CRT-ICD + MT compared with CRT-P + MT, on incremental cost per quality adjusted 
life year (QALY) and life year using data from two landmark clinical trials. METHODS AND 
RESULTS: A Markov model with Monte Carlo simulation to assess costs, life years, and 
QALYs associated with CRT (+/- ICD) and MT in patients with heart failure and cardiac 
dyssynchrony, on the basis of a UK healthcare perspective was constructed. NYHA class 
distribution and transitions, associated health utilities, rates and cause of hospitalisation 
and death were estimated from individual patient data from the CArdiac REsychronisation 
in Heart Failure (CARE-HF trial). The estimated additional benefit on survival of an ICD 
was based on results from COMPANION. The base case analysis used 10 000 individual 
life-time simulations assuming a battery life of 6 years for CRT-P and 7 years for CRT-ICD. 
From a life-time perspective in a 65-year-old patient, the incremental cost-effectiveness of 
CRT-P compared with MT is 7538 euros (95% CI 5325-11,784 euros) per QALY gained and 
7011euros (95% CI 5346-10,003 euros) per life year gained. The incremental cost-effec-
tiveness of CRT-ICD compared with CRT-P is 47,909 euros (95% CI 35,703-79,438 euros) 
per QALY gained, and 35,864 euros (95% CI 26,709-56,353 euros) per life year gained. 
CONCLUSION: Long-term treatment with CRT-P appears cost-effective compared with MT 
alone. From a life-time perspective, assuming a reasonable life expectancy when receiving 
effective treatment for heart failure, CRT-ICD may also be considered cost-effective when 
compared with CRT-P + MT.
Title: The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treat-
ment: based on 2-year follow-up HERA trial data.
Reference: Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. Breast Cancer Res 
Treat. 2008 Jun;109(3):559-66. Epub 2007 Jul 28.
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Several randomized controlled trials have confirmed the use-
fulness of trastuzumab as an adjuvant therapy for HER2-overexpressed breast cancer 
patients; however, the costs for 1-year treatment are high. Therefore, we performed an 
economic analysis regarding the efficient distribution of medical resources. METHODS: 
To analyze the cost-effectiveness for a 1-year adjuvant trastuzumab treatment group 
compared with the observation group, we constructed a Markov model adopting a 3% 
per year discount rate for costs and outcomes. The time horizon was 50 years. The per-
spective was that of health-care payers, as only direct medical costs were calculated. The 
outcome was measured as life-year gained (LYG) from 2-year follow-up HERA trial data. 
RESULTS: The ICER of the standard setting (5 years efficacy and 50-60 kg patient weight) 
was JPY 2,600,000 (<euro>17,000) per LYG. The calculation results of other weight class 
ICER were JPY 2,200,000 (<euro>15,000) and JPY 3,300,000 (<euro>22,000) per LYG for 
the patients, respectively, who weighed less than 50 kg, and 60-75 kg. In the sensitivity 
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analysis, the period of trastuzumab efficacy was the most influential parameter for the 
result of cost-effectiveness. However, even if the trastuzumab efficacy were to continue 
for only 2 years, at least, which is a conservative setting judging from the joint analysis 
(NSABP B-31 and NCCTG N9831 trials), the ICER remains acceptable for any weight class. 
CONCLUSION: These results suggest that the 1-year adjuvant trastuzumab treatment is 
cost-effective. Both clinical and economic benefits were superior for the 1-year adjuvant 
trastuzumab treatment group compared with the observation group.
Title: Cost-effectiveness of magnetic resonance angiography versus intra-arterial digital 
subtraction angiography to follow-up patients with coiled intracranial aneurysms.
Reference: Schaafsma JD, Koffijberg H, Buskens E, velthuis BK, van der Graaf Y, dekk.
Stroke. 2010 Aug;41(8):1736-42. doi: 10.1161/STROKEAHA.110.585083. Epub 2010 Jul 1.
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND AND  PURPOSE: To follow up patients with coiled intracranial 
aneurysms, magnetic resonance angiography (MRA) is a promising noninvasive alterna-
tive to current standard intra-arterial digital subtraction angiography (IA-DSA). MRA test 
results do not always concord with those of IA-DSA, and the impact of discrepancies on 
health benefits and costs is unknown. We evaluated the cost-effectiveness of follow-up 
with MRA vs IA-DSA to assess whether in this setting MRA may replace IA-DSA. METHODS: 
We studied aneurysm occlusion on MRA in addition to follow-up IA-DSA in 310 patients 
with 341 coiled intracranial aneurysms. The observed sensitivity (82%) and specificity 
(89%) of MRA for detection of reopening with IA-DSA as a reference were used as input 
for a Markov decision-analytic model. Other determinants were derived from the litera-
ture. We compared life expectancy, quality-adjusted life-years (QALY), costs, and expected 
number of events for the two strategies. RESULTS: Follow-up with MRA yielded similar 
life expectancy (MRA, 26.66 years; IA-DSA, 26.63 years; difference, 0.03 years; 95% CI, 
-0.17-0.23) and QALY (MRA, 10.96; IA-DSA, 10.95; difference, 0.01 QALY; 95% CI, -0.05-
0.08) at lower costs (MRA, $7003; IA-DSA, $8241 per patient; difference, -$1238; 95% 
CI, -2617--36). The expected number of events was comparable except for complications 
from IA-DSA. CONCLUSIONS: MRA provided equivalent health benefits as IA-DSA and was 
cost-saving. MRA dominates and should replace routine IA-DSA to follow-up patients with 
coiled aneurysms.
Title: From accuracy to patient outcome and cost-effectiveness evaluations of diagnostic 
tests and biomarkers: an exemplary modelling study.
Reference: Koffijberg H, van Zaane B, Moons KG. BMC Med Res Methodol. 2013 Jan 
31;13:12. 
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Proper evaluation of new diagnostic tests is required to reduce 
overutilisation and to limit potential negative health effects and costs related to testing. A 
decision analytic modelling approach may be worthwhile when a diagnostic randomized 
controlled trial is not feasible. We demonstrate this by assessing the cost-effectiveness of 
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modified transesophageal echocardiography (TEE) compared with manual palpation for 
the detection of atherosclerosis in the ascending aorta. METHODS: Based on a previous 
diagnostic accuracy study, actual Dutch reimbursement data, and evidence from litera-
ture we developed a Markov decision analytic model. Cost-effectiveness of modified TEE 
was assessed for a life time horizon and a health care perspective. Prevalence rates of 
atherosclerosis were age-dependent and low as well as high rates were applied. Prob-
abilistic sensitivity analysis was applied. RESULTS: The model synthesized all available 
evidence on the risk of stroke in cardiac surgery patients. The modified TEE strategy con-
sistently resulted in more adapted surgical procedures and, hence, a lower risk of stroke 
and a slightly higher number of life-years. With 10% prevalence of atherosclerosis the 
incremental cost-effectiveness ratio was € 4,651 and € 481 per quality-adjusted life year 
in 55-year-old men and women, respectively. In all patients aged 65 years or older the 
modified TEE strategy was cost saving and resulted in additional health benefits. CON-
CLUSIONS: Decision analytic modelling to assess the cost-effectiveness of a new diagnos-
tic test based on characteristics, costs and effects of the test itself and of the subsequent 
treatment options is both feasible and valuable. Our case study on modified TEE suggests 
that it may reduce the risk of stroke in cardiac surgery patients older than 55 years at 
acceptable cost-effectiveness levels.
Title: Effectiveness and costs of screening for aneurysms every 5 years after subarach-
noid hemorrhage.
Reference: Wermer MJ, Koffijberg H, van der Schaaf IC; ASTRA Study Group.
Source: MEDLINE (through PubMed)
Abstract: BACKGROUND: Patients who survive after subarachnoid hemorrhage (SAH) are 
at risk for a recurrence despite successful treatment of the ruptured aneurysm and may 
therefore benefit from screening for new aneurysms.
METHODS: We screened 610 patients with SAH with CT angiography 2-18 years after 
clipping of the aneurysms. Results of screening were used as input for a Markov decision 
model. We compared the expected number of recurrent hemorrhages, life expectancy, 
quality-adjusted life-years (QALYs), and costs associated with the strategies ‘screening 
every 5 years’ and ‘no screening.’ RESULTS: Screening individuals with previous SAH pre-
vented almost half of the recurrences, slightly increased life expectancy (from 21.06 to 
21.08 years), but reduced QALYs (from 12.18 to 12.04) and increased costs (from $2,750 
to $4,165 per patient). Screening was cost-saving without increasing QALYs in patients 
with a more than twofold risk above baseline of both aneurysm formation and rupture 
and it was cost-saving while increasing QALYs if both risks were at least 4.5 times high-
er. In patients with reduced quality of life because of fear for a recurrence, screening in-
creased QALYs at a maximum cost of $17,422 per QALY. CONCLUSIONS: In general, screen-
ing patients with previous subarachnoid hemorrhage (SAH) cannot be recommended. 
Screening can save costs and increase quality-adjusted life-years (QALYs) in patients with 
a relatively high risk of both aneurysm formation and rupture, and increases QALYs at ac-
ceptable costs in patients with fear for a recurrence. More data are needed on risk factors 
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for aneurysm formation and rupture in patients with previous SAH and on management 
of fear for a recurrence to identify patients who can benefit from screening.
Title: Optimal screening strategy for familial intracranial aneurysms: a cost-effectiveness 
analysis.
Reference: Bor AS, Koffijberg H, Wermer MJ, Rinkel GJ. Neurology. 2010 May 
25;74(21):1671-9. 
Source: MEDLINE (through PubMed)
Abstract: OBJECTIvE: Individuals with a family history of subarachnoid hemorrhage 
(SAH), defined as 2 or more affected first-degree relatives, have an increased risk of an-
eurysm formation and rupture. Screening such individuals for intracranial aneurysms is 
advocated, but its effectiveness and cost-effectiveness are unknown, as are the optimal 
age ranges and interval for screening. METHODS: With a Markov model and Monte Carlo 
simulations we compared screening with no screening in individuals with a family his-
tory of SAH. We varied age ranges (starting screening at 20, 30, or 40 years old, ending 
screening at 60, 70, or 80 years old) and screening intervals (2-, 3-, 5-, 7-, 10-, and 15-
year interval), and analyzed the impact in costs and quality-adjusted life years (QALY). 
RESULTS: Screening individuals with a family history of SAH is cost-effective. The strat-
egy with the lowest costs per QALY was to screen only twice, at 40 and 55 years old. Se-
quentially lengthening the screening period and decreasing the screening interval yielded 
additional health benefits at acceptable costs up to screening from age 20 to 80 every 7 
years. More frequent screening within this age range still provided extra QALYs, with an 
incremental cost-effectiveness ratio more favorable than 26,308/QALY ($38,410/QALY). 
CONCLUSION: This study provides evidence for recommendations to screen individuals 
with 2 or more first-degree relatives with subarachnoid hemorrhage. The optimal screen-
ing strategy according to our model is screening from age 20 until 80 every 7 years given a 
cost-effectiveness threshold of 20,000/quality-adjusted life year (QALY) ($29,200/QALY).
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appEndix v  
statistical mEthods to 
corrEct for confounding 
in non-randomisEd (dirEct 
EvidEncE) study approachEs
In this Appendix we briefly explain different methods that can be used in non-ran-
domised studies to limit or adjust the potential for bias or confounding bias (see also 
the references in main text). 25 
A. Methods used at the study design (set-up) stage
A1. Restriction
In this method, the aim is to create two groups that are similar on one or more known 
and major confounding variables by restricting the inclusion or exclusion criteria. For 
example, if age, gender or a specific disease variant are known to have a major influ-
ence on the mechanism/pathway of the device’s benefits, we can restrict the two study 
groups only to a specific gender, age range, or disease variant. Another method is to 
exclude subgroups which are known a priori to influence the pathway of the device’s 
effect. A disadvantage of restriction is that the results may have limited applicability – 
reduced generalizability of device use – because they are based on a more homogene-
ous and less representative study group.
A2. Matching
Matching is the process of searching, for each individual in the index (device) group, a 
subject in the control group who is similar on the set of most important confounding 
25  Cousens S., Hargreaves J., Bonell C., Armstrong B., Thomas J., Kirkwood B.R., Hayes R., Al-
ternatives to randomisation in the evaluation of public-health interventions: statistical analysis 
and causal inference. J Epidem Community Health 2011;65:576-581; McNamee R., Regression 
modelling and other methods to control confounding. Occup Environ Med 2005;62:500-506 
doi:10.1136/oem.2002.001115.
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variables. For example, for an index-group female, 40 years of age, no previous disease, 
particular disease stage, we would search and include a control-group female with a 
similar age range (40-45), no previous disease and same disease stage. One limitation 
to matching is that it is tedious work and therefore an expensive undertaking when 
there are many known a priori confounding variables. It is therefore often performed 
only for the two or three most important confounders. 
B. Methods used during statistical analysis26
B1. Stratification
This method involves stratifying the study participants by the main confounders for 
which results should be controlled (e.g. by age groups or gender), and estimating the 
effect of the device per stratum (e.g. per age or gender group). In order to ensure that 
strata with a larger group of participants receive larger weights when estimating the 
association between the difference in device use and the observed benefits, we simply 
estimate a weighted average for the benefits of the device over these strata. We then 
end up knowing the unbiased and valid effect of the device’s use compared to the 
control group, and adjust for those confounding variables. The most common statis-
tical weighting approach used in this case is the Mantel-Haenszel method. Stratifi-
cation also allows us to assess whether the device has different benefits in different 
subgroups, provided we have large enough numbers per subgroup. One disadvantage 
of this method is that strata with larger numbers of participants will generate more 
precise estimates of the device’s benefits (with a smaller standard error) than smaller 
strata. 
B2. Regression modelling
This statistical approach is used to control for many confounders simultaneously, 
unlike all the above methods, which control for one or a few confounders. Regression 
modelling adjustment is the most widely used and perhaps the best method to adjust 
for other influential factors when studying the benefits of device use versus a control 
group in a non-randomised study. The use of this method only requires that inves-
tigators predefine the known influential or confounding factors for the device and 
outcome being studied and subsequently measure the presence or absence of each 
predefined confounder in each study participant in both study groups. One disadvan-
tage of these analyses is that confounders can only be controlled for if they are known 
a priori and properly measured in each study participant.
26  To correct for confounding during the analysis phase, the process of designing and con-
ducting a non-randomised study on the benefits of a device must meet certain requirements. 
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B3. Propensity score methods
This relatively novel approach – which also uses a regression modelling approach – is 
used most notable in Non Randomised Studies on the benefits of interventions where 
the number of study participants is limited and the number of confounders is rela-
tively large. A propensity score is also called a multiple confounder score, with the 
value of each study participant’s characteristics and confounders being summarised 
to a single variable. It has two major stages. First, when comparing the two non-ran-
domised groups – participants with the device versus those without the device – we 
estimate the probability that each individual had received the device according to their 
characteristics and confounding variables (using a logistic regression model). The 
probability per participant is known as the propensity score. Second, we then restrict, 
match or stratify the two study groups according to this propensity score variable, or 
use a regression model. There has been extensive research comparing the advantages 
and disadvantages of propensity methods for confounder control to the traditional 
methods described above.
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appEndix vi  
concisE comparison 
mEdical dEvicEs vErsus 
pharmacEuticals
In this appendix we compare medical devices and medicinal products (pharmaceuti-
cals) on all aspects relevant to clinical research. Table 1 summarises the similarities 
between the two groups. In essence, basic regulatory systems are in place for both 
pharmaceuticals and medical devices. There are European directives (three for devices 
and one for pharmaceuticals) defining what a device or pharmaceutical is, and exten-
sive guidelines for market access are available in both cases. These guidelines describe 
a process that must meet certain requirements rather than request that a specific 
approach be used to produce predefined results. Decisions are always on a case-
by-case basis, depending on the evidence presented. Evidence is based on a dossier 
provided by the manufacturer. Whereas for pharmaceuticals global harmonisation 
has been achieved, it is still underway for medical devices. Once the product has been 
marketed for a specific indication or intended purpose, off-label use is common for 
medical devices and pharmaceuticals. As in the case of pharmaceuticals, postmarket-
ing surveillance (PMS) is required for medical devices. For medical devices implemen-
tation of PMS could improve.
Table 1: Similarities between regulation of medical devices and pharmaceuticals
Medical devices (see Appendix III) Pharmaceutical products
3 European directives covering all products (MDD, 
AIMD, IvDD, see Appendix III)
1 European directive (2001/83/EC)
CE marking for (technical) safety Good Manufacturing Practice (GMP) guidelines 
according to ICH 
NEN-ISO 1455 for GCP guidelines Good Clinical Practice (GCP) guidelines according 
to ICH
GHTF is working on harmonisation but is not yet 
finished > difference USA & EU
International Conference on Harmonisation of 
Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) global 
harmonisation of guidelines for access
Clinical evaluation based on the literature, existing 
studies or new clinical investigations according to 
risk category and depending on equivalence data
General requirements for phase 1, 2 and 3 studies + 
judgement by experts at the EMA’s CHMP
One device is often useful for many different indica-
tions; implicit frequent off-label use
Off-label use is frequent 
Postmarketing Surveillance (PMS) is required; in 
place but improvement is needed
PMS is required, and in place.
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Table 2 indicates differences between medical devices and pharmaceuticals that are 
beyond the remit of this committee. One relevant issue is that the European Medicines 
Agency (EMA) is an EU agency, whereas the Notified Bodies that judge the application 
dossiers are independent and thus more difficult to monitor. The main differences 
are related to differences between the two industrial sectors, medical devices and 
pharmaceuticals, i.e. the life cycle and innovation process. The pharmaceutical busi-
ness model is under pressure owing to an empty pipeline, with only a small number 
of innovative pharmaceutical products entering the market. In contrast, the medical 
devices industry (often SMEs) is still considered innovative and collaborates closely 
with health care professionals and hospitals. One major difference is that, once 
approved, a pharmaceutical product does not change during its lifetime and so the 
relevant clinical data remain valid. In medical devices, regular incremental changes 
(and improvements) alter the product over time, making it more difficult to interpret 
the clinical data in light of the latest version. Another difference is the stronger focus 
on efficacy at the point of market access for pharmaceuticals. The CE marking proce-
dure tends to look more closely at technical safety and performance than at clinical 
benefit. Health technology assessment (both theory and practice) is applied regularly 
for pharmaceuticals, and the reimbursement system in the Netherlands builds on 
different legislation.
Table 2: Differences between medical devices and pharmaceuticals beyond the remit of 
the committee
Medical devices Pharmaceutical products
Notified Bodies and Competent Authorities responsi-
ble for market access
EMA procedure for all new medicinal products to 
obtain market access
R&D trajectory ~ 1-5 years; life cycle of product ~ 2.5 
years
R&D trajectory ~ 15 years; life cycle of product > 
20 years
Product may change every 18 months; clinical data 
are no longer valid for the new version
Product remains unchanged for 20 years; clinical 
data therefore remain valid
Dynamic industry with many SMEs: Buyer’s market 
(prices depend on market, with budget for research 
and marketing therefore under pressure)
Static, conservative, almost institutional industry. 
Seller’s market (high prices for a quick ROI)
Innovation, often in close collaboration with clini-
cians/industry
Big pharma has an empty research and develop-
ment pipeline
Little application of health economics, cost-effective-
ness and HTA
Frequently application of health economics, 
cost-effectiveness, and HTA 
Reimbursement based on Stand van Wetenschap en 
praktijk (CvZ) and DBCs (NZA)
Reimbursement based on pharmacoeconomic dos-
sier for new drug, me-toos in cluster with average 
pricing; CvZ responsible
Table 3 compares differences between medical devices and pharmaceuticals that are 
crucial for designing research into device safety, performance and clinical benefit.27 
This relates to the risk categories, the mode of action, user interference, direct and 
27  Therapeutic and diagnostic devices outcomes research. S.J. Ackerman, M. Dix Smith, J. 
Ehreth, R. Eldessouki, E. Sullivan (Eds). ISPOR 2011: ISBN 978-09743289-2-8. Page 12.
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indirect effect, learning curves and all aspects that are described in more detail in 
Chapters 2 and 4 of this report. These differences are reflected in the way clinical eval-
uation is designed, and in the burden of proof that is required by the experts judging 
the data. This is why the committee is not in favour of applying a burden of proof for 
medical devices similar to that required for pharmaceuticals.
Table 3: Differences between medical devices and pharmaceuticals with consequences for 
clinical study approaches
Medical devices Pharmaceutical products
Different risk categories (high to low) No specific risk categories
Performance (of the product) compared to risk Efficacy (in subject receiving the drug) is based on 
benefit/risk ratio
Frequent indirect effect, user interference or inter-
mediate decision 
Always direct effect without user interference
Local, supportive, or information-generating effect, 
based on mechanical engineering, materials or 
physical, electrophysical or chemical principles
Biologically active, based on pharmacological, 
immunological, or metabolic action
Clinical evaluation based on literature, existing stud-
ies or new clinical investigations according to risk 
category and depending on equivalence data
General requirements for phase 1, 2 and 3 studies + 
judgement by experts at the EMA’s CHMP
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appEndix vii  
intErviEws and ExtErnal 
consultations
Consulted people (with affiliation)
Hans Arendzen, Leiden University Medical Center (LUMC), Innovative Medical Devices Initiative 
(IMDI)
Gert Bos, BSI Group and European Association of Notified Bodies for Medical Devices 
Bart Blokhuis, Medtech Partners
Robert Geertsma, National Institute for Public Health and the Environment (RIvM)
Michiel Jannink, Demcon
Marijke Janssens, Netherlands Organisation for Health Research and Development (ZonMw) 
Eric Klasen, Medtronic
Jos Kraus, Academic Medical Center (AMC)
Frits Lekkerkerker, Nederlandse vereniging Medisch Ethische Toetsings Commissies (NvMETC)
Gerry Ligtenberg, Health Insurance Board (CvZ)
Susanne Ludgate, Medicines and Healthcare products Regulatory Agency (MHRA), European 
Commission and Global Harmonization Task Force (GHTF)
Maarten Simoons, Erasmus MC
veronica van Nederveen, Ministry of Health, Welfare and Sport, The Netherlands
Hans Reiber, Medis, IMDI
Kees Smaling, Siemens Nederland
Henk viëtor, Skyline Diagnostics,
Fokko Wieringa, TNO Science & Industry
Gert-Jan van der Wilt, UMC St Radboud, Nijmegen
Review Committee
At the request of the Board of the KNAW a draft of this report was reviewed by four reviewers 
with different backgrounds. They are not responsible for the final report.
Bert Boer, Health Insurance Board (CvZ)
Adam Cohen, Center for Human Drug Research (CHDR)
Hans Hofstraat, Philips Research
Chris Hyde, University of Exeter and National Institute for Health and Care Excellence (NICE)
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